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Abstract	
	
The	recapitulation	of	tissue	organization	and	function	 in	vitro	 is	one	of	the	main	objectives	of	tissue	engineering.	
The	increasing	need	for	tissue	replacements	in	order	to	overcome	donor	organ	shortages	and	to	provide	better	tissue	
models	for	research	has	placed	the	engineering	of	tissue	constructs	in	the	spotlight.	
In	order	 to	 reproduce	natural	 tissue	as	 closely	as	possible,	 three-dimensional	 (3D)	 structure	and	architecture	of	
normal	 tissue	 must	 be	 examined.	 Indeed,	 proper	 tissue	 function	 strongly	 depends	 on	 the	 spatial	 assembly	 and	
interactions	between	key	components	such	as	cells,	growth	factors,	signaling	cues	and	extracellular	matrix	(ECM).	The	
ECM	in	particular	is	of	utmost	importance	in	the	design	of	engineered	tissues,	since	it	not	only	provides	support	but	
also	actively	interacts	with	cells	and	growth	factors	to	regulate	tissue	function.	The	field	of	tissue	engineering	has	thus	
pushed	 towards	 the	 development	 of	 novel	 biocompatible	 and	 biodegradable	 materials	 that	 are	 capable	 of	 both	
supporting	 and	 interacting	 with	 cells.	 Furthermore,	 such	 biomaterials	 are	 expected	 to	 allow	 the	 positioning	 of	
different	 cell	 types	 and	 the	 localization	 of	 biological	 factors,	 as	 well	 as	 having	 controlled	 adhesive	 properties	 and	
stiffness.	
Yet,	 despite	 the	 constant	 improvement	 on	 biomaterial	 design,	 technological	 advances	 and	 the	 increasing	
knowledge	 gained	on	 tissue	 functions,	 the	 synthesis	 of	 artificial	 tissues	 and	organs	 still	 remains	 a	 goal	 that	 lies	 far	
ahead.	Current	achievements	in	research	have	enabled	the	generation	of	engineered	constructs	with	either	controlled	
positioning	of	cells	or	patterning	of	growth	factors.	But	the	combination	of	both	aspects	in	a	reproducible	and	high-
throughput	strategy	still	remains	a	task	at	hand,	especially	for	the	complex	3D	architectures	found	in	normal	tissue.	
Another	limitation	of	tissue	engineering	is	the	current	inability	to	recreate	stable	vascularization	in	tissue	constructs.	
Vascularization	 is	 a	 compulsory	aspect	of	 engineering	artificial	 tissues,	 since	 survival	 of	 any	 clinical-sized	 constructs	
depends	on	 the	availability	of	oxygen	and	nutrients,	which	are	mainly	provided	by	blood	circulation	 in	 vivo.	 Such	a	
shortcoming	 is	 directly	 linked	 to	 the	 necessity	 of	 establishing	 new	 strategies	 for	 the	 localized	 control	 of	 cellular	
function	in	3D-arranged	microenvironments.	Indeed,	vascularization	is	a	complex	and	well-orchestrated	phenomenon	
that	requires	various	processes,	such	as	cell	migration	and	differentiation	under	the	control	of	specific	guidance	and	
signaling	cues.		
To	 this	 end,	 a	 platform	 for	 the	 synthesis	 of	 tunable	 tissue	 constructs	was	developed	 in	 this	 thesis	work.	 Taking	
advantage	 of	 the	 enzymatically	 cross-linked	 poly(ethylene	 glycol)	 hydrogel	 platform,	 which	 is	 biocompatible	 and	
highly	customizable,	a	strategy	for	the	controlled	incorporation	of	bioactive	factors	via	peptide	linkers	was	developed.	
The	 successful	 localized	 immobilization	 of	 growth	 factors	 and	 their	 ability	 to	 differentiate	 cells	 in	 a	 3D-controlled	
manner	was	demonstrated	by	 the	osteogenic	differentiation	of	mesenchymal	cells	by	 tethered	bone	morphogenice	
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protein-2.	 Furthermore,	 using	 the	 same	 model,	 the	 release	 dynamics	 of	 the	 immobilized	 growth	 factors	 were	
investigated	 and	 a	 cell-dependant	 release	 strategy	 was	 devised	 by	 designing	 a	 proteolytically	 degradable	 peptide	
linker.	 The	 availability	 of	 immobilization	 strategies	 that	 are	 cell-responsive	 and	 that	 can	mimic	 ECM	properties	 is	 a	
desirable	 feature	 that	 can	 also	 contribute	 to	 the	 improvement	 of	 growth	 factor	 dose-response	 relationship.	
Additionally,	selected	factors	modulating	angiogenesis	were	evaluated	for	their	potential	role	and	use	in	the	design	of	
tissue	constructs.	Pro-angiogenic,	anti-angiogenic	effects	and	 influence	on	cell	migration	were	assessed	 in	vitro	 and	
using	the	highly	vascularized	chicken	chorioallantoic	membrane.	Preliminary	experiments	support	the	hypothesis	that	
the	selected	growth	factors	could	be	used	for	establishing	pre-vascular	structures	in	engineered	constructs.	
Summing	 up,	 this	 thesis	 presents	 new	 tools	 for	 the	 development	 of	 engineered	 tissue	 constructs.	 It	 shows	 the	
successful	differentiation	of	cells	in	spatially	controlled	manner,	as	well	as	evaluates	potential	growth	factors	for	the	
regulation	of	vascular	development	 in	vitro.	Due	to	the	versatile	nature	of	these	biomimetic	scaffolds,	 it	 is	expected	
that	 this	 strategy	will	 be	 employed	 for	 the	 development	 of	 various	 types	 of	 tissues	 and	will	 allow	 the	 progression	
towards	more	complex	3D	tissue	architectures.	
	
	
Keywords:	 3D	 microenvironments,	 biomimetic	 matrices,	 poly(ethylene	 glycol),	 growth	 factor	 delivery,	 proteolytic	
release,	cell	differentiation,	protein	positioning,	bone	morphogenetic	protein-2,	netrin,	ephrins		
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Résumé	
	
L’ingénierie	des	tissues	possède	parmi	ses	objectifs	principaux	la	génération	de	substituts	tissulaires	in	vitro	capables	
de	 reproduire	 l’organisation	et	 la	 fonction	des	 tissus	normaux.	Ce	domaine	de	 la	 recherche	a	notamment	gagné	en	
intérêt	dû	à	l’augmentation	de	la	demande	en	greffes	d’organe	ainsi	qu’au	besoin	croissant	de	modèles	de	tissus	pour	
la	recherche.	
Il	 est	 important	 d’examiner	 et	 comprendre	 la	 structure	 tridimensionnelle	 (3D)	 ainsi	 que	 l’architecture	 de	 tissus	
normaux,	 afin	 de	 pouvoir	 fabriquer	 des	 tissus	 artificiels	 fonctionnels.	 En	 effet,	 les	 fonctions	 essentielles	 d’un	 tissu	
dépendent	principalement	de	la	répartition	spatiale	et	des	interactions	entre	divers	facteurs	clés,	dont	notamment	les	
cellules,	 les	 facteurs	de	croissance,	des	signaux	moléculaires	et	 la	matrice	extracellulaire	 (MEC).	La	MEC	mérite	une	
considération	particulière	dans	le	développement	de	tissus	synthétiques	car	en	plus	d’assurer	le	soutien	structurel	du	
tissu,	 elle	 interagit	 activement	 avec	 les	 cellules	 et	 facteurs	 de	 croissance	 afin	 de	 réguler	 la	 fonction	 des	 tissus.	 Le	
domaine	de	 l’ingénierie	 tissulaire	a	donc	 fortement	évolué	en	direction	du	développement	de	nouveaux	matériaux	
biocompatibles	et	biodégradables	capables	d’interagir	avec	 les	cellules	et	de	 leur	apporter	un	soutien	structurel.	En	
outre,	il	est	également	souhaitable	que	ce	genre	de	biomatériaux	puissent	permettre	le	positionnement	de	différents	
types	 cellulaires	 et	 la	 localisation	 de	 facteurs	 biologiques,	 tout	 en	 garantissant	 un	 contrôle	 sur	 leurs	 propriétés	
adhésives	et	leur	rigidité.	
Pourtant,	la	fabrication	de	tissus	et	organes	artificiels	reste	un	objectif	lointain,	malgré	les	avancées	technologiques	et	
l’augmentation	des	connaissances	acquises	sur	le	fonctionnement	des	tissus.	L’état	actuel	de	la	recherche	permet	la	
génération	 de	 tissus	 synthétiques	 offrant	 des	 possibilités	 pour	 le	 positionnement	 précis	 des	 cellules	 ou	 pour	 la	
création	 de	motifs	 de	 facteurs	 de	 croissance.	 Cependant	 la	 combinaison	 de	 ces	 deux	 aspects	 pour	 la	 synthèse	 de	
matrices	 à	 haut	 rendement	 et	 de	 manière	 reproductible	 reste	 une	 tâche	 à	 effectuer,	 en	 particulier	 pour	 la	
reproduction	 d’architectures	 3D	 complexes	 présentes	 dans	 les	 tissus	 normaux.	 Une	 autre	 limite	 de	 l’ingénierie	
tissulaire	 est	 l’incapacité	 de	 recréer	 un	 réseau	 vasculaire	 stable	 dans	 les	 tissus	 artificiels.	 Le	 processus	 de	
vascularisation	est	en	effet	un	aspect	crucial	lors	de	la	fabrication	de	tissus	artificiels	qui	ont	une	pertinence	clinique,	
puisque	 la	survie	du	tissu	dépend	de	 l’oxygénation	et	 l’acheminement	de	nutriments	normalement	prodigués	par	 la	
circulation	sanguine	in	vivo.	Une	telle	lacune	est	directement	liée	au	besoin	impératif	d’établir	de	nouvelles	stratégies	
permettant	un	contrôle	localisé	des	fonctions	cellulaires	dans	leur	microenvironnement	3D.	La	vascularisation	est	en	
effet	 un	 phénomène	 complexe	 qui	 requiert	 la	 coordination	 de	 plusieurs	 processus,	 dont	 la	 migration	 et	 la	
différentiation	de	cellules	sous	le	contrôle	d’une	grande	variété	de	facteurs	et	signaux	biologiques	spécifiques.	
Résumé	
vi	
Afin	de	répondre	à	ce	besoin,	une	plateforme	modulable	pour	la	fabrication	de	tissus	synthétiques	a	été	développée	
dans	 ce	 travail	 de	 thèse.	 Le	 système	 de	 gélification	 enzymatique	 d’hydrogels	 en	 poly(éthylène	 glycol)	 qui	 est	
biocompatible	et	facilement	adaptable	a	été	utilisé	à	son	avantage	pour	le	développement	d’une	stratégie	permettant	
l’immobilisation	 de	 facteurs	 bioactifs	 par	 des	 peptides	 de	 liaison.	 Ce	 système	 a	 été	 utilisé	 pour	 démontrer	
l’incorporation	 contrôlée	 de	 facteurs	 de	 croissances	 dans	 un	 hydrogel	 permettant	 la	 différentiation	 localisée	 de	
cellules	en	3D	par	le	biais	de	cellules	mésenchymateuses	différenciées	osteogénétiquement	en	présence	de	protéine	
morphogénétique	osseuse-2.	De	plus,	 la	 libération	de	facteurs	de	croissance	par	ce	type	de	matrice	a	été	examinée	
afin	 de	 développer	 une	 stratégie	 utilisant	 des	 peptides	 de	 liaison	 sensibles	 aux	 protéases,	 permettant	 ainsi	 la	
libération	de	facteurs	en	réponse	à	l’activité	cellulaire.	En	effet,	il	est	fortement	désirable	d’avoir	accès	à	des	moyens	
d’immobilisation	qui	 réagissent	à	 l’activité	 cellulaire	afin	d’avoir	des	 conditions	proches	de	 la	MEC	naturelle	et	 afin	
d’améliorer	 le	 rapport	 dose-réponse	 des	 facteurs	 de	 croissance	 immobilisés.	 Finalement,	 la	 dernière	 partie	 de	 ce	
travail	de	 thèse	s’est	 intéressée	aux	effets	angiogéniques	de	certains	 facteurs	de	croissance	et	 à	 leur	 rôle	potentiel	
dans	la	fabrication	de	tissus	synthétiques.	Les	effets	pro-	et	anti-angiogéniques	de	ces	facteurs	ainsi	que	leur	influence	
sur	la	migration	cellulaire	ont	été	examinés	in	vitro	et	sur	la	membrane	chorioallantoique	du	poulet.	Ces	expériences	
préliminaires	 indiquent	 fortement	 que	 les	 facteurs	 sélectionnés	 pourraient	 être	 utilisés	 pour	 la	 formation	 de	
structures	pré-vasculaires	dans	les	tissus	artificiels.	
En	bref,	ce	travail	de	thèse	a	permis	le	développement	de	nouveaux	outils	pour	la	fabrication	de	tissus	synthétiques.	
Des	cellules	ont	pu	être	différenciées	de	manière	locale	et	contrôlée	et	de	potentiels	facteurs	de	croissances	ont	été	
évalués	 pour	 leur	 rôle	 dans	 la	 formation	 de	 vaisseaux	 sanguins	 in	 vitro.	 La	 stratégie	 présentée	 ici	 constitue	 un	
fondement	 important	 pour	 la	 génération	 de	 différents	 types	 de	 tissus	 artificiels	 et	 la	 progression	 vers	 des	
architectures	cellulaires	3D	plus	complexes	grâce	à	ses	propriétés	modulables.	
	
	
Mots-clés	:	microenvironnements	3D,	matrices	biomimétiques,	poly(éthylène	glycol),	facteurs	de	croissances,	clivage	
protéolytique,	 différentiation	 cellulaire,	 positionnement	 de	 protéines,	 protéine	 morphogénétique	 osseuse-2,	
ephrines,	netrines	
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Chapter	1 Introduction	
	
	
1.1 Tissue	engineering	
Tissue	engineering	is	an	interdisciplinary	engineering	field,	which	aims	to	provide	adequate	and	functional	
substitutes	for	tissues	and	organs.	One	of	the	great	expectations	from	this	field	is	the	ability	to	respond	to	the	current	
limitations	 in	 organ	 transplantation,	 due	 to	 the	 shortage	 of	 organ	 donors,	 the	 occurrence	 of	 immunological	
incompatibility	 and	 the	 required	 long-term	 use	 of	 immunosuppressive	 drugs.[1-3]	 A	 further	 aspect	 of	 developing	
engineered	tissues	is	the	providing	of	suitable	 in	vitro	tissue	or	organ	models.	These	models	would	provide	valuable	
and	more	precise	information	than	current	2D	cell	culture	models,	allowing	better	understanding	of	tissue	functions,	
diseases	and	more	accurate	assessment	of	new	treatments	and	drugs.[3]	
	
1.1.1 Engineered	tissues	for	transplantation	
In	 recent	years,	 technological	advances	have	allowed	breakthrough	progress	 in	 tissue	engineering.	Many	efforts	
made	 in	 the	 development	 of	 novel	 manufacturing	 techniques,	 new	 biomaterials	 and	 better	 understanding	 of	
biological	 and	 cellular	 processes	 have	 shown	 that	 tissue	 engineering	 could	 meet	 the	 demands	 of	 organ	
transplantation,	 as	 well	 as	 answer	 some	 of	 its	 limitations.[4]	 Indeed,	 bioengineered	 organs	 such	 as	 the	 bladder[5],	
trachea[6],	urethra[7]	or	pulmonary	artery[8]	have	already	been	successfully	transplanted	into	human	patients.	Yet,	one	
of	the	many	challenges	remains	in	the	ability	to	recreate	the	complexity	of	certain	tissues	and	organs.	As	the	previous	
examples	 of	 successfully	 transplanted	 engineered	 tissues	 show,	 flat,	 tubular	 and	 hollow	 structures	 can	 already	 be	
assembled	 in	a	satisfying	and	functional	manner.	But	organs	such	as	the	 liver,	 the	heart	or	 the	kidney	have	a	much	
higher	complexity,	which	is	why	the	regeneration	of	such	tissues	is	usually	a	more	difficult	task.	Recapitulation	of	such	
complex	architectures	requires	technologies	that	are	able	to	combine	multiple	cell	types,	gradients	or	localized	supply	
of	growth	factors,	vascularization,	as	well	as	3D	structural	arrangements,	but	they	must	also	be	compatible	with	high-
throughput	manufacturing.	To	this	end,	employed	strategies	often	involve	the	use	of	either	acellular	matrices,	which	
will	necessitate	new	tissue	growth	from	the	host,	or	matrices	that	contain	cells	originating	from	a	donor	tissue,	which	
can	 be	 of	 autogeneic,	 allogeneic	 or	 xenogeneic	 source.[1]	 In	 both	 cases,	 the	 presence	 of	 a	 structural	 and	 biological	
environment	that	closely	mimics	the	properties	of	the	native	organs	is	of	utmost	importance	in	order	to	support	and	
direct	the	cells	for	tissue	formation.	Options	to	provide	this	environment	encompass	two	main	strategies:	(1)	organs	
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from	allogeneic	or	xenogeneic	origin	can	be	completely	decellularized,	 leaving	only	 the	extracellular	matrix	and	 the	
vascular	architecture	behind,	ready	to	be	repopulated	by	autologous	cells,	or	(2)	synthetic	scaffolds	can	be	created	to	
mimic	 the	 mechanical,	 biological	 and	 architectural	 properties	 of	 the	 extracellular	 matrix	 in	 order	 to	 provide	 the	
necessary	 cell	 support.[9,	 10]	 In	 both	 strategies,	 the	 extracellular	 matrix	 plays	 an	 important	 role	 and	 in	 order	 to	
recapitulate	 it,	 engineered	 scaffolds	 must	 be	 dynamic	 and	 hierarchically	 organized,	 but	 also	 provide	 the	 required	
growth	factors	and	cues	to	regulate	cellular	functions.	
	
1.1.2 In	vitro	tissue-engineered	3D	models	
Although	two-dimensional	cell	culture	models	are	still	commonly	used	 in	research	and	provide	a	vast	amount	of	
knowledge	 on	 various	 cell	 and	 tissue	 functions,	 it	 has	 become	 clear	 in	 the	 last	 two	 decades	 that	 the	 cellular	
microenvironment	 has	 an	 important	 influence	 on	 the	 properties,	 functions	 and	 behavior	 of	 cells	 and	 tissues.[11,	 12]	
Thus,	 the	 transition	 to	 3D	 cell	 culture	models	 is	 an	 important	 step	 in	 the	 development	 of	 physiologically	 relevant	
tissue	models.	 In	addition	to	gaining	better	 insights	on	normal	 tissue	 functions,	3D	tissue	models	also	contribute	to	
the	development	of	better	injury	or	disease	modeling	strategies	and	drug	screening	platforms.	And	in	some	cases,	the	
availability	 of	 relevant	 3D	 tissue	models	 could	 reduce	 the	use	of	 animal	models	 by	providing	high-throughput,	 less	
expensive,	and	more	tightly	controlled	systems.	
In	 order	 for	 such	 3D	 tissue	models	 to	 be	 successful,	 the	natural	 cellular	microenvironment	has	 to	 be	mimicked	
closely.	Complex	cell-cell	and	cell-extracellular	matrix	 interactions,	mechanical	 forces,	as	well	as	the	presentation	of	
signaling	 factors	 thus	 need	 to	 be	 recapitulated	 in	 vitro.	 But	 despite	 what	 could	 seem	 a	 difficult	 task,	 several	
engineered	3D	tissue	models	have	been	created	and	used	to	reproduce	biological	functions	or	study	diseases	in	vitro.	
Examples	include	engineered	cardiac[13],	liver[14,	15],	kidney[16]	and	bone	tissues[17,	18],	as	well	as	cancer	models[19,	20].		
Bone	 tissue	 engineering	 is	 of	 particular	 interest,	 since	 in	 the	 following	 chapters	 of	 this	 thesis,	 osteogenic	
differentiation	has	been	used	as	a	model	to	evaluate	our	new	tissue	engineering	strategies.	Bone	tissue	can	be	divided	
into	two	types	of	structures:	(1)	trabecular	bone,	which	is	porous	and	provides	support	for	the	bone	marrow,	and	(2)	
cortical	bone,	which	is	the	compact	bone	that	surrounds	the	marrow	region	and	provides	mechanical	strength.	Both	
types	of	bone	are	subject	to	maturation,	differentiation	and	resorption	via	cellular	 interactions	involving	osteocytes,	
osteoblasts,	 osteoclasts	 and	 their	 extracellular	 matrix.[21]	 Healthy	 bone	 is	 maintained	 via	 remodeling,	 where	
osteoblasts	are	mainly	responsible	 for	new	bone	formation,	and	osteoclasts	resorb	old	bone	tissue.	The	outer	 layer	
covering	 the	 surface	 of	 cortical	 bone	 is	 known	 as	 the	 periosteum	 and	 contains	 mainly	 blood	 vessels	 as	 well	 as	
osteoblasts	and	progenitor	cells	activated	during	bone	repair.	Although	bone	has	regenerative	properties,	large	bone	
defects	cannot	be	fully	healed	by	the	body	and	require	external	intervention,	often	in	the	form	of	bone	grafts.	Bone	
tissue	engineering	has	thus	become	popular	and	many	advances	have	been	made,	especially	regarding	cell	sources,	
scaffold	design	and	identification	of	key	growth	factors	that	regulate	bone	formation	and	vascularization.[21-23]	Better	
understanding	of	the	bone	extracellular	matrix	and	its	remodeling	has	especially	contributed	to	the	development	of	
new	 scaffold	 biomaterials.	 Bone	 matrix	 is	 highly	 mineralized	 with	 calcium	 and	 phosphate	 in	 the	 form	 of	
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hydroxyapatite	 crystals	 distributed	 across	 the	 collagen	 fibers,	 which	 confer	 mechanical	 strength	 and	 resistance	 to	
impact.[21]	Thus,	ideal	scaffolds	for	bone	tissue	engineering	have	to	provide	a	certain	rigidity	for	the	support	of	cells,	as	
well	as	being	porous	and	having	osteoinductive	properties.	
Regardless	 of	 the	 type	 of	 tissue,	 it	 becomes	 evident	 that	 the	 extracellular	 matrix	 plays	 a	 crucial	 role	 in	 the	
maintenance	 of	 healthy	 tissue.	 Understanding	 its	 functions	 and	 interactions	 with	 cells	 and	 signaling	 factors	 is	
therefore	an	important	key	factor	in	the	establishment	of	tissue-engineered	constructs.		
	
1.2 The	extracellular	matrix	
The	extracellular	matrix	 (ECM)	 is	 the	 scaffold	 that	 surrounds	 and	 supports	 cells	 in	 living	 tissues,	 but	 also	
influences	 their	 behavior	 via	 physical	 and	 chemical	 mechanisms	 (Figure	 1.1).	 Distinction	 is	 made	 between	 the	
interstitial	 connective	 tissue	 matrix,	 which	 surrounds	 cells	 and	 provides	 support	 to	 tissues	 in	 general,	 and	 the	
basement	membrane,	which	is	a	specialized	type	of	ECM	that	separates	epithelium	from	stroma	and	is	usually	more	
compact	than	the	interstitial	matrix.[24]		
The	 cells	 within	 each	 tissue	 regulate	 the	 establishment	 and	 maintenance	 of	 the	 ECM.	 Its	 composition	 and	
remodeling	 rely	 on	 tightly	 controlled	 processes	 and	 are	 essential	 during	 development,	 wound	 healing	 and	 normal	
tissue	 homeostasis.[25]	 The	 main	 components	 of	 the	 ECM	 are	 collagens,	 elastin,	 fibrin,	 laminins,	 fibronectin,	 and	
proteoglycans	(some	of	which	are	highlighted	in	the	following	section)	and	the	overall	composition	varies	according	to	
each	type	of	tissue	and	can	be	influenced	by	binding	and	releasing	of	growth	factors.[24,	26]		
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Figure	1.1.	Functions	of	the	ECM.	
The	ECM	provides	structural	support	to	cells,	but	it	also	actively	interacts	with	them.	The	ECM	can	thus	participate	in	the	regulation	
of	cell	activity,	which	in	return	can	regulate	ECM	homeostasis.1	
	
1.2.1 Main	components	of	the	ECM	
Collagens	are	one	of	the	most	abundant	proteins	of	the	ECM	and	are	predominantly	synthesized	by	fibroblasts,	but	
in	some	cases	also	by	epithelial	cells.	They	are	secreted	by	cells	as	procollagens,	which	have	extra	domains	that	need	
to	be	cleaved	outside	 the	cells	by	 specific	proteinases	before	being	able	 to	assemble	 into	collagen	 fibrils,	 and	 then	
fibers.	Organization	and	alignment	of	collagens	can	be	influenced	by	matrix	tension	exerted	by	fibroblasts.	Together	
collagen	type	I,	II	and	III	constitute	around	90%	of	all	collagens	in	the	body	and	are	very	common	in	connective	tissue.	
The	basement	membrane	usually	contains	collagen	type	IV.[27,	28]		
Elastin	is	another	ECM	protein,	which	often	associates	with	collagens.	Elastin	is	mainly	responsible	for	the	elastic	
properties	of	tissues	such	as	arteries,	skin	and	tendons.	Elastin	is	secreted	by	various	cells	as	a	precursor	that	forms	
into	 elastic	 fibers	 by	 associating	 with	 other	 ECM	 components.	 Together,	 the	 balance	 between	 elastic	 fibers	 and	
collagen	fibers	determine	the	mechanical	properties	of	the	ECM.	[27-29]		
																																																																										
1	Adapted	from:	D	Hubmacher	and	S	Apte,	The	biology	of	the	extracellular	matrix:	novel	insights,	Curr	Opin	Rheumatol,	2013	Jan,	
25(1):	65–70.	
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Cellular	fibronectin	is	another	type	of	fibrous	ECM	protein	and	is	secreted	by	many	cell	types	including	fibroblasts,	
endothelial	cells	and	chondrocytes.	It	helps	organize	the	ECM	by	binding	to	other	ECM	components	and	offering	cell-
binding	sites,	mostly	via	the	Arg-Gly-Asp	(RGD)	motif	that	interacts	with	cell-surface	integrins.[27,	28,	30]		
Proteoglycans	 are	 another	 important	 component	 of	 the	 ECM	 and	 are	 composed	 of	 glycosaminoglycans	 chains	
covalently	attached	to	a	core	protein	(except	for	hyaluronic	acid).	They	are	hydrophilic	and	contribute	in	the	hydrogel-
like	nature	of	 the	ECM	and	 its	 resistance	 to	high	 compressive	 forces.	 In	 addition	 to	 interacting	 to	both	 cell-surface	
receptors	and	other	ECM	components,	proteoglycans	can	also	bind	to	a	variety	of	growth	factors,	thus	sequestering	
them	to	specific	parts	of	the	ECM.[27,	29]	
	
1.2.2 Cell-ECM	interactions	and	remodeling	
The	 ECM	 provides	 a	 structural	 support	 and	 a	 dynamic	 microenvironment	 for	 the	 cells,	 by	 presenting	 various	
tethered	or	soluble	signaling	cues	such	as	growth	factors	to	guide	cellular	process	(e.g.	morphogenesis,	proliferation,	
differentiation,	migration).	Furthermore,	many	sequences	of	the	ECM	can	be	recognized	by	cell-surface	receptors	such	
as	integrins.	Integrins	are	transmembrane	receptors	that	bind	among	other	target	sequences	to	the	RGD	motif,	which	
was	first	discovered	in	fibronectin	but	is	also	present	in	various	other	ECM	components.	They	are	the	main	receptors	
involved	in	the	formation	of	focal	adhesions	and	are	essential	for	cell	migration,	due	to	their	interaction	with	the	actin	
cytoskeleton.[31,	32]	Integrins	are	thus	important	for	cell	attachment	to	the	ECM,	but	can	also	trigger	signaling	cascades	
leading	 to	 gene	 expression	 with	 varying	 outcomes	 involved	 in	 cell	 survival,	 apoptosis,	 growth	 or	 receptor	
phosphorylation,	depending	on	ECM	composition.[33]		
In	addition	 to	 influencing	cells,	 the	ECM	 is	also	highly	 responsive	 to	cell	behavior.	 Indeed	 the	ECM	 is	 constantly	
being	remodeled	by	the	cells	through	proteolytic	degradation	and	by	deposition	of	new	ECM	components,	which	 in	
turn	can	again	have	an	effect	on	cell	behavior.	This	means	 that	 the	cells	and	 their	 surrounding	ECM	are	constantly	
influencing	each	other	in	a	reciprocal	manner.[33,	34]			
	ECM	 remodeling	 happens	 throughout	 cellular	 processes	 such	 as	 development,	 healing	 or	 homeostasis	 and	 is	 a	
tightly	 controlled	 feature	 of	 the	 ECM.	 In	 order	 to	 be	 proteolytically	 degraded,	 most	 proteins	 composing	 the	 ECM	
possess	 cleavage	 sites	 for	 enzymes	 secreted	 by	 the	 cells,	 such	 as	 matrix-metalloproteinases	 (MMPs),	 plasmin	 or	
cathepsin.[34]	MMPs	are	on	 the	major	 type	of	 enzymes	 involved	 in	matrix	 degradation.	 They	 are	 zinc-	 and	 calcium-
dependent	endopeptidases	 that	 take	part	 in	 the	digestion	of	 collagens,	proteoglycans,	and	other	glycoproteins	and	
can	be	distributed	into	five	families	according	to	their	substrate	specificity.	Amongst	them	are	collagenases	(MMP-1	
and	MMP-8),	which	principally	 degrade	 type	 I,	 II	 and	 III	 collagens,	 and	 gelatinases	 (MMP-2	 and	MMP-9,	which	 can	
digest	type	IV	and	VII	collagens.[35]	The	expression	and	activity	of	MMPs	is	regulated	at	different	levels	including	gene	
transcription,	proenzyme	activation	and	endogenous	inhibition.	One	example	of	such	inhibitors	are	tissue	inhibitors	of	
metalloproteinases	(TIMPs),	which	together	with	MMPs	play	a	very	important	role	in	maintaining	the	balance	of	the	
cellular	microenvironment.[34,	36,	37]		
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1.2.3 Role	of	the	ECM	in	would	healing	
The	 synthesis	 and	deposition	of	 the	ECM	components	 is	 also	a	 key	 factor	 in	 the	process	of	wound	healing.	 The	
repair	 of	 an	 injured	 tissue	 depends	 strongly	 on	 the	 interactions	 between	 platelets,	 cells	 (such	 as	 neutrophils,	
monocytes,	fibroblasts),	growth	factors	and	ECM.[38-40]	
First	 the	 ECM	 serves	 as	 structural	 support	 for	 repair	 processes	 in	 areas	 that	 have	 been	 injured,	 by	 providing	 a	
temporary	 matrix.	 For	 instance,	 platelets	 undergo	 adhesion	 and	 aggregation	 upon	 contact	 with	 collagen	 from	
damaged	blood	vessels.	This	is	the	start	of	a	cascade	of	events	that	include	activation	of	thrombin,	polymerization	of	
fibrinogen	 and	 lead	 to	 the	 formation	 of	 a	 blood	 clot,	 which	 will	 serve	 as	 a	 temporary	 matrix	 facilitating	 the	
interactions	between	signaling	cues	and	recruited	cells.[41-43]	
Then,	 the	 ECM	 also	 actively	 participates	 in	 signal	 transduction	 and	 actively	 regulates	 biological	 processes	 by	
facilitating	 cell	 adhesion	 and	 migration.	 The	 ECM	 regulates	 interaction	 among	 cells,	 between	 cells	 and	 ECM,	 and	
between	various	ECM	components.	 For	example,	during	 the	 inflammatory	phase	of	wound	healing,	monocytes	will	
migrate	from	blood	vessels	to	the	ECM	where	they	differentiate	into	macrophages	under	the	influence	of	fibrin	and	
fibronectin	fragments	originating	from	the	degradation	of	the	temporary	wound	matrix.	In	turn,	macrophages	secrete	
proteinases	that	will	degrade	the	ECM	but	release	factors	that	will	stimulate	the	synthesis	of	new	matrix.	Thus,	 the	
temporary	matrix	that	consists	mainly	of	fibrin	and	fibronectin	is	slowly	replaced	by	granulation	tissue,	composed	of	
collagen	 and	 enriched	with	 proteoglycans	 and	 other	 glycoproteins,	which	 contributes	 to	 the	 restoration	 of	 normal	
tissue	function.[38,	44,	45]	
In	the	final	phases	of	wound	healing,	the	granulation	tissue	is	replaced	by	scar	tissue.	This	involves	the	remodeling	
of	the	ECM,	where	both	the	composition	and	the	spatial	organization	are	rearranged	to	increase	the	tensile	strength.	
This	shows	that	the	ECM	plays	a	fundamental	role	in	tissue	repair	and	understanding	the	mechanisms	by	which	ECM	
components	influence	the	different	phases	of	wound	healing	can	be	an	important	advantage	for	the	development	of	
therapeutic	strategies.[43,	46,	47]	
	
All	these	aspects	show	that	the	ECM	provides	far	more	than	only	mechanical	and	structural	support.	Not	only	does	
it	 contribute	 to	establishing	a	 spatial	 context	 for	 signaling	events	between	cells,	 growth	 factors	and	other	 signaling	
molecules	and	proteins,	but	it	also	actively	participates	in	all	these	biological	processes,	including	wound	healing.	
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1.3 Growth	factors	interactions	with	the	ECM	
As	 mentioned	 previously,	 growth	 factors	 are	 important	 key	 players	 of	 the	 ECM.	 Indeed,	 many	 growth	
factors	can	bind	to	ECM	proteins	such	as	 fibronectin,	collagen	and	 	proteoglycans,	either	directly	or	 in	combination	
with	heparin	 and	heparan	 sulfate.[48,	 49]	Moreover,	 binding	of	 growth	 factors	 is	 often	 facilitated	by	 the	presence	of	
conserved	binding	motifs	present	in	the	sequence	of	ECM	proteins,	such	as	the	FN	III	12–14	repeats	in	fibronectin,[50]	
or	the	heparin-binding	domain	of	fibrinogen.[51]	This	creates	a	reservoir	of	growth	factors	that	can	be	either	bound	by	
cell-surface	 receptors	 directly	 in	 their	 tethered	 form	 or	 in	 their	 soluble	 form	 when	 the	 surrounding	 ECM	 is	
degraded.[52]	The	immobilization	to	the	ECM	also	has	for	effect	the	protection	and	stabilization	of	the	growth	factor	
active	conformation.	Thus	the	ECM	plays	an	essential	role	not	only	in	the	spatial	localization,	but	also	on	the	activity	
and	stability	of	the	growth	factors.[34,	53]	In	turn,	growth	factors	can	also	regulate	the	composition	of	the	ECM	by	either	
inducing	the	deposition	of	more	ECM	components	by	cells	or	by	stimulating	the	production	of	proteases,	which	break	
down	the	ECM.[32,	39,	52]	
Several	growth	factors	are	good	examples	of	the	indispensable	interactions	taking	place	in	the	ECM.	For	instance,	
basic	 fibroblast	 growth	 factor	 (FGF-2),	which	 can	 stimulate	 the	 growth	 of	 fibroblasts	 and	 endothelial	 cells,	 is	 often	
bound	by	heparan	sulfate,	a	glycosaminoglycan	present	in	the	ECM.	This	interaction	has	been	shown	to	participate	not	
only	in	the	preservation	of	the	growth	factor	bioactivity,	but	also	stabilizes	its	binding	to	the	FGF	receptor.[54,	55]	
Vascular	 endothelial	 growth	 factor	 (VEGF)	 is	 another	 example	 for	 growth	 factor-ECM	 binding	 and	 interactions.	
Amongst	the	most	abundant	 isoforms	of	this	growth	factor,	VEGF165,	VEGF189	and	VEGF206	contain	a	heparin-binding	
region,	whereas	VEGF121	 lacks	 this	binding	domain.	This	has	 for	consequence	that	VEGF121	produced	by	cells	can	be	
freely	released,	whereas	VEGF165,	VEGF189	and	VEGF206	are	partially	sequestered	by	the	ECM	due	to	their	affinity	for	
heparan	sulfate.	This	can	constitute	a	reservoir	of	growth	factor	that	will	be	slowly	released	over	time	by	heparanases	
or	can	be	released	more	rapidly	by	specific	proteases	such	as	plasmin.[56,	57]	Furthermore,	VEGF	also	strongly	interacts	
with	integrins,	which	are	cell-surface	receptors	that	allow	cells	to	attach	to	the	ECM.	Indeed,	crosstalk	between	VEGF	
receptors	 and	 integrins	 has	 been	 shown	 in	 research	 and	 is	 essential	 for	 VEGF-induced	 angiogenesis	 during	
development	and	during	wound	healing,	showing	that	cell	attachment	to	the	ECM	is	often	required	for	the	induction	
of	an	efficient	cell	response	to	growth	factors.[58,	59]	
Examples	 of	 growth	 factors	 that	 can	 influence	 the	 composition	 of	 the	 ECM	 are	 platelet-derived	 growth	 factor	
(PDGF)	 that	can	 induce	the	production	of	collagen,	and	transforming	growth	 factor	beta	 (TGF-β)	 that	also	 increases	
collagen	 production,	 as	well	 as	 fibronectin	 and	 hyaluronic	 acid	 in	 certain	 cell	 lines.[39,	 60,	 61]	 Additionally	 TGF-β	 also	
influences	the	ECM	composition	by	decreasing	the	production	of	proteases	and	increasing	the	production	of	protease	
inhibitors.[62]		
A	final	example	of	growth	factor,	which	interacts	strongly	with	the	ECM,	is	bone	morphogenetic	protein-2	(BMP-2),	
a	factor	mainly	known	for	its	role	in	bone	and	cartilage	formation.	Indeed	BMP-2	binding	to	ECM	components	such	as	
collagen	 is	 thought	 to	 preserve	 its	 bioactivity	 as	 well	 as	 enhance	 its	 interaction	 with	 BMP	 receptors.[32,	 63,	 64]	
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Furthermore,	BMP-2	has	also	been	shown	to	stimulate	collagen	and	proteoglycan	production,	and	plays	an	important	
role	cartilage	ECM	remodeling.[65]	
These	examples	of	growth	 factor-ECM	 interactions,	which	are	only	a	 few	amongst	others,	 clearly	 show	 that	 the	
ECM	represents	a	complex	system	and	all	these	properties	need	to	be	taken	into	consideration	when	trying	to	develop	
ECM-mimicking	platforms	for	tissue	engineering.	
	
1.4 Approaches	to	recreate	the	ECM		
As	previously	stated,	tissue	engineering	strategies	often	involve	combinations	of	biomaterial	scaffolds,	cells	
and	 signaling	molecules	 for	 the	 repair	 of	 damage	 tissues	 or	 the	 development	 of	 tissue	models.	With	 advances	 in	
biomaterial	science	and	increasing	understanding	of	the	natural	ECM,	scaffolds	are	constantly	evolving	and	improving	
at	 mimicking	 natural	 properties	 of	 the	 ECM.	 Some	 of	 the	 biomaterials	 used	 as	 scaffolds	 include	 naturally	 derived	
polymers,	such	as	collagen	or	hyaluronic	acid,	but	many	synthetic	materials	have	also	been	developed	to	be	able	to	
provide	an	environment	compatible	with	cell	growth.	The	key	advantage	of	using	naturally	occurring	materials	is	that	
they	 have	 the	 intrinsic	 ability	 to	 support	 cell	 attachment,	 proliferation	 and	 differentiation,	 in	 addition	 to	 being	
enzymatically	degradable.	But	due	to	their	nature,	there	is	often	a	great	variability	in	their	different	properties,	such	
as	 degradation	 kinetics	 or	 mechanical	 strength	 or	 batch-to-batch	 inconsistencies	 and	 sometimes	 immunogenic	
responses	 upon	 implantation.[9,	 66]	 As	 a	 result,	 many	 synthetic	 materials	 are	 continuously	 being	 developed	 and	
improved	in	order	to	recapitulate	structural	and	biological	functions	of	the	ECM,	while	increasing	biocompatibility	and	
control	 over	 material	 variability.	 Some	 important	 features	 that	 need	 to	 be	 considered	 for	 the	 development	 of	
synthetic	matrices	include	topography,	mechanical	strength	and	physiochemical	cues,	which	can	all	have	an	effect	on	
cell	 behavior,	 as	 well	 as	 the	 three-dimensionality	 of	 the	matrix,	 which	 has	 an	 effect	 on	 localization,	 diffusion	 and	
transport	of	signaling	cues	and	proteins.[66]	Amongst	the	various	material	strategies	that	have	evolved	to	answer	the	
need	 of	 biomaterial	 scaffold,	 hydrogels	 are	 an	 appealing	 solution	 due	 to	 their	 similarity	 to	 the	 ECM	 viscoelastic	
properties,	their	biocompatibility	and	ease	of	processing.	Furthermore,	many	cross-linking	methods	for	the	formation	
of	 such	hydrogel	 scaffolds,	 such	as	Michael-type	addition,	photopolymerization	or	enzymatic	 cross-linking,	 are	mild	
enough	processes	to	allow	the	viable	encapsulation	of	cells.[67]	
Although	 hydrogels	 can	 be	 composed	 of	 naturally	 occurring	 ECM	 components	 (such	 as	 collagen,	 fibrin	 or	
hyaluronic	 acid),	 many	 synthetic	 hydrogel	 strategies	 have	 emerged	 and	 evolved.	 Benefitting	 of	 important	
breakthroughs	in	polymer	chemistry,	3D	patterning	techniques	and	biomimetic	design,	hydrogels	based	on	synthetic	
polymers	have	become	highly	reproducible	and	allow	precise	tuning	of	mechanical	properties,	while	remaining	easy	to	
process	and	manufacture.[68,	69]	
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1.4.1 Poly(ethylene	glycol)	as	a	biopolymer	for	engineering	scaffolds	
An	example	of	 synthetic	biomaterial	used	 for	 the	 formation	of	hydrogels	 is	poly(ethylene	glycol)	 (PEG).	PEG	 is	a	
very	 important	polymer	 for	biomedical	 applications	because	 it	 is	 biocompatible,	non-immunogenic	 and	 resistant	 to	
protein	adsorption.[70,	71]	It	is	therefore	widely	used	for	surface	modification,	drug	delivery	and	tissue	engineering.	But	
because	PEG	is	biologically	inert,	it	has	to	be	modified	in	order	to	support	important	cellular	processes.	One	concept	
that	 has	 been	 explored	 to	 synthesize	 cell-compatible	 PEG	 hydrogels	 relies	 on	 the	 incorporation	 of	 ECM-derived	
peptides	into	the	PEG	scaffold	in	order	to	mimic	the	functions	of	the	natural	ECM.[72,	73]		
	
1.4.2 Enzymatically	cross-linked	PEG	hydrogel	platform	
	Amongst	the	variations	of	this	concept,	one	system	in	particular	utilizes	star-shaped	PEG	macromeres	containing	
MMP-sensitive	domains	 in	their	backbone	as	well	as	Factor	XIII	 (FXIII)	 transglutaminase	(TG)	substrate	sequences	to	
obtain	enzymatically	cross-linked	hydrogels,	in	which	bioactive	peptides	also	containing	FXIII	substrate	sequences	can	
be	 simultaneously	 incorporated	 (Figure	 1.2).[74,	 75]	 FXIII	 is	 the	 enzyme	 normally	 responsible	 for	 the	 cross-linking	 of	
fibrin,	therefore	the	incorporation	of	FXIII	substrate	sequences	in	the	backbone	of	this	PEG-based	hydrogel	platform	
allows	 for	 a	 site-specific	 coupling	 of	 the	 hydrogel	 components	 in	 presence	 of	 FXIII.	 Furthermore,	 the	 enzymatic	
reaction	 is	used	 for	 the	covalent	 incorporation	of	an	adhesion	 ligand	composed	of	 the	 fibronectin-derived	 integrin-
binding	 RGD	 motif.	 And	 because	 the	 PEG	 backbone	 contains	 a	 protease-sensitive	 sequence	 (degraded	 mostly	 by	
MMP-1	and	MMP-2,	but	also	collagenases	and	plasmin),[74,	 76]	 the	obtained	hydrogels	are	proteolytically	degradable	
and	 can	 thus	 be	 remodeled	 by	 cells.	 This	 platform,	 hereafter	 referred	 to	 as	 TG-PEG	 hydrogel	 platform,	 has	 been	
successfully	used	to	sustain	3D	culture	of	various	cell	types	in	vitro.[77-80]		
Furthermore,	these	hydrogel	scaffolds	are	also	highly	tunable	and	the	enzymatic	cross-linking	reaction	can	be	used	
to	 incorporated	 several	 bioactive	 molecules,	 especially	 growth	 factors.	 Indeed,	 growth	 factors	 can	 be	 indirectly	
immobilized	via	affinity	linkers	that	are	cross-linked	to	the	hydrogel	backbone.	One	such	linker	is	the	Gln-ZZ	linker	that	
consists	of	a	FXIII	substrate	sequence	(Gln)	followed	by	two	repeats	of	the	synthetic	protein	A	analogue	(Z).[81]	Due	to	
the	high	affinity	of	 the	ZZ	domain	 for	 the	 fragment	crystallizable	 (Fc)	 region	of	antibodies,	proteins	 that	have	been	
engineered	to	contain	an	Fc-tag	can	be	stably	immobilized	in	PEG	hydrogels,	while	remaining	biologically	active.	
Such	 tools	 represent	 an	 interesting	 approach	 on	 the	 development	 of	 ECM-mimicking	 scaffold	 for	 tissue	
engineering,	 because	 they	 allow	 for	 a	 great	 flexibility	 regarding	 the	 incorporation	 of	 growth	 factors	 and	 other	
bioactive	 signals.	 As	 such,	 they	 could	 be	 used	 to	 answer	 one	 of	 the	 current	 limitations	 of	 hydrogels,	 which	 is	 the	
absence	of	 spatiotemporal	 heterogeneity,	which	 is	 often	present	 in	 the	natural	 ECM	and	 important	 for	 certain	 cell	
interactions.	 Although	 many	 efforts	 still	 need	 to	 be	 made	 in	 regard	 of	 evolution	 and	 change	 of	 the	 cellular	
microenvironment	over	 time	 for	 the	design	ECM-mimicking	 scaffolds,	many	alternatives	already	exist	 regarding	 the	
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spatial	arrangement	and	structure	of	hydrogels.	Several	patterning	techniques	such	as	photopatterning	or	bio-printing	
have	been	developed	to	increase	control	over	the	three-dimensional	structure	and	localization	of	biological	cues.[66]		
Since	 the	 above	 described	 PEG-based	 hydrogel	 platform	 could	 be	 potentially	 compatible	 with	 bio-printing	
techniques[82],	 the	 development	 of	 various	 affinity	 linker	 is	 of	 great	 interest	 for	 the	 localized	 immobilization	 and	
release	 of	 growth	 factors	 in	 synthetic	 scaffolds.	 Different	 sets	 of	 linkers	 could	 be	 combined	 to	 assemble	modular	
microenvironment	and	allow	the	highly	controlled	 immobilization	of	biological	 factors,	but	each	 linker	could	also	be	
designed	in	order	to	have	cell-responsive	or	cell-specific	features.	
	
Figure	1.2.	TG-PEG	hydrogel	system.	
Two	 PEG	macromeres,	 possessing	 either	 a	 glutamine	 acceptor	 substrate	 (8-PEG-Gln)	 or	 a	matrix	 metalloproteinase-degradable	
lysine	donor	substrate	(8-PEG-MMPsensitive-Lys)	containing	MMP-sensitive	domains	in	their	backbone,	can	be	enzymatically	cross-
linked	 by	 activated	 Factor	 XIII	 (FXIII)	 transglutaminase	 (TG)	 to	 form	 hydrogels.	 The	 enzymatic	 reaction	 allows	 the	 simultaneous	
covalent	incorporation	of	an	RGD	motif	for	cell	adhesion	into	the	scaffold.	
	
1.5 Vascularization	and	tissue	engineering	models	
Another	 aspect	 of	 tissue	 engineering	 addressed	 in	 this	 thesis	 is	 the	 limitation	 due	 to	 the	 difficulty	 of	
obtaining	vascularized	constructs.	 Indeed,	appropriate	vascularization	is	necessary	to	provide	nutrient	perfusion	and	
mass	transport	across	tissues	and	thus	needs	to	be	replicated	in	engineered	constructs.	Vascularization	is	particularly	
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important	for	oxygen	transport	and	thus	for	cell	survival.	The	ability	of	oxygen	to	diffuse	across	a	tissue	is	a	key	factor	
that	will	limit	the	size	of	any	construct.	It	also	plays	an	important	role	for	the	spatial	integrity	of	the	constructs,	since	
unwanted	oxygen	gradients	can	potentially	produce	variation	in	cells	numbers	and	phenotypes.[83]	
Many	approaches	seek	to	establish	pre-vascularized	networks	in	the	constructs,	which	would	allow	anastomosis	to	
the	host	vasculature	upon	implantation.	Common	methods	include	the	modular	assembly	of	smaller	cellular	units	to	
created	vascular	networks	and	the	functionalization	of	scaffolds	with	angiogenic	factors.[83,	84]	To	that	purpose,	many	
different	 techniques	 for	 the	 immobilization	 of	 growth	 factors,	 such	 as	 the	 incorporation	 of	 growth	 factor	 binding	
domains	to	the	scaffolds,	creation	of	fusion	proteins,	or	the	simple	coating	or	loading	of	the	scaffolds,	can	be	used.	As	
with	many	tissue	engineering	approaches,	one	important	constraint	for	immobilization	of	such	molecules	is	that	their	
delivery	has	to	be	tightly	controlled	in	a	spatial	and	temporal	manner,	which	emphasizes	again	the	need	for	a	modular	
platform	for	the	incorporation	of	growth	factors.[85]	
	
1.5.1 Regulation	of	angiogenesis	
Angiogenesis	 is	 generally	 defined	 as	 the	 formation	 of	 new	 blood	 vessels	 from	 existing	 ones.	 It	 is	 an	 important	
biological	process	 that	 takes	places	 in	physiological	 conditions,	but	also	 in	 several	 types	of	diseases	such	as	cancer.	
Angiogenesis	 is	 a	 tightly	 orchestrated	 system	 that	 involves	 many	 signaling	 factors	 and	 depends	 on	 complex	
interactions	between	endothelial	cells	(ECs),	pericytes	and	other	surrounding	cells,	and	their	association	with	the	ECM	
via	 integrins,	and	also	with	 the	basement	membrane.[86]	Typically,	 the	cells	of	adult	mature	vasculature	remain	 in	a	
quiescent	state.	The	ECs	line	the	interior	of	blood	vessels	forming	tight	cell-cell	junctions	to	ensure	smooth	blood	flow,	
limit	vascular	leaks	and	minimize	blood	coagulation.	The	ECs	also	interact	with	the	underlying	lamina,	anchoring	the	
cells	to	the	basement	membrane.	Scattered	across	the	exterior	of	capillaries	and	venules	are	pericytes,	which	are	in	
contact	with	neighboring	ECs.	Interactions	between	pericytes	and	endothelial	cells	are	critical	for	the	stabilization	and	
support	of	 the	 capillary	 structures.	 This	 combination	of	 strong	 junctions,	 support,	 anchorage,	 and	 low	proliferation	
allows	 for	 the	 formation	 of	 very	 resistant	 mature	 vascular	 structure.	 However	 this	 state	 can	 be	 changed	 upon	
induction	 of	 angiogenesis,	 which	 can	 be	 prompted	 by	 a	 variety	 of	 angiogenic	 factors	 that	 include	 growth	 factors,	
polysaccharides	and	 lipids.	This	 is	mainly	a	 local	process	 that	occurs	 in	a	series	of	steps	starting	with	the	binding	of	
growth	 factors	 and	 cell	 signaling,	 followed	 by	 genetic	 and	 behavioral	 changes	 in	 vascular	 cells,	 leading	 to	 the	
remodeling	of	the	cellular	environment	and	invasion	of	newly	formed	blood	vessels,	and	finally	reaching	a	maturation	
stage,	where	cells	ultimately	return	to	a	quiescent	state.	At	each	of	 these	steps,	 interactions	between	cells	and	the	
ECM	are	important	in	determining	the	outcome	of	the	angiogenic	process.[87]	
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1.5.2 The	role	of	the	extracellular	matrix	in	angiogenesis	
The	ECM	plays	a	central	role	during	various	aspects	of	angiogenic	processes.	Indeed,	adhesion	of	ECs	to	the	ECM	
has	 been	 shown	 to	 be	 critical	 for	 the	 proper	 activation	 of	 angiogenic	 signaling	 pathways	 (e.g.	 via	 crosstalk	 with	
integrins),	as	well	as	having	an	anti-apoptotic	effect	on	ECs,[88,	89]	and	is	thus	necessary	to	enable	EC	proliferation.[90]	
Furthermore,	ECs	also	need	to	adhere	to	the	ECM	for	migration,	which	is	required	for	the	sprouting	and	formation	of	
new	blood	vessels.	Research	has	shown	evidences	that	although	EC	migration	is	mainly	initiated	by	signaling	factors,	
migration	 and	 morphogenesis	 later	 strongly	 depend	 on	 ECM	 configuration.[88,	 91]	 The	 ECM	 also	 allows	 cells	 to	
communicate	 over	 longer	 distances	 via	 tension.	 ECs	 can	 exert	 mechanical	 forces	 on	 the	 ECM,	 which	 can	 then	 be	
transduced	 to	 cells	 further	 away,	 thus	 creating	 a	 guidance	 pathway	 for	 the	 formation	 of	 higher	 architectures.[92]	
Angiogenesis	also	includes	the	degradation	and	remodeling	of	the	microenvironment	of	ECs	via	protease	like	MMPs.	
Upon	degradation	and	release,	 these	ECM	components	 themselves	such	as	collagens,	 fibronectins	and	 laminins	can	
regulate	and	guide	EC	migration	and	new	ECM	deposition.[93,	94]	Finally,	as	mentioned	in	Section	1.3,	the	ECM	provides	
a	reservoir	for	growth	factors	and	cytokines	and	thus	contributes	to	the	modulation	and	presentation	of	angiogenic	
growth	factors	in	order	to	regulate	the	formation	of	new	blood	vessels.[95]	
	
1.5.3 Angiogenic	growth	factors	
The	main	growth	factors	involved	in	angiogenesis	include	members	of	the	VEGF,	TGF,	PDGF	and	FGF	family,	as	well	
angiopoietins,	 tumor	necrosis	 factor-α	 (TNF-α),	and	 interleukins.[86]	The	work	of	this	thesis	 is	mainly	 focused	on	the	
pro-angiogenic	effects	of	VEGF,	as	well	as	subsidiary	factors	taking	part	in	angiogenesis,	namely	ephrins	and	their	Eph	
receptors,[86,	 96]	 and	 netrins,	 which	 have	 be	 shown	 to	 act	 during	 placental	 angiogenesis	 have	 also	 been	 used	 in	
therapeutic	angiogenesis.[97,	98]	
1.5.3.1 Vascular	endothelial	growth	factors	
VEGF-A	is	probably	the	most	studied	and	best	understood	member	of	the	VEGF	family.	VEGF-A	interacts	with	its	
corresponding	receptors,	VEGFR-1	and	VEGFR-2	(expressed	on	vascular	ECs),	as	well	as	neuropilin	receptors	NP-1	and	
NP-2	 (expressed	 on	 neurons	 but	 also	 by	 the	 vascular	 endothelium).	 It	 is	 widely	 described	 as	 an	 inducer	 of	 EC	
proliferation,	 sprouting	 and	 tube	 formation	 and	 can	 be	 linked	 to	 vasodilatation	 and	 vessel	 leakiness.	 Amongst	 its	
different	 isoforms,	 the	 heparin-binding	 VEGF165	 is	 the	most	 characterized	 and	 is	widely	 used	 in	 research	 to	 induce	
angiogenesis.[99-101]	
1.5.3.2 Ephrins	and	Eph	receptors	
Ephrin	 ligands	 and	 Eph	 receptors	 can	 be	 linked	 to	many	 biological	 processes,	 such	 as	 embryonic	 development,	
axonal	guidance,	or	carcinogenesis.	But	 in	the	past	years,	more	and	more	research	has	shown	that	ephrins	and	Eph	
receptors	play	an	essential	role	in	angiogenesis,	especially	regarding	the	guidance	of	cell	migration.	Eph	receptors	are	
a	unique	 family	of	 receptor	 tyrosine	kinases	 (RTKs)	 in	 that	 they	can	bind	cell	 surface-bound	 ligands	and	activate	bi-
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directional	signaling	pathways.	Interactions	between	ephrins	and	Eph	receptors	thus	necessitate	cell-cell	contact	and	
can	prompt	various	cellular	responses	including,	adhesion,	repulsion	or	boundary	formation.	It	is	also	recognized	that	
the	signaling	outcome	can	be	 influenced	by	 the	clustering	of	Eph	 receptor-ephrin.[102,	 103]	The	ephrin	 ligands	can	be	
attached	to	the	cell	membrane	through	either	a	GPI	anchor	or	a	transmembrane	domain	and	are	divided	accordingly	
in	classes	A	and	B	respectively.	The	receptors	are	distributed	into	EphA	and	EphB	classes	as	well,	depending	on	which	
type	of	ephrin	their	preferentially	bind.[104-106]	Amongst	the	various	ephrins	and	receptors,	ephrin-B2	and	EphB4	have	
attracted	 the	most	 interest.	 Expression	 of	 ephrin-B2	 is	 predominant	 in	 arterial	 ECs,	 whereas	 its	 receptor	 EphB4	 is	
mostly	specific	to	venous	ECs,	and	so	they	have	been	used	efficiently	as	specific	markers	of	arterial	or	venous	blood	
vessels.[96,	107]	
1.5.3.3 Netrin-4	
Netrins	are	a	family	of	proteins	related	to	laminins,	which	have	been	initially	identified	as	guidance	cues	for	axonal	
migration.	 Since	 then,	 netrins	 have	 been	 found	 to	 participate	 in	 many	 other	 biological	 processes,	 including	
angiogenesis.	Netrin-4	has	been	widely	studied	and	reported	to	bind	to	certain	integrins	and	laminins	and	to	regulate	
endothelial	cell	migration.	But	it	is	still	unclear	whether	it	has	pro-angiogenic	or	anti-angiogenic	role,	since	reports	in	
literature	tend	to	contain	opposing	conclusions.[108-110]	Nevertheless,	many	 in	vitro	 studies	have	shown	that	netrin-4	
can	 inhibit	 endothelial	 proliferation	 and	 tube-like	 formation,	 specifically	 for	 human	 vein	 endothelial	 cells	 (HUVECs)	
and	could	thus	be	an	interesting	anti-angiogenic	candidate.[97,	111-113]		
	
1.6 Motivation	and	objectives	
Considering	 the	all	 the	above-mentioned	aspects	of	 tissue	engineering,	 the	main	 focus	of	 this	 thesis	 is	 to	
develop	news	tools	for	the	recapitulation	of	the	ECM	and	the	microenvironment	of	cells.	In	order	to	do	so,	we	have	
based	our	strategy	on	the	pre-existing	TG-PEG	hydrogel	platform	described	earlier,	which	is	well	characterized	and	has	
been	used	to	cultivate	cells	successfully.	We	have	mainly	sought	to	understand	and	develop	new	ways	of	immobilizing	
growth	 factors,	 in	 a	 manner	 that	 resembles	 the	 interactions	 between	 cells,	 ECM	 and	 bound	 growth	 factors	 more	
closely.	As	we	already	possessed	the	protein	A-based	“Gln-ZZ”	 linker	able	to	bind	Fc-tagged	proteins,	we	wanted	to	
develop	additional	TG-PEG	compatible	 linkers	 in	order	to	have	 immobilization	possibilities	for	more	types	of	growth	
factors.	 Importantly,	 we	 wanted	 to	 develop	 tools	 that	 allowed	 flexibility	 regarding	 the	 selection	 of	 target	 growth	
factors.	 The	 streptavidin-biotin	 interaction	was	 thus	an	 ideal	 candidate	due	 to	 the	 strong	affinity	and	 the	 relatively	
easy	biotinylation	process	for	proteins.		
In	 Chapter	 2	 of	 this	 thesis,	 we	 synthesized	 and	 characterized	 a	 peptide	 linker	 that	 allows	 the	 versatile	
immobilization	 of	 biotinylated	 growth	 factors.	 The	 peptide	 is	 composed	 of	 a	 FXIII	 domain	 for	 the	 covalent	
incorporation	into	the	TG-PEG	hydrogel	backbone	and	of	a	streptavidin	domain	able	to	bind	biotinylated	proteins.	This	
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binding	 strategy	 was	 used	 efficiently	 to	 immobilize	 biotinylated	 BMP-2	 and	 induce	 the	 3D	 spatially	 controlled	
osteogenic	differentiation	in	mesenchymal	stem	cells,	which	to	our	knowledge	had	not	been	achieved	yet.	
In	 Chapter	 3	 we	 developed	 a	 degradable	 streptavidin-linker	 containing	 domains	 that	 can	 be	 cleaved	 by	 cell	
proteases	 in	 order	 to	 increase	 the	 release	 of	 the	 immobilized	 growth	 factor	 in	 a	 cell-dependant	 manner.	 By	
synthesizing	 a	 streptavidin	 linker	 containing	 MMP-sensitive	 sites,	 we	 were	 able	 to	 improve	 the	 dose-response	
relationship	of	the	immobilized	growth	factor.	
Another	aspect	of	tissue	engineering	was	studied	in	Chapter	4,	where	we	investigated	the	effects	of	netrin-4	and	
ephrins	on	blood	vessel	development.	The	objective	was	 to	evaluate	 these	growth	 factors	as	potential	 cues	 for	 the	
regulation	 of	 angiogenesis	 and	 thus	 as	 tools	 for	 the	 establishment	 of	 pre-vascular	 structures	 in	 TG-PEG	 tissue	
constructs.	This	was	achieved	by	studying	 the	effects	of	 the	selected	proteins	on	 the	developing	vasculature	of	 the	
chicken	allantoic	membrane.	Furthermore	we	investigated	the	effects	of	ephrins	on	endothelial	cell	migration.	
The	 overall	 work	 of	 this	 thesis	 thus	 presents	 new	 tools	 for	 the	 creation	 of	 tunable	 cellular	microenvironment.	
Chapter	5	summarizes	the	main	findings	and	discusses	future	directions	and	outlooks	of	this	research.	
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poly(ethylene	glycol)	matrices	for	the	controlled	3D-localized	osteogenic	differentiation	
of	mesenchymal	stem	cells,	Adv	Healthc	Mater,	2015	Mar	11;4(4):550-8	
	
	
2.1 Introduction	
Living	 tissues	 are	 composed	 of	 hierarchically	 organized	 three-dimensional	 (3D)	 cellular	 structures,	 which	
interact	with	and	are	supported	by	the	components	of	the	extracellular	matrix	 (ECM).	Tissue	formation	depends	on	
morphogenetic	 processes	 that	 are	 tightly	 regulated	 by	 the	 dynamic	 presentation	 of	 spatially	 confined	 soluble	 or	
immobilized	cell-instructive	cues.	These	tightly	orchestrated	signaling	events	are	only	partially	understood	and	cannot	
be	easily	recapitulated	in	vitro	due	to	technical	limitations.	However,	it	is	hypothesized	that	structured	3D	assembly	of	
tissue	progenitor	cells	within	cell-type	specific	cell-instructive	matrices	 is	sufficient	as	a	starting	point	to	 initiate	 late	
morphogenetic	processes,	 leading	 to	at	 least	partially	physiological	 relevant	 tissue	mimetics.[114]	 For	 the	creation	of	
such	 constructs,	 the	positioning	of	multiple	 cell	 types	 and	 the	 local	 immobilization	of	 biological	 cues	 in	 provisional	
ECM	with	 defined	 degradability,	 stiffness	 and	 adhesive	 properties	 is	 essential.	 Increasing	 precision	 for	 localized	 3D	
positioning	of	cells	and	biomaterials	 is	expected	to	coincide	with	ever	 improving	manufacturing	techniques,	such	as	
printing,	molding	or	microfluidics.[115-117]		
In	order	to	take	advantage	of	such	novel	techniques,	great	strides	have	been	made	towards	the	rational	design	of	
biomimetic	 matrices,	 which	 can	 be	 tuned	 towards	 specific	 applications	 and	 can	 even	 be	 locally	 and	 dynamically	
modified	in	a	user-defined	fashion.[118,	119]	The	binding	and	immobilization	of	various	bioactive	molecules	by	affinity	or	
covalent	 interactions	have	been	established.	These	strategies	based	on	chemical	or	genetic	engineering	 rely	on	 the	
incorporation	of	naturally	occurring	growth	factor-binding	sites	 (such	as	collagen,	 laminin,	 fibronectin,	heparin)	 into	
matrices,	 the	 fusion	 of	 growth	 factors	 to	 matrix-binding	 domains	 or	 enzyme	 recognition	 sequences,	 and	 the	
modification	of	matrices	and	growth	factors	with	the	respective	high-affinity	molecular	binding	partners	(dissociation	
constants	ranging	 from	10-7-10-15	M)	such	as	barnase-barstar,	streptavidin-biotin,	or	protein	A-Fc	 fragment.[81,	 120-125]	
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Although	 very	 elegant	 strategies	 for	 the	 antibiotic-,	 small	 molecule-,	 and	 light-controlled	 release	 or	 localized	
presentation	of	cell-instructive	signals	has	become	available,	 the	site-specific	3D	differentiation	of	 tissue	progenitor	
cells	 using	 therapeutically	 relevant	 growth	 factors	 has	 so	 far	 not	 been	 addressed.[126-128]	 Bone	 marrow-derived	
mesenchymal	 stem/progenitor	 cells	 (BM-MSCs)	 are	 a	 clinically	 relevant	 cell	 source,[129,	 130]	 which	 also	 due	 to	 their	
relatively	 good	 availability,	 their	 high	 proliferative	 potential,	 and	 their	 ability	 to	 readily	 differentiate	 towards	 the	
osteogenic	 lineage	 have	 been	widely	 used	 for	 the	 generation	 of	 tissue-engineered	 bone.	 BM-MSCs	 in	 combination	
with	 endothelial	 cells	 have	 recently	 been	 employed	 to	 generate	 transplantable	 vascularized	 constructs.[131]	
Additionally,	the	sequential	differentiation	of	MSCs	in	3D	porous	scaffolds	by	osteoinductive	medium	and	seeding	of	
endothelial	cells	has	been	described	to	enable	the	generation	of	pre-vascularized	constructs,	which	anastomose	with	
the	host	vasculature	and	form	mineralized	bone.[132]	Thus,	 the	3D	structured	assembly	of	BM-MSCs	and	endothelial	
cells	 (from	healthy	or	 diseased	 individuals)	 and	 the	 localized	osteogenic	 differentiation	of	 BM-MSCs	 in	 presence	of	
endothelial	cells	hold	great	promise	for	the	in	vitro	generation	of	bone	tissue	mimetics.	
We	 have	 previously	 described	 a	 fibrin-mimicking	 polyethylene	 glycol	 (PEG)-based	 hydrogel	 system	 (TG-PEG)	 for	
the	 modular	 and	 flexible	 design	 of	 biomimetic	 matrices.[75]	 In	 this	 system,	 8-arm	 star-shaped	 PEG	 precursors,	
possessing	either	a	glutamine	acceptor	substrate	(8-PEG-Gln)	or	a	matrix	metalloproteinase-degradable	lysine	donor	
substrate	(8-PEG-MMPsensitive-Lys),	are	cross-linked	by	the	thrombin-activated	transglutaminase	(TG)	Factor	XIII	(FXIIIa)	
to	form	hydrogels.	Noteworthy	is	that	any	peptide	or	protein	containing	either	substrate	sequence	can	be	added	on	
demand	 to	 the	 reaction	 mixture	 and	 will	 be	 covalently	 linked	 to	 the	 forming	 hydrogel.[74,	 75]	 When	 formulated	 in	
presence	of	Gln-RGD	and	with	adequate	mechanical	properties	(94	±	25	to	482	±	77	Pa)	these	hydrogels	were	shown	
to	 be	 excellent	 substrates	 for	 the	 3D	 culture	 of	 osteogenic	 cells	 in	 vitro.[133]	 By	 3D-positioning	 of	 osteogenic	
(osteoblasts	and	osteocytes)	and	endothelial	cells	within	such	hydrogels,	a	first	step	towards	the	formation	of	bone-
like	structures	could	be	achieved.[77]	However,	in	order	to	obtain	structured	and	fully	differentiated	bone	constructs	in	
vitro,	the	specific	provision	of	multiple	osteogenic	or	endothelial	cues	to	the	individual	bone	or	blood	vessel	forming	
cell	types	would	be	needed.	
As	 a	 stepping	 stone	 towards	 the	 in	 vitro	 formation	 of	 physiologically	 relevant	 bone	 constructs,	 consisting	 of	
multiple	 cell	 types	 such	 as	 differentiated	 osteoblasts	 and	 blood	 vessels,	 we	 here	 aimed	 at	 the	 localized	 3D	
differentiation	of	BM-MSCs	by	stable,	specific,	and	orthogonal	matrix-immobilization	of	bone	morphogenetic	protein-
2	(BMP-2).	BMP-2	is	one	of	the	most	potent	bone-inducing	factors	and	has	been	known	to	direct	the	differentiation	of	
MSCs	 towards	bone.[134]	Since	genetic	engineering	strategies	such	as	 fusion	with	an	Fc	domain	or	 the	Gln	sequence	
largely	 compromised	 BMP-2	 function	 and	 was	 not	 compatible	 with	 enzymatic	 immobilization	 (own	 unpublished	
observations)	 we	 established	 a	 streptavidin-biotin	 based	 strategy.	 Optimal	 conditions	 for	 the	 biotinylation	 of	
recombinant	 human	 BMP-2	 (rhBMP-2)	 without	 compromising	 its	 bioactivity	 were	 determined.	 A	 Gln-streptavidin	
linker	peptide	(consisting	of	a	FXIII-substrate	and	a	streptavidin	sequence)	that	is	covalently	integrated	in	the	forming	
TG-PEG	 hydrogels	 (Figure	 2.1A)	 was	 designed	 and	 recombinantly	 expressed.	 Streptavidin-modified	 hydrogels	 were	
shown	to	capture	biotinylated	proteins	and	present	them	in	an	active	form.	Finally,	3D	patterned	TG-PEG	hydrogels	
were	designed	 to	prove	 that	BMP-2	presenting	hydrogels	 can	promote	 the	osteogenic	differentiation	of	 the	C2C12	
myogenic	cell	line	and	human	BM-MSCs	within	locally	predefined	areas	(Figure	2.1B).		
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Figure	2.1.	Scheme	of	the	Gln-streptavidin	linker	incorporation	and	localized	differentiation	strategy.		
(A)	Streptavidin-modified	TG-PEG	hydrogels	are	 formed	by	 the	cross-linking	of	8-PEG-MMPsensitive-Lys	and	8-PEG-Gln	components	
via	FXIIIa	and	the	addition	of	Gln-streptavidin	linker	in	the	polymerization	reaction.	Biotinylated	proteins	can	be	either	immobilized	
during	hydrogel	 formation	or	 captured	 subsequently.	 (B)	Mesenchymal	 cells	 are	 cultured	 for	up	 to	9	days	 in	a	TG-PEG	hydrogel	
construct	with	rhBMP-2-biotin	locally	immobilized	in	the	center	via	Gln-streptavidin.	The	cells	exposed	to	the	immobilized	BMP-2	
environment	differentiate	towards	to	osteogenic	lineage.	
	
2.2 Results	and	Discussion	
2.2.1 Design	of	streptavidin/biotin-based	growth	factor-presenting	TG-PEG	hydrogels		
For	the	production	of	streptavidin-modified	hydrogels,	a	recombinant	peptide	consisting	of	the	glutamine	acceptor	
substrate	Gln	fused	to	the	N-terminus	of	monomeric	streptavidin	was	designed.	The	resulting	Gln-streptavidin	linker	
can	be	covalently	incorporated	in	FXIIIa-formed	TG-PEG	hydrogels	when	added	during	the	cross-linking	reaction.	The	
localized	 capturing	 of	 biotinylated	 growth	 factors	 due	 to	 the	 very	 strong	 binding	 affinity	 of	 biotin	 for	 streptavidin	
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(dissociation	constant	Kd	of	∼10-15	M)[135]	allows	their	efficient,	non-covalent	immobilization	to	streptavidin-modified	
PEG	 hydrogels	 and	 can	 be	 achieved	 both	 during	 and	 after	 gel	 formation.	 In	 contrast	 to	 naturally	 occurring	 and	
synthetic	biomaterials	functionalized	with	commercially	available	maleimide-streptavidin	[125,	136],	genetic	engineering	
and	 recombinant	 expression	 provides	 the	 possibility	 to	 further	 modify	 streptavidin-linkers	 such	 as	 to	 integrate	
proteolytic	cleavage	sites	for	the	tuning	of	growth	factor	release	properties.		
	
2.2.2 Production	and	characterization	of	streptavidin-modified	TG-PEG	hydrogels	
The	Gln-streptavidin	linker	was	expressed	in	high	yields	(20	mg·L-1	culture)	in	E.	coli	strain	BL21-Gold(DE3)	pLysS	
(Figure	 2.2A).	 It	 could	 be	 purified	 via	 biotin	 affinity	 chromatography,	which	 additionally	 allowed	 for	 a	 selection	 of	
functional	streptavidin	(Figure	2.2B).	The	FXIIIa-mediated	coupling	of	Gln-streptavidin	to	8-PEG-MMPsensitive-Lys	and	
the	preservation	of	the	biotin	binding	activity	after	the	PEGylation	reaction	were	confirmed	by	the	detection	of	a	high	
molecular	weight	PEGylated	Gln-streptavidin	on	a	Western	blot	using	a	biotinylated	antibody	(Figure	2.2C).		
	
	
	
Figure	2.2.	The	Gln-streptavidin	linker	was	produced,	purified	and	assessed	for	functionality.		
(A)	The	expression	of	Gln-streptavidin	in	E.	coli	BL21-Gold(DE3)	pLysS	was	assessed	at	different	time	points	after	IPTG	induction	by	
SDS-PAGE	 of	 bacterial	 lysate	 samples.	 (B)	 Presence	 of	 the	 expressed	 Gln-streptavidin	 was	 determined	 at	 various	 steps	 of	 the	
purification	 process	 through	 an	 iminobiotin	 agarose	 column	 by	 SDS-PAGE	 (FT:	 flow-through).	 (C)	 The	 functionality	 of	 the	 Gln-
streptavidin	 linker	was	evaluated	 for	 its	 TG-PEG	hydrogel	 compatibility.	Gln-streptavidin	was	 reacted	with	8-PEG-MMPsensitive-Lys	
with	or	without	FXIIIa	and	cross-linking	was	evaluated	by	SDS-PAGE	and	Western	blotting	(with	rat	IgG-biotin,	followed	by	anti-rat	
IgG-HRP).	The	white	arrow	 indicates	 the	non-cross-linked	Gln-streptavidin	and	 the	black	arrow	shows	the	high	molecular	weight	
Gln-streptavidin	that	is	cross-linked	to	8-PEG-MMPsensitive-Lys.	
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To	 show	 the	 ability	 of	 matrix-immobilized	 Gln-streptavidin	 to	 capture	 biotinylated	 proteins,	 hydrogels	 with	
increasing	amounts	of	Gln-streptavidin	linker	were	immersed	in	solutions	containing	biotinylated	alkaline	phosphatase	
(ALP-biotin).	The	amount	of	 remaining	ALP-biotin	 in	the	 immersion	solution	was	quantified	by	determination	of	 the	
ALP	activity	over	a	period	of	5	days.	Figure	2.3	shows	that	increasing	the	concentration	of	the	Gln-streptavidin	linker	
in	the	hydrogels	leads	to	both	an	accelerated	and	more	extensive	uptake	of	ALP-biotin	from	its	environment.	Whereas	
with	5	μM	Gln-streptavidin	the	enzymatic	activity	of	the	biotinylated	ALP	was	reduced	only	to	42.9	±	1.9%,	with	125	
μM	the	enzymatic	activity	had	decreased	to	7.6	±	2.4%	after	5	days.	Of	note,	most	of	the	protein	is	bound	after	the	
first	24	hours	and	equilibrium	is	almost	reached	after	48	hours	with	125	μM	Gln-streptavidin.	Based	on	these	results,	a	
Gln-streptavidin	concentration	of	100	µM	was	chosen	for	the	reliable	binding	of	biotinylated	proteins	in	all	following	
experiments.	
	
Figure	2.3.	Streptavidin-modified	hydrogels	capture	biotinylated	proteins.		
TG-PEG	 hydrogels	 containing	 0,	 5,	 25	 and	 125	 μM	 Gln-streptavidin	 were	 incubated	 in	 a	 solution	 containing	 ALP-biotin.	 The	
enzymatic	activity	of	ALP-biotin	in	the	solution	was	measured	after	1,	4,	8,	24,	48	and	120	hours	of	incubation	with	the	hydrogels	
via	SEAP	assay.	
	
	
2.2.3 Biotinylation	of	BMP-2	
Protein	engineering	not	only	is	a	labor-,	time-	and	cost-intensive	process,	but	is	also	associated	with	the	risk	of	loss	
of	 functionality	 and	 stability	 by	 the	 proteins	 upon	 modification.	 It	 is	 thus	 tempting	 to	 speculate	 that	 this	 holds	
especially	true	for	proteins	like	BMP-2,	which	in	their	native	form	can	only	be	stably	dissolved	at	higher	concentrations	
than	 200	 nM	 at	 a	 low	 pH	 or	 in	 presence	 of	 chaotropic	 agents.	 For	 such	 proteins,	 biotinylation	 by	 commercially	
available	 bi-functional	 chemical	 linkers	 can	 be	 readily	 applied	 in	 a	 broad	 range	 of	 buffer	 conditions,	which	 can	 be	
adjusted	 to	 the	 protein	 specific	 requirements,	 and	 is	 a	 straightforward	 alternative	 to	 modification	 by	 genetic	
engineering.	
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To	 generate	 fully	 functional	 rhBMP-2-biotin,	 commercially	 available	 amine-specific	 NHS-PEG4-Biotin	 was	
employed.	Since	the	solubility	of	rhBMP-2	is	relatively	 limited	at	physiological	pH,[137]	and	the	number	of	biotins	per	
BMP	molecule	is	inversely	related	to	its	biological	function,[138]	biotinylation	was	first	tested	at	different	molar	ratios,	
reaction	durations	and	pH	conditions.	As	expected,	the	degree	of	biotinylation	decreased	with	the	reduction	of	molar	
ratio	(NHS-PEG4-Biotin:protein),	time,	and	pH	(from	8.0	to	6.5)	as	determined	by	western	blot	analysis	(Figure	2.4A,	
C).	To	determine	the	influence	of	biotinylation	on	the	biological	activity,	preparations	of	the	above-generated	rhBMP-
2	with	variable	incubation	time	and	degree	of	biotinylation	(Figure	2.4B,	D)	were	employed	to	stimulate	immortalized	
murine	myoblastic	C2C12	cells.		
	
	
Figure	2.4.	The	rhBMP-2	biotinylation	degree	of	depends	on	pH,	time	and	molar	ratio	of	biotin	and	influences	its	biological	activity.		
(A,	 C)	 rhBMP-2	 was	 biotinylated	 at	 different	 incubation	 times	 or	 molar	 ratios	 of	 biotin	 reagent.	 Biotinylation	 was	 assessed	 by	
Western	 blotting.	 The	 black	 arrows	 indicate	 the	 bands	 representing	 rhBMP-2-biotin.	 A	 slight	 shift	 in	 molecular	 weight	 can	 be	
observed	depending	on	 the	degree	of	biotinylation.	 (B,	D)	The	biological	activity	of	 rhBMP-2	biotinylated	at	different	 incubation	
times	and	molar	ratios	of	biotin	was	assessed	on	C2C12	cells	with	the	ALP	activity	assay.		
	
These	cells	upon	stimulation	with	BMP-2	differentiate	 towards	 the	osteogenic	 lineage,	change	their	morphology	
from	spindle-shaped	to	a	cuboidal	morphology,	and	in	an	almost	linear	dose-response	curve	increase	the	expression	
of	alkaline	phosphatase	 [139],	making	 them	a	valuable	 tool	 to	quantify	 the	 fraction	of	 functional	BMP.	 In	agreement	
with	 previously	 published	 data	 by	 Hu	 et	 al.,[140]	 initial	 evaluations	 indicated	 that	 only	 a	 low	 degree	 of	 BMP-2	
biotinylation	was	compatible	with	a	high	residual	bioactivity,	whereas	higher	degrees	of	biotinylation	even	resulted	in	
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a	complete	 loss	of	bioactivity	(Figure	2.4D).	Thus,	final	biotinylation	of	BMP-2	was	performed	for	30	minutes	with	a	
1:2	molar	 excess	 of	 NHS-PEG4-Biotin	 at	 pH	 6	 and	 the	 obtained	 rhBMP-2-biotin	 retained	 almost	 98%	 of	 its	 original	
biological	activity,	and	was	thus	comparable	to	that	of	rhBMP-2	(Figure	2.5).	
The	level	of	biotinylation	as	quantified	ranged	between	3.7-3.9	moles	of	biotin	per	mole	of	dimeric	rhBMP-2.	Due	
to	the	lower	pKa	(7.6	to	8.0)	of	N-terminal	α-amines	than	the	one	of	α-amino	group	of	lysine	(10.0–10.2),[141]	it	can	be	
assumed	that	under	the	chosen	biotinylation	conditions	a	substantial	number	of	modifications	are	localized	to	the	N-
terminus.	 This	 is	 also	 consistent	with	 the	 achieved	high	 functionality	 of	 BMP-2-biotin	 and	 the	observed	number	 of	
modifications	(approximately	4	moles	of	biotins	per	mole	of	dimeric	BMP-2)	under	moderate	pH	(7.0)	conditions,	low	
molar	excess	of	NHS	(2-fold	over	BMP-2)	and	reaction	time	of	30	minutes.		
	
	
Figure	2.5.	The	biotinylation	process	was	optimized	for	maximal	functionality	of	rhBMP-2-biotin.		
C2C12	cells	were	stimulated	with	500	ng·mL-1	of	either	rhBMP-2	or	rhBMP-2-biotin	and	the	ALP	activity	was	measured	after	7	days	
in	culture.	(A)	C2C12	cells	exposed	to	rhBMP-2	or	rhBMP-2-biotin	assumed	a	cuboidal	morphology	compared	to	the	spindle-shaped	
control	 C2C12	 cells	 (scale	bar	 =	 250	μm).	 (B)	 Cells	 stimulated	with	 rhBMP-2-biotin	 showed	98%	of	ALP	enzymatic	 activity	when	
compared	to	the	enzymatic	activity	measured	with	rhBMP-2	stimulation.	
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2.2.4 Binding	and	release	of	rhBMP-2-biotin	from	Gln-streptavidin	hydrogels	
Next,	we	aimed	at	determining	whether	streptavidin-modified	hydrogels	could	specifically	capture	rhBMP-2-biotin	
and	whether	 the	 captured	 proteins	 remained	 bound	 to	 the	 gel	 over	 time.	 Therefore,	 20	 μL-sized	 TG-PEG	hydrogel	
discs	containing	0	or	100μM	Gln-streptavidin	were	immersed	in	200	μL	cell	culture	medium,	containing	250	ng·mL-1	
rhBMP-2-biotin	or	rhBMP-2.	BMP-2	ELISA	measurements	reveal	that	from	the	initial	amount	of	rhBMP-2-biotin	in	the	
immersion	solution	87.95%	were	captured	by	the	streptavidin-modified	hydrogel	(13.05	%	remained	in	solution)	and	
even	 by	 thorough	 washing	 steps	 were	 not	 released.	 In	 contrast,	 after	 incubation	 with	 streptavidin	 linker-free	
hydrogels	 84.19%	of	 the	 rhBMP-2-biotin	 remained	unbound	and	during	washing	 steps	most	of	 the	hydrogel-bound	
rhBMP-2-biotin	was	 released	 (Figure	 2.6).	 Together,	 these	 data	 show	 that	 streptavidin-modified	 TG-PEG	 hydrogels	
bind	rhBMP-2-biotin	with	high	specificity	while	streptavidin	linker-free	hydrogels	indicate	weak	unspecific	binding.		
	
	
Figure	2.6.	Uptake	and	release	of	rhBMP-2	from	streptavidin-modified	gels.		
Hydrogels	 containing	 0	 or	 100	 μM	 Gln-streptavidin	 linker	 were	 incubated	 in	 a	 250	 ng·mL-1	 solution	 of	 rhBMP-2-biotin	 at	 4°C	
overnight.	 (A)	 RhBMP-2-biotin	 remaining	 in	 solution	 was	 determined	 by	 ELISA.	 A	 reaction	 tube	 containing	 the	 rhBMP-2-biotin	
solution	but	no	hydrogel	 served	as	 a	 control.	 (B)	 The	 release	of	 rhBMP-2-biotin	 from	 the	 same	hydrogels	was	measured	over	 a	
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period	of	5	days	and	compared	to	the	BMP-2	release	from	streptavidin	linker-free	hydrogels	containing	soluble	rhBMP-2	or	rhBMP-
2-biotin.	The	concentration	of	released	BMP-2	was	determined	by	ELISA.	Data	are	presented	as	mean	±	SD	(n=3).	
	
	
2.2.5 Osteogenic	differentiation	of	C2C12	cells	on	hydrogels	with	immobilized	BMP-2	
The	 bioactivity	 of	 hydrogel-captured	 rhBMP-2-biotin	 was	 validated	 by	 differentiating	 C2C12	 cells	 on	 BMP-2-
presenting	hydrogels	towards	the	osteogenic	lineage	in	an	MSC-like	process.[139]	C2C12	cells	were	cultured	for	5	days	
on	 top	of	TG-PEG	hydrogels	 that	contained	250	ng·mL-1	 immobilized	 rhBMP-2-biotin	on	 the	surface,	or	 throughout	
the	 bulk	 of	 the	 material	 by	 incorporating	 the	 growth	 factor	 together	 with	 Gln-streptavidin	 directly	 in	 the	 gel.	
Alongside,	empty	hydrogels	(containing	no	Gln-streptavidin	 linker)	with	or	without	rhBMP-2-biotin	added	to	the	cell	
culture	 medium,	 and	 hydrogels	 with	 only	 the	 Gln-streptavidin	 linker	 were	 also	 formed	 as	 control	 conditions.	
Osteogenic	differentiation	in	response	to	matrix-mediated	BMP-2	presentation	was	assessed	by	colorimetric	staining	
of	ALP	expressing	cells	of	using	5-bromo-4-chloro-3-indolylphosphate	(BCIP)/nitro	blue	tetrazolium	(NBT).	
The	hydrogels	presenting	immobilized	rhBMP-2-biotin	contained	differentiated	cell	clusters,	which	stained	positive	
for	 ALP,	whereas	 such	 staining	was	 not	 observed	 in	 control	 conditions	 (Figure	 2.7).	 Enzymatic	 ALP	 activity	 of	 cells	
stimulated	with	 immobilized	 biotinylated	 rhBMP-2	was	 comparable	 to	 the	 one	 of	 cells	 stimulated	with	 the	 soluble	
growth	 factor	 (84%	 of	 the	 enzymatic	 activity).	 Furthermore,	 binding	 of	 rhBMP-2-biotin	 to	 the	 PEG	 hydrogels	 was	
confirmed	 to	be	a	 specific	 interaction	as	 seen	 in	 the	binding	and	 release	 study.	 Indeed,	 cells	 seeded	on	 the	empty	
hydrogel	that	had	been	incubated	with	rhBMP-2-biotin	were	not	stimulated,	indicating	that	the	growth	factor	can	be	
efficiently	washed	away.	Also,	the	cells	cultured	on	top	of	the	gels	containing	only	the	Gln-streptavidin	linker	did	not	
show	any	significant	sign	of	ALP	expression,	excluding	any	effect	due	to	the	linker	itself.	
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Figure	2.7.	Differentiation	of	C2C12	cells	on	streptavidin-modified	hydrogels.		
C2C12	cells	were	cultured	atop	PEG	hydrogels	with	or	without	 immobilized	rhBMP-2-biotin	for	7	days	and	then	assessed	for	ALP	
expression.	 The	 cells	were	 either	 stimulated	with	 soluble	 rhBMP-2	 in	 the	medium	 (B)	 or	 rhBMP-2-biotin	 bound	 to	 streptavidin-
modified	hydrogels	 (E).	Additionally,	cells	were	seeded	on	Gln-streptavidin	 linker-free	hydrogels,	which	had	been	 incubated	with	
rhBMP-2-biotin	and	then	washed	 (C),	as	well	as	on	hydrogels	containing	only	Gln-streptavidin	 (D).	Cells	 seeded	on	an	empty	gel	
served	as	control.	ALP	expression	was	evaluated	through	colorimetric	staining	with	the	BCIP/NBT	substrate	solution	and	with	ALP	
activity	assay.	Scale	bar	=	250;	data	are	presented	as	mean	±	SD	(n=6).	
	
2.2.6 Localized	3D	osteogenic	differentiation	of	mesenchymal	stem	cells	
The	ability	of	hydrogel-captured	rhBMP-2	to	specifically	and	locally	induce	the	differentiation	of	either	the	C2C12	
cell	 line	 or	 mesenchymal	 stem	 cells	 towards	 the	 osteogenic	 lineage	 was	 investigated	 by	 forming	 3D-structured	
hydrogels	which	contained	no,	soluble	or	matrix	immobilized	rhBMP-2-biotin.		
Localization	of	rhBMP-2	inside	TG-PEG	constructs	was	achieved	by	forming	a	small	5	μL	PEG	hydrogel	containing	
100	μM	Gln-streptavidin	and	5	μg·mL-1	rhBMP-2-biotin.	This	gel	(inner	gel)	was	then	embedded	in	a	bigger	20	μL	PEG	
gel	 (outer	gel)	 that	 contained	no	 linker	or	growth	 factor	 (Figure	2.1B).	Both	gels	 contained	equal	 concentrations	of	
C2C12	 cells,	 which	 were	 either	 incorporated	 as	 single	 cells	 or	 as	 cell	 spheroids.	 The	 importance	 of	 having	 bound	
growth	factors	was	assessed	with	hydrogel	constructs	containing	soluble	rhBMP-2-biotin	in	the	inner	hydrogel	without	
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Gln-streptavidin	linker	and	looking	at	the	cell	differentiation.	The	constructs	were	then	cultured	for	9	days,	so	that	the	
C2C12	 cells	 in	presence	of	 rhBMP-2-biotin	 could	differentiate	 towards	 the	osteogenic	 lineage.	As	 can	be	 seen	with	
BCIP/NBT	 staining	 (Figure	 2.8A),	 cells	 exposed	 to	 the	 unbound	 rhBMP-2	 showed	 only	 weak	 signs	 of	 ALP	 activity,	
whereas	the	cells	presented	with	the	bound	rhBMP-2	environment	expressed	significant	amounts	of	ALP.	In	addition,	
in	the	case	of	the	unbound	growth	factor,	cells	both	on	the	inner	gel	and	the	outer	gel	showed	a	very	weak	but	similar	
staining	for	ALP,	indicating	that	rhBMP-2	is	diffusing	out	of	the	inner	gel	to	the	rest	of	the	construct.	In	contrast,	when	
rhBMP-2-biotin	 is	 bound	 via	 Gln-streptavidin,	 a	 strong	 localization	 of	 the	 differentiation	 pattern	 can	 be	 observed.	
These	results	could	be	observed	in	the	case	of	single	cells	and	cell	spheroids.		
Immunostaining	 of	 the	 cell	 spheroids	 furthermore	 revealed	 that	 there	 was	 a	 clear	 boundary	 between	 the	
differentiated	 and	 non-differentiated	 cells.	 C2C12	 cells	 contained	 in	 the	 inner	 gel	 with	 the	 bound	 rhBMP-2-biotin	
expressed	ALP	throughout	the	bulk	of	the	gel,	whereas	the	cells	located	in	the	outer	gel	showed	no	staining	for	ALP	
with	exception	for	a	few	cells	located	very	close	to	the	inner	gel.	Regarding	the	single	cell	experiment,	the	fluorescent	
signal	after	 immunostaining	was	 too	 low	 to	detect	any	differences	between	 the	cells	 from	the	 inner	and	outer	gel,	
although	these	same	cells	showed	localized	differentiation	with	the	colorimetric	staining.	
Finally,	 BM-MSCs,	 which	 crucially	 contribute	 to	 the	 biological	 healing	 of	 bone	 and	 other	 tissues,	 were	 locally	
differentiated	 by	 matrix-immobilized	 BMP-2-biotin.	 When	 single	 dispersed	 BM-MSCs	 were	 encapsulated	 in	 the	
hydrogels	 containing	 immobilized	 BMP-2	 for	 up	 to	 9	 days,	 expression	 of	 ALP	was	 insufficient	 to	 be	 detected	with	
BCIP/NBT	 staining	or	 immunostaining	 (data	not	 shown).	However,	 a	 localized	 cell	 differentiation	 could	be	achieved	
successfully	with	BM-MSCs	spheroids.	As	shown	 in	Figure	2.8B,	a	strong	staining	showing	a	clear	 limit	between	the	
ALP	expressing	cells	in	the	BMP-2-presenting	areas	and	the	non-differentiated	cells	in	the	surrounding	areas	could	be	
seen.	
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Figure	2.8.	C2C12	cells	and	BM-MSCs	could	be	locally	differentiated	with	immobilized	rhBMP-2-biotin.		
PEG	 hydrogel	 constructs	 containing	 C2C12	 cells	 (A)	 and	 BM-MSCs	 (B)	 were	 cultured	 for	 9	 days	 in	 TG-PEG	 hydrogel	 constructs	
containing	 a	 central	 area	 presenting	 either	 no,	 soluble	 or	 immobilized	 rhBMP-2-biotin.	 ALP	 expression	 was	 assessed	 via	 the	
colorimetric	BCIP/NBT	substrate	staining	(upper	row,	scale	bar	=	2	mm).	The	expression	of	ALP	was	confirmed	by	immunostaining	
(lower	row,	blue:	nucleus,	green:	ALP,	scale	bar	=	200	μm,	xy	axis	in	the	main	panel,	xz	and	yz	in	the	side	panels).	
	
To	better	understand	the	disparity	between	the	ALP	staining	 in	BM-MSCs	as	single	cells	and	as	spheroids	and	to	
confirm	the	change	in	mRNA	expression,	an	early	osteogenic	marker,	Runt-related	transcription	factor	2	(Runx2)	and	
the	 later	osteogenic	marker	ALP[142]	were	assessed	by	quantitative	real-time	polymerase	chain	reaction	(Figure	2.9).	
Expression	levels	of	Runx2	in	BM-MSCs	after	9	days	of	culture	and	stimulation	with	various	concentrations	of	rhBMP-2	
were	 not	 significantly	 upregulated	 (Figure	 2.9A).	However,	 ALP	 expression	 levels	 correlated	with	 concentrations	 of	
soluble	 rhBMP-2	 (Figure	 2.9B).	 Expression	 levels	 of	 ALP	 in	 response	 to	 100	 ng·mL-1	 of	 soluble	 rhBMP-2	 were	
stimulated	 in	BM-MSCs,	which	were	 cultured	as	 single	dispersed	 cells	 (ca.	 36-fold)	 and	as	micro-tissues	 (ca.	 3-fold)	
(Figure	2.9C).	In	contrast,	for	equal	amounts	of	bound	rhBMP-2-biotin	ALP	expression	was	not	increased	in	single	cells,	
while	 it	 showed	 a	 significant	 expression	when	 cells	were	 seeded	 as	 spheroids	 (ca.	 6-fold),	 confirming	 our	 previous	
findings.	
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Figure	2.9.	mRNA	expression	of	two	standard	osteogenic	markers.		
BM-MSCs	 were	 seeded	 in	 TG-PEG	 hydrogels	 as	 single	 cells	 and	 stimulated	 with	 increasing	 concentrations	 of	 soluble	 rhBMP-2	
supplemented	to	the	culture	medium.	Expression	levels	of	mRNA	for	Runx2	(A)	and	ALP	(B)	were	measured	via	qPCR.	(C)	Expression	
levels	of	ALP	mRNA	were	 compared	between	BM-MSCs	present	 in	 the	hydrogels	as	 single	 cells	or	 spheroids	and	 in	presence	of	
soluble	rhBMP-2	or	rhBMP-2-biotin	bound	to	the	hydrogel	via	Gln-streptavidin.	
	
The	 tethering	of	growth	 factors	 to	 the	hydrogel	matrix	with	high	affinity	 (Kd	of	∼10-15	M)	 results	 in	a	 repository	
only	with	a	very	limited	release	of	the	payload	through	dissociation.	Thus,	the	availability	of	the	immobilized	growth	
factor	will	largely	depend	on	the	proteolytic	degradation	of	the	matrix	backbone	or	the	immobilization	linker.	This,	in	
turn,	will	be	the	result	of	the	cell	secreted	proteases	and	the	proteolytic	susceptibility	of	the	hydrogel	components.	As	
the	release	of	proteolytic	enzymes	in	the	vicinity	of	cell	clusters	is	expected	to	be	manifold	higher	than	in	the	vicinity	
of	single	dispersed	cells,	the	absence	of	ALP-activity	in	encapsulated	single	cells	indicates	limited	availability	of	BMP-2	
under	these	conditions.	Furthermore,	the	significant	increase	in	ALP	activity	in	micro-tissues	embedded	in	hydrogels	
containing	 bound	 BMP-2	 indicates	 that	 cells	 are	 mainly	 stimulated	 by	 released	 BMP-2.	 Thus,	 tuning	 the	 release	
properties	of	BMP-2	by	proteolytically	 sensitive	 streptavidin	 linker	peptides	could	be	a	mean	 to	control	 the	 release	
efficiency	and	consequently	tailor	the	differentiation	of	tissue	progenitor	cells.	
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Bi-functional	peptide	linkers	such	as	Gln-streptavidin	represent	an	elegant	way	for	the	development	of	biomimetic	
scaffolds.	In	combination	with	similar	linker	peptides	that	recognize	and	bind	different	tags	(such	previously	described	
Gln-ZZ	linker[81]	that	allows	the	immobilization	of	Fc-tagged	proteins),	the	controlled	immobilization	of	several	growth	
factors	 in	 distinct	 patterns	 becomes	 conceivable.	 This	 important	 feature	 is	 critical	 for	 the	 spatial	 control	 of	 cell	
behavior,	which	is	normally	regulated	by	the	ECM.		
	
2.3 Conclusion	
We	 investigated	 the	 use	 of	 modular	 designed,	 streptavidin-modified	 PEG	 hydrogels	 for	 the	 controlled	
presentation	of	rhBMP-2	and	the	consequent	3D-localized	differentiation	of	MSCs.	This	system	was	shown	to	be	an	
alternative	and	efficient	way	 to	deliver	bioactive	molecules,	which	 cannot	be	easily	produced	as	engineered	 fusion	
proteins.	As	 it	 is	compatible	with	other	modes	of	growth	factor	delivery	biotin/streptavidin	based	 immobilization	of	
rhBMP-2	will	provide	a	basis	for	the	creation	of	3D	multi-factorial	growth	factor	presentation	and	delivery	as	will	be	
needed	 for	 the	 generation	 of	more	 sophisticated	 tissue	mimetics	 in	 vitro.	 The	 advantage	 of	 growth	 factors,	which	
strongly	interact	with	the	matrix,	would	be	their	tightly	controlled	effect	on	differentiation	of	cells	in	confined	areas	
while	preventing	their	influence	on	other	cell	types	and	tissue	areas.	
Overall,	 this	PEG-based	BMP-2	delivery	 strategy	holds	great	promise	 to	become	a	printable	 ink	which	would	be	
needed	for	example	for	the	formation	(by	printing,	microfluidics	or	direct	molding)	of	distinct	osteogenic	areas	during	
the	in	vitro	creation	3D-bone-mimicking	tissues.		
Furthermore,	 this	 tool	 can	 be	 adapted	 for	 the	 controlled	 immobilization	 and	 tunable	 release	 of	 other	 growth	
factors	and	can	be	of	high	value	for	the	development	of	specific	cell-instructive	bio-inks,	which	will	ideally	be	designed	
to	mimic	ECM	properties	occurring	in	natural	microenvironments.	 In	future,	the	highly	 localized	assembly	of	various	
cell	 types	 in	 their	matched	 cell-instructive	matrices	 holds	 great	 promise	 for	 the	 fabrication	 of	 3D	 tissue	mimetics,	
which	recapitulate	histoarchitectures	of	native	tissues.	
	
2.4 Experimental	Section	
Cloning	of	the	Gln-streptavidin	linker:		
To	 construct	 plasmid	 pPL8	 (PT7-α2PI1–8-Strep),	 the	 streptavidin	 sequence	 from	 pWW801	 [143]	 was	 cloned	
(NheI/BamHI)	into	pPL19	[81],	resulting	in	an	expression	vector	for	the	Gln-streptavidin	linker	protein	under	control	of	
the	phage	T7	promoter.	
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Production	of	the	Gln-streptavidin	linker:		
Expression	and	purification	of	the	Gln-streptavidin	linker	protein	was	adapted	from	Humbert	et	al.	describing	the	
production	 of	 T7-Tag	mature	 streptavidin	 in	 E.	 coli	 [144].	 In	 brief,	 pPL8	was	 transformed	 into	 E.	 coli	 Bl21-Gold(DE3)	
pLysS	(Agilent	Technologies,	La	Jolla,	CA,	USA)	and	pre-cultures	were	grown	overnight	at	37°C	 in	200	ml	LB	medium	
(Scharlab,	 S.L.,	 Barcelona,	 ES)	 containing	 60	 μg·mL-1	 carbenicillin	 and	 34	 μg·mL-1	 chloramphenicol	 under	 orbital	
shaking	(230	RPM).	Main	cultures	of	1	L	LB	medium	containing	60	μg·mL-1	carbenicillin,	34	μg·mL-1	chloramphenicol	
and	0.4%	glucose	were	inoculated	to	OD600	=	0.1	and	grown	at	37°C	under	orbital	shaking	(230	RPM).	Expression	was	
induced	with	1	mM	IPTG	at	OD600	=	1.0	and	cells	were	harvested	three	hours	after	induction	by	centrifugation	(4’000	
RPM,	4°C,	10	min).	The	cell	pellet	was	 resuspended	 in	denaturing	buffer	 (15	mL	per	1	L	 initial	 culture	volume,	6	M	
guanidium	 hydrochloride	 pH	 1.5).	 Cell	 disruption	 was	 achieved	 by	 French	 press	 lysis	 (Thermo	 Fisher	 Scientific,	
Waltham,	MA,	USA)	at	15’000	psi	and	cell	debris	were	eliminated	by	centrifugation	(14’000	RPM,	4°C,	60	min).	The	cell	
lysate	was	dialyzed	(10’000	kDa	MWCO,	Thermo	Scientific,	Rockford,	IL,	USA)	against	denaturing	buffer	for	24	hours	at	
room	temperature,	renaturing	buffer	(20	mM	Tris-HCl	pH	7.4)	for	24	hours	at	room	temperature,	and	dialysis	against	
iminobiotin-binding	buffer	(50	mM	Na2Co3	0.5	M	NaCl	pH	9.8)	for	24	hours	at	4°C.	Protein	precipitates	were	removed	
by	centrifugation	(47’000	x	g,	30	min,	3°C)	 followed	by	filtration	using	a	0.45	μm	filter	and	a	0.22	μm	filter.	Protein	
solution	 was	 loaded	 onto	 a	 2-iminobiotin	 agarose	 column	 (I4507,	 Sigma-Aldrich,	 Switzerland)	 and	 washed	 with	
iminobiotin-binding	buffer	until	no	protein	could	be	detected	by	measuring	optical	density	at	280	nm	 in	 the	eluted	
fractions.	Bound	protein	was	eluted	with	5	column	volumes	elution	buffer	(0.1	M	acetic	acid	pH	2.9)	into	1.25	column	
volumes	neutralization	solution	(2	M	Tris-HCl	pH	7.4).	Pure	protein	was	dialyzed	against	storage	buffer	(50	mM	Tris-
HCl	pH	7.6)	for	24	hours	at	4°C	and	concentrated	by	ultrafiltration	(10	kDa	MWCO,	Millipore,	Carrigtwohill,	IE).	Protein	
was	 passed	 through	 a	 0.22	 μm	 syringe	 filter	 and	 stored	 at	 -80°C.	 Protein	 content	 was	 determined	 by	 A280	 nm	
measurements.	The	FXIIIa-mediated	coupling	of	Gln-streptavidin	to	8-PEG-MMPsensitive-Lys	was	verified	by	Western	
blotting	 of	 reaction	 mixtures	 of	 both	 components	 in	 presence	 or	 absence	 of	 FXIIIa.	 A	 rat	 anti-mouse	 IgG-biotin	
(eBioScience,	 Switzerland)	 followed	 by	 a	 goat	 anti-rat	 IgG-HRP	 (Life	 Technologies,	 Switzerland)	 were	 used	 for	
detection.	
Formation	of	hydrogels:		
TG-PEG	hydrogels	were	formed	by	FXIIIa	cross-linking	of	equimolar	blends	of	two	8-arm	PEG	macromeres	(8-PEG-
MMPsensitive-Lys	 and	 8-PEG-Gln)	 as	 previously	 described	 [74,	 75].	 Briefly,	 FXIII	 (200	 U·mL-1,	 Fibrogammin	 P,	 CSL	
Behring,	Switzerland)	was	activated	with	thrombin	(2	U·mL-1,	Sigma-Aldrich,	Switzerland)	for	30	minutes	at	37°C	and	
stored	 in	 small	 aliquots	 at	 -80°C.	 Stoichiometrically	 balanced	 solutions	 of	 8-PEG-Gln	 and	 8-PEG-MMPsensitive-Lys	
were	prepared	in	50	mM	Tris,	pH	7.6	buffer	containing	50	mM	calcium	chloride.	Precursor	solutions	for	hydrogels	with	
a	final	dry	mass	content	of	1.7,	2	or	5%	TG-PEG	were	prepared	leaving	a	spare	volume	of	12.5%	v/v	for	the	addition	of	
growth	 factors,	 RGD	 and	 linker	 peptides.	 The	 cross-linking	 reaction	 was	 initiated	 by	 addition	 of	 10	 U·mL-1	 FXIIIa	
followed	 by	 vigorous	 mixing.	 Disc-shaped	 matrices	 were	 obtained	 by	 sandwiching	 the	 liquid	 reaction	 mixtures	
between	sterile	hydrophobic	glass	microscope	slides	(treated	with	SigmaCote,	Sigma-Aldrich,	Switzerland)	separated	
by	1	mm	thick	spacers,	clamped	with	binder	clips	and	incubated	for	additional	30	minutes	at	37°C.	
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Binding	of	biotinylated	alkaline	phosphatase	to	the	Gln-streptavidin	linker:		
The	 Gln-streptavidin	 linker	was	 incorporated	 into	 20	 μL	 PEG	 (2%	w/v)	 hydrogels	 via	 FXIIIa	 cross-linking	 to	 final	
concentrations	of	0,	5,	25	and	125	μM.	The	polymerized	gels	were	then	incubated	in	Eppendorf	tubes	containing	500	
μL	of	Tris	Buffered	Saline	(TBS;	50	mM	Tris,	150	mM	NaCl,	pH	7.6)	and	left	on	a	shaker	at	4°C	overnight	to	wash	out	
any	 unbound	 linker.	 Gels	 were	 transferred	 to	 Eppendorf	 tubes	 containing	 5.5	 μg·mL-1	 biotinylated	 alkaline	
phosphatase	(ALP)	(Thermo	Scientific,	Switzerland)	in	500	μL	TBS	and	incubated	at	4°C	for	5	days.	Buffer	samples	of	20	
μL	were	taken	from	the	tubes	after	1,	4,	8,	24,	48	and	120	hours	and	the	remaining	content	of	biotinylated	ALP	was	
quantified	with	the	secreted	alkaline	phosphatase	(SEAP)	assay.	
SEAP	assay:		
For	each	sample,	1	µL	of	buffer	containing	biotinylated	ALP	was	diluted	 in	80	μL	TBS.	100	μL	of	assay	buffer	 (20	
mM	 L-homoarginine,	 1mM	 CaCl2,	 21%	 diethanolamine,	 pH	 9.8)	 were	mixed	 with	 20	 μL	 of	 120	mM	 p-nitrophenyl	
phosphate	 (diluted	 in	 assay	 buffer)	 and	 then	 added	 to	 80	 μL	 of	 diluted	 samples	 or	 TBS	 (blank)	 in	 a	 96-well	 plate.	
Absorbance	 was	 measure	 at	 405	 nm	 every	 minute	 for	 15	 minutes	 in	 a	 microplate	 reader	 (Synergy	 HT,	 Bio-Tek	
Instruments,	 Switzerland).	 The	 absorbance	 was	 plotted	 against	 time	 and	 slope	 of	 each	 curve	 was	 determined.	
Enzymatic	 activity	 was	 calculated	 by	 subtracting	 the	 slope	 value	 of	 the	 blank	 from	 all	 other	 slope	 values	 and	
multiplying	by	the	constant	256.8	(calculated	from	the	Beer-Lambert	law)	and	the	dilution	factor.	
Biotinylation	of	BMP-2:		
Dimeric	rhBMP-2	was	produced	as	previously	described	 [145].	RhBMP-2	was	biotinylated	using	EZ-Link	NHS-PEG4-
Biotin	 reagent	 (No	Weigh™	Format,	Thermo	Scientific,	Switzerland)	according	 to	 the	manufacturer’s	guidelines.	The	
reaction	was	 carried	 out	 in	 20	mM	HEPES,	 6M	 urea	 at	 pH	 7.2	with	 a	 2-fold	molar	 excess	 of	 biotin	 reagent	 for	 30	
minutes	on	 ice.	The	reaction	was	stopped	by	the	addition	of	the	same	volume	of	50mM	Tris,	pH	7.6	buffer.	Finally,	
rhBMP-2-biotin	was	dialyzed	 (Spectra/Por	3,	MWCO	3500,	Spectrum	Laboratories,	Germany)	against	20	mM	HEPES,	
6M	urea	at	pH	7.2	 for	2	days	at	4°C	 to	 remove	any	excess	un-reacted	biotin	 reagent.	Biotinylation	of	 rhBMP-2	was	
verified	 by	 Western	 blot.	 500	 ng	 of	 rhBMP-2	 and	 rh-BMP-2-biotin	 were	 separated	 on	 a	 15%	 SDS-PAGE	 gel	 and	
transferred	 to	 a	 nitrocellulose	 membrane	 (Protran®	 Nitrocellulose	 Transfer	 Membranes,	 Schleicher	 &	 Schuell,	
Germany).	The	membrane	was	incubated	with	1%	dry	milk,	0.1%	Triton	X-100	in	TBS	overnight	at	4°C.	After	washing	(3	
x	 5	minutes)	 in	 TBS,	 the	membrane	was	 incubated	 with	 anti-biotin-POD	 (Fab	 Fragments,	 Roche,	 Switzerland)	 at	 a	
1:200	dilution	 in	TBS	 for	1	hour	at	 room	temperature.	After	washing,	detection	was	performed	with	ECL™	Western	
Blotting	Detection	Reagents	(GE	Healthcare,	United	Kingdom).		
Quantification	of	the	biotinylation	was	performed	with	Pierce®	Biotin	Quantitation	Kit	(Thermo	Scientific,	Switzerland)	
using	 the	manufacturer’s	 protocol.	 Biotinylated	ALP	was	 used	 as	 a	 standard	 to	 determine	 the	 number	 of	moles	 of	
biotin	per	mole	of	rhBMP-2.	
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Uptake	and	release	of	rhBMP-2	from	Gln-streptavidin	hydrogels:		
For	 the	 uptake,	 20	 µL	 PEG	 hydrogels	 (5%	 w/v)	 were	 formed	 with	 0	 or	 100	 µM	 of	 Gln-streptavidin	 linker.	 The	
polymerized	gels	were	then	 incubated	 in	Eppendorf	 tubes	with	500	μL	TBS	and	 left	on	a	shaker	at	4°C	overnight	 to	
wash	out	any	unbound	linker.	Gels	were	then	transferred	to	Eppendorf	tubes	containing	200	µL	TBS	with	or	without	
rhBMP-2-biotin	at	250	ng·mL-1	and	incubated	on	a	shaker	at	4°C	overnight.	As	a	control,	an	Eppendorf	tube	with	200	
µL	TBS	containing	250	ng·mL-1	rhBMP-2-biotin	was	incubated	along	without	any	gel.	
For	 the	 release,	 the	 gels	 were	 retrieved	 and	 placed	 in	 an	 Eppendorf	 tube	 containing	 200	 µL	 Dulbecco’s	 modified	
Eagle’s	 medium	 (DMEM).	 Additionally,	 20	 µL	 PEG	 hydrogels	 (5%	w/v,	 streptavidin	 linker-free)	 containing	 50	 ng	 of	
either	rhBMP-2	or	rhBMP-2-biotin	were	formed	and	also	placed	in	Eppendorf	tubes	with	200	µL	DMEM.	The	medium	
was	then	collected	and	replaced	with	 fresh	medium	each	day	during	5	days.	The	concentration	of	 rhBMP-2	and	rh-
BMP-2-biotin	remaining	in	the	buffer	and	medium	was	quantified	via	ELISA.	
ELISA	of	BMP-2:		
ELISAs	were	performed	using	the	Human	BMP-2	ELISA	Development	Kit	(PeproTech,	United	Kingdom)	according	to	
the	 manufacturer’s	 guidelines.	 Samples	 and	 standard	 solutions	 were	 diluted	 in	 DMEM.	 The	 standard	 curve	 was	
established	with	the	rhBMP-2	that	was	used	for	all	other	experiments.	
Binding	of	biotinylated	BMP-2	to	Gln-streptavidin	hydrogels:	40	µL	PEG	hydrogels	(5%	w/v)	containing	50	μM	Lys-RGD	
were	formed	with	0	or	100	µM	of	Gln-streptavidin.	The	polymerized	gels	were	then	incubated	in	Eppendorf	tubes	with	
500	μL	TBS	and	left	on	a	shaker	at	4°C	overnight	to	wash	out	any	unbound	linker.	Gels	were	transferred	to	Eppendorf	
tubes	 containing	 500	 µL	 TBS	 with	 or	 without	 rhBMP-2-biotin	 at	 250	 ng·mL-1	 and	 incubated	 on	 a	 shaker	 at	 4°C	
overnight.	All	hydrogels	were	finally	washed	for	48	hours	in	DMEM	at	4°C	with	gentle	shaking.	
Cell	culture:		
All	cells	were	cultured	at	37°C	in	a	humidified	atmosphere	at	5%	CO2.		
Myoblastic	 mouse	 C2C12	 cells	 (ATCC®	 CRL-1772™)	 were	 maintained	 in	 DMEM	 supplemented	 with	 10%	 fetal	 calf	
serum	(FCS),	1%	penicillin-streptomycin	and	2mM	L-glutamine.	The	cells	were	trypsinized	and	passaged	every	2-3	days	
at	 70%	 confluence.	 For	 differentiation	 assays,	 cells	 were	 cultured	 in	 differentiation	 medium	 (Minimum	 Essential	
Medium	Alpha	(MEMα)	supplemented	with	10%	FCS,	1%	penicillin-streptomycin	and	50	μg·mL-1	L-ascorbic	acid).		
Bone	marrow-derived	mesenchymal	 stem	 cells	 (BM-MSCs)	 [146]	were	maintained	 in	MEMα	 supplemented	with	 10%	
FCS,	1%	penicillin-streptomycin	and	5	ng·mL-1	bFGF.	For	differentiation	assays,	 the	cells	were	cultured	 in	 the	 same	
medium	supplemented	with	50	μg·mL-1	L-ascorbic	acid.	
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Stimulation	of	C2C12	cells	with	rhBMP-2-biotin:		
For	comparing	the	biological	activity	of	rhBMP-2-biotin	to	rhBMP-2,	C2C12	cells	were	seeded	in	a	24-well	plate	at	a	
density	of	4⋅104	cells·cm-2	with	1	mL	per	well	of	differentiation	medium.	The	cells	were	stimulated	with	250	ng·mL-1	
of	either	rhBMP-2	or	rhBMP-2-biotin	for	5	days	and	then	processed	for	the	measurement	of	ALP	activity.	
For	immobilization	of	the	rhBMP-2,	PEG	hydrogels	containing	0	or	100	μM	Gln-streptavidin	were	formed.	They	were	
then	incubated	in	a	solution	of	250	ng·mL-1	rhBMP-2-biotin,	at	4°C	overnight.	Biotinylated	rhBMP-2	was	also	added	
directly	 in	 the	 hydrogel	 at	 concentration	 of	 250	 ng·mL-1,	 by	 incubating	 it	 first	with	 the	 linker	 for	 1	 hour	 and	 then	
adding	 it	 directly	 to	 the	 hydrogel	 precursor	 solution	 before	 the	 onset	 of	 gelation.	 For	 all	 conditions,	 the	 hydrogels	
were	washed	for	48	hours	in	DMEM	to	remove	any	unbound	protein.	The	PEG	gels	were	then	glued	on	the	bottom	of	
a	24-well	plate	and	C2C12	cells	were	seeded	on	top	of	the	gels	at	a	density	of	4⋅104	cells·cm-2.	As	a	positive	control,	
C2C12	 cells	 were	 seeded	 on	 top	 of	 empty	 PEG	 hydrogel	 (containing	 no	 linker),	 and	 their	 culture	 medium	 was	
supplemented	with	either	0	or	250	ng·mL-1	rhBMP-2.	The	cells	were	cultured	on	the	hydrogels	 for	5	days	and	then	
either	stained	with	an	ALP	staining	kit	or	lysed	and	further	processed	for	measurement	of	ALP	activity.	
Alkaline	phosphatase	colorimetric	staining	and	activity	assay:	
ALP	 staining	 was	 performed	 using	 SIGMAFAST™	 BCIP®/NBT	 tablets	 (Sigma-Aldrich,	 Switzerland).	 Medium	 was	
removed	from	the	wells	and	the	cells	were	washed	with	PBS.	To	each	well	500	μL	of	ALP	substrate	solution	at	dilutions	
recommended	by	the	manufacturer	was	added.	When	visually	sufficient	color	has	developed	in	positive	controls	(5-10	
minutes)	the	solution	was	replaced	with	PBS	in	all	conditions	and	cells	were	imaged	with	a	light	microscope.	
To	measure	ALP	activity,	the	medium	was	removed	from	the	wells	and	the	cells	were	washed	with	PBS.	For	each	well,	
cells	were	collected	in	500	μL	lysis	buffer	(0.56	M	2-amino-2-methyl-1-propanol,	0.2%	Triton	X-100,	pH	10	in	H2O)	and	
homogenized	 for	1	minute.	The	cell	 lysate	was	centrifuged	at	10'000	RPM	for	10	minutes	and	 the	supernatant	was	
collected.	ALP	reagent	(20	mM	4-nitrophenyl	phosphate	disodium	salt	hexahydrate,	4	mM	MgCl2	in	lysis	buffer)	was	
added	to	the	cell	lysates	in	a	96-well	plate	and	incubated	at	37°C	for	10-20	minutes	before	absorbance	was	measure	
at	410	nm	with	a	microplate	reader.	
Local	differentiation	of	cells	in	3D	and	immunostaining	of	ALP:		
Small	5	μL	PEG	gels	(1.7	%	w/v)	containing	50	μM	Lys-RGD	and	10	μM	Gln-Alexa	Fluor®	546	and	combinations	of	
either	0	or	100	μM	Gln-streptavidin	linker,	0	or	5	μg·mL-1	rhBMP-2	and	0	or	5	μg·mL-1	rhBMP-2-biotin	were	formed	
with	either	single	cells	at	the	concentration	of	0.2⋅106	cells·mL-1	or	cell	spheroids	at	500	cells/spheroid.	These	gels	
were	 then	embedded	 into	20	μL	PEG	gels	 (1.7%	w/v)	 containing	50	μM	Lys-RGD	and	cells,	 but	no	 linker	or	 growth	
factor.	 The	 gels	 were	 then	 glued	 to	 the	 bottom	 of	 a	 well	 plate	 and	 covered	 with	 the	 corresponding	 cell	 culture	
medium.	Medium	was	replaced	every	day	for	C2C12	cells	and	every	second	day	for	BM-MSCs	and	cells	were	cultured	
for	 up	 to	 9	 days.	 The	 constructs	 were	 then	 stained	 for	 alkaline	 phosphatase,	 followed	 by	 fixation	 in	 4%	
paraformaldehyde	for	20	minutes	and	immunostaining.	Cell	nuclei	were	stained	with	DAPI	and	presence	of	ALP	was	
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assessed	with	mouse	anti-bone	alkaline	phosphatase	primary	antibody	(Abcam,	United	Kingdom)	at	a	1:500	dilution	
and	goat	anti-mouse	IgG	H&L	(Alexa	Fluor®	488)	secondary	antibody	(Abcam,	United	Kingdom)	at	a	1:1000	dilution.	
RNA	isolation	and	quantitative	polymerase	chain	reaction	for	Runx2	and	ALP:		
BM-MSCs	were	 seeded	 in	10	µL	PEG	hydrogels	 (1.7%	w/v)	 containing	50	μM	Lys-RGD,	100	µM	Gln-streptavidin,	
with	 or	 without	 5	 µg·mL-1	 rhBMP-2-biotin,	 either	 as	 single	 cells	 (1⋅106	 cells·mL-1)	 or	 as	 spheroids	 (500	
cells/spheroid).	The	cells	were	cultured	with	either	0,	50,	100,	200,	400	ng·mL-1	soluble	rhBMP-2	 in	the	medium	or	
hydrogel-bound	 rhBMP-2-biotin	 for	 9	 days	 and	 then	 the	 hydrogels	were	 dissolved	with	 a	 2	mg·mL-1	 collagenase	A	
solution	 (Roche,	 Switzerland)	 for	 20	 minutes	 on	 ice.	 Total	 RNA	 was	 extracted	 using	 the	 RNeasy	 kit	 (Qiagen,	
Switzerland).	Reverse	transcriptions	were	performed	in	50	μL	reactions	using	Transcriptor	First	Strand	cDNA	Synthesis	
Kit	(Roche,	Switzerland).	Reactions	were	incubated	for	10	minutes	at	25°C,	followed	by	60	minutes	at	50°C	and	finally	
5	minutes	at	85°C.	After	cDNA	synthesis,	reactions	were	frozen	at	−80°C.	The	resultant	cDNA	was	subjected	to	real-
time	 PCR	 with	 the	 corresponding	 gene-specific	 primers	 (Qiagen,	 Switzerland)	 using	 FastStart	 SYBR	 Green	 Master	
(Roche,	Switzerland)	and	MyIQ	detection	system	(Bio-Rad)	according	to	the	manufacturer’s	instructions.	
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Chapter	3 Engineered	 poly(ethylene	 glycol)	 matrices	
for	 cell-dependent	 proteolytic	 release	 of	
growth	factors	
	
Adapted	from:	
S	Metzger,	 U	 Blache,	 PS	 Lienemann,	M	 Karlsson,	 FE	Weber,	W	Weber,	M	 Ehrbar,	 Cell-
mediated	 proteolytic	 release	 of	 growth	 factors	 from	 poly(ethylene)	 glycol	 matrices,	
submitted	for	publication.	
	
	
3.1 Introduction	
In	order	to	engineer	functional	tissues	as	faithfully	as	possible,	various	cell	types	need	to	be	assembled	in	
their	specific	3D	microenvironment.	 In	 living	tissue,	 this	microenvironment	 is	determined	by	cell-cell	as	well	as	cell-
matrix	 interactions,	 physical	 cues	 and	 soluble	 or	 matrix-immobilized	 biochemical	 cues	 comprising	 hormones,	
cytokines	or	growth	factors.[27,	147,	148]	Growth	factors	and	cytokines	(henceforth	referred	to	only	as	growth	factors)	are	
proteins	 that	 regulate	cell	behavior	and	trigger	cellular	processes	such	as	proliferation,	migration	or	differentiation.	
Therefore,	they	are	widely	applied	in	tissue	engineering	to	instruct	cellular	behavior	in	3D	scaffolds.[149]	 Importantly,	
distribution,	availability	and	function	of	growth	factors	in	living	tissue	are	significantly	modulated	by	their	binding	to	
the	 extracellular	matrix	 (ECM).	 	 This	 results	 in	 the	 spatiotemporal	 and	 the	 physiologically	 relevant	 presentation	 of	
growth	 factors,	which	 then	 interact	with	 cell-surface	 receptors	 to	 influence	 cell	 behavior.[52,	 150]	 Additionally	 during	
physiological	 or	 healing-induced	 tissue	 remodeling,	 participating	 cells	 degrade	 ECM	 components	 by	 the	 tightly	
regulated	 secretion	 and	 local	 activation	 of	 proteases	 or	 polysaccharide	 lyases,	 resulting	 in	 the	 release	 of	 matrix	
fragments	and	growth	factors	from	the	ECM	“reservoir”.[48,	151]	Proteases	that	most	significantly	contribute	to	the	ECM	
degradation	 belong	 to	 the	 families	 of	 matrix	 metalloproteinases	 (MMPs).[152,	 153]	 These	 facts	 together	 with	
appreciation	 that	 adequate,	 engineering-compatible	 growth	 factor	 presentation	 strategies	 are	 required	 have	
encouraged	 the	 development	 of	 smart	 biomaterials	 that	 can	 mimic	 the	 ECM	 and	 present	 and/or	 release	 growth	
factors.[73,	122]	In	this	regard,	synthetic	materials	such	as	poly(ethylene	glycol)	(PEG)	hydrogels	have	been	used	for	the	
substitution	 of	 the	 naturally	 occurring	 ECM	 as	 they	 can	 be	 tailored	 toward	 specific	 requirements.[34,	 154,	 155]	 PEG	
hydrogels	 are	 synthetic	 matrices	 that	 are	 formed	 under	 chemically	 controlled	 conditions	 and	 are	 biocompatible,	
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biologically	 inert,	 besides	 offering	 a	 highly	 tunable	 platform	 in	 order	 to	 support	 cell	 growth.	 We	 have	 previously	
developed	an	enzymatically	cross-linked	PEG	system	in	which	eight-arm	star-shaped	PEG	precursors,	containing	either	
a	glutamine	acceptor	substrate	(8-PEG-Gln)	or	a	MMP-degradable	 lysine	donor	substrate	(8-PEGMMPsensitive-Lys),	are	
cross-linked	 by	 the	 transglutaminase	 (TG)	 Factor	 XIII	 (FXIII)	 to	 form	 hydrogels.[74,	 75]	 When	 functionalized	 with	 the	
adhesion	 peptide	 RGD,	 the	 resulting	 hydrogels	 were	 shown	 to	 be	 excellent	 in	 vitro	 platforms	 for	 3D	 cell	 culture	
reaching	from	short-term	culture	of	preosteoblastic	cells	to	long-term	microvascularized	osteogenic	tissue	mimics.[77,	
80,	133]	Moreover,	we	have	used	this	platform	to	functionally	immobilized	growth	factors	into	the	PEG	matrix	by	stable	
or	 affinity-based	 immobilization.[75,	 79,	 81,	 156]	 For	 instance,	 we	 have	 covalently	 incorporated	 a	 streptavidin	 linker	
consisting	of	an	FXIII-substrate	peptide	(Gln-streptavidin)	 in	TG-PEG	hydrogels	by	FXIII	cross-linking.	By	this	we	were	
able	 to	 locally	 immobilize	biotinylated	 recombinant	human	bone	morphogenetic	protein-2	 (rhBMP-2-biotin)	 via	 the	
Gln-streptavidin	 linker	 to	 PEG	 and	 obtained	 the	 corresponding	 localized	 osteogenic	 differentiation	 of	 human	 bone	
marrow-derived	mesenchymal	stem	cells	(hBM-MSCs).[79]		
Although	 working,	 this	 system	 relies	 on	 a	 PEG	 hydrogel	 that	 contains	 a	 type	 I	 collagen-derived	 degradation	
sequence	 (GPQGIWGQ)	 sensitive	 to	 multiple	 MMPs,	 as	 it	 was	 previously	 optimized	 towards	 cell	 migration	 and	
spreading.[72,	157]	Due	to	the	relatively	slow	degradation	kinetic	of	this	sequence	and	the	dependence	of	growth	factor	
release	 on	 hydrogel	 degradation,[158]	 it	 is	 assumed	 that	 a	 significant	 portion	 of	 the	 immobilized	 BMP-2	 remains	
inaccessible	for	the	encapsulated	cells,	causing	a	dampening	of	the	expected	growth	factor	effect	in	vitro.	
Here,	we	aimed	at	the	decoupling	of	the	hydrogel	backbone	properties	from	the	mode	of	growth	factor	release	in	
order	to	generate	advanced	modular	building	blocks	that	allow	both	more	specific	tailoring	and	the	release	of	growth	
factors	on	cellular	demand	by	proteases	(Figure	3.1).	Toward	this	goal,	we	selected	the	previously	described	peptide	
VPMSMRGG,	being	sensitive	to	MMP-1	and	2.[158,	159]	Subsequently,	we	designed	a	new	streptavidin	linker	consisting	
of	 a	 hydrogel	 immobilization	 Gln-sequence	 followed	 by	 three	 repetitions	 of	 the	MMP-degradable	 sequence	 and	 a	
streptavidin	domain,	named	Gln-M3-streptavidin	(Figure	3.1B).	To	characterize	the	new	degradable	streptavidin	linker,	
we	assessed	its	FXIIIa	mediated	cross-linking	to	hydrogel	backbone	precursors	as	well	as	its	degradability	by	proteases.	
We	 show	 that	 hydrogels	 modified	 with	 this	 new	 engineered	 streptavidin	 linker	 have	 the	 capacity	 to	 capture	
biotinylated	 proteins	 from	 cell	 culture	medium	 and	 stably	 retain	 them	 under	 cell	 culture	 conditions.	 Streptavidin-
modified	hydrogels	containing	immobilized	rhBMP-2-biotin	could	present	the	growth	factor	to	C2C12	cells	and	hBM-
MSCs	 and	 induce	 their	 osteogenic	 differentiation.	 Finally,	 higher	 enzyme	 activity	 of	 the	 osteogenic	 differentiation	
marker	alkaline	phosphatase	(ALP)	was	achieved	when	rhBMP-2-biotin	was	presented	by	the	new	degradable	Gln-M3-
streptavidin	linker	to	cells,	which	shows	the	potential	of	a	cell-responsive	linker	as	a	tool	for	the	engineering	of	tissue	
mimetics.	
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3.2 Results	and	Discussion	
3.2.1 Design	of	a	proteolytically	degradable	streptavidin	peptide	linker	
The	 previously	 developed	 streptavidin	 linker	 [79]	 is	 composed	 of	 a	 glutamine	 acceptor	 peptide	 fused	 to	 the	 N-
terminus	of	a	streptavidin	monomer.	This	linker	peptide	can	be	covalently	incorporated	in	TG-PEG	hydrogels	via	FXIIIa	
cross-linking	and	the	streptavidin	domain	is	used	to	bind	biotinylated	molecules	with	a	strong	affinity	(Kd	≈	10
-15	M).[135]	
To	design	the	new	proteolytically	degradable	linker,	three	repeats	of	the	protease	cleavage	site	VPMSMRGG	(sensitive	
to	MMP-1	and	MMP-2)	selected	from	a	list	of	peptide	sequences	tested	for	their	MMP	sensitivity[158,	159]	were	inserted	
in	between	these	two	domains,	as	illustrated	in	Figure	3.1B.	The	amino	acid	sequences	of	the	non-degradable	linker	
(Gln-streptavidin)	and	the	new	MMP-sensitive	linker	(Gln-M3-streptavidin)	are	indicated	in	Table	3.1.		
 
 
Figure	3.1.	Rationale	behind	the	design	of	the	protease-degradable	linkers.		
A)	 3D	 encapsulated	 cells	 by	 secretion	 and	 activation	 of	 proteases	 degrade	 the	 surrounding	 synthetic	 network	 and	 by	 matrix	
degradation	release	matrix	immobilized	growth	factors.	B)	The	protease-sensitive	linker	contains	three	repeats	of	a	proteolytically	
degradable	site	between	the	FXIIIa	substrate	sequence	Gln	and	the	streptavidin	domain	of	Gln-streptavidin	and	was	designed	to	be	
highly	 susceptible	 to	 MMP	 degradation.	 C)	 In	 slowly	 proteolytically	 degradable	 hydrogels	 such	 fast	 degradable	 linkers	 allow	
decoupling	of	growth	factors	and	matrix	degradation.	
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Linker Name Size [kDa] Proteolytic site Sequence1 
Gln-streptavidin 17.8 - 
M N Q E Q V S P L A S M T G G Q Q M G R D Q E A G I T G T W Y N Q L G S T F I V T A G A
D G A L T G T Y E S A V G N A E S R Y V L T G R Y D S A P A T D G S G T A L G W T V A W
K N N Y R N A H S A T T W S G Q Y V G G A E A R I N T Q W L L T S G T T E A N A W K S T
L V G H D T F T K V K P S A A S I D A A K K A G V N N G N P L D A V Q Q G S L  
Gln-M3-streptavidin 21.4 MMP-1, MMP-2 
M N Q E Q V S P L A S V D V P M S M R G G S V D V P M S M R G G S V D V P M S M R G
G S V D M T G G Q Q M G R D Q E A G I T G T W Y N Q L G S T F I V T A G A D G A L T G T
Y E S A V G N A E S R Y V L T G R Y D S A P A T D G S G T A L G W T V A W K N N Y R N
A H S A T T W S G Q Y V G G A E A R I N T Q W L L T S G T T E A N A W K S T L V G H D T
F T K V K P S A A S I D A A K K A G V N N G N P L D A V Q Q G S L  
	
Table	3.1.	Amino	acid	sequences	of	the	streptavidin	linkers.	
(1)	The	glutamine	acceptor	substrate	Gln	 indicated	by	a	single	underline,	the	proteolytically	degradable	sites	are	 in	bold	and	the	
streptavidin	sequence	is	in	italics	and	indicated	by	a	dashed	underline.	Peptide	orientation	is	from	N-terminus	to	C-terminus.	
 
3.2.2 Production	and	characterization	of	the	degradable	streptavidin	linker	
The	 linker	was	produced	 in	Escherichia	coli	with	yields	varying	between	5	and	20	mg	per	1L	of	bacterial	culture.	
Purification	 was	 carried	 out	 via	 biotin	 affinity	 chromatography,	 also	 ensuring	 the	 bioactivity	 of	 the	 streptavidin	
domain.	The	covalent	cross-linking	of	 the	 linker	 to	 the	8-PEG-MMPsensitive-Lys	component	of	 the	TG-PEG	system	was	
assessed	 via	 polyacrylamide	 gel	 electrophoresis	 (SDS-PAGE)	 and	Western	 blot	 analysis	 of	 streptavidin.	 As	 shown	 in	
Figure	3.2A,	a	shift	of	the	streptavidin	 linkers	to	higher	molecular	weight	was	detected	when	cross-linked	to	8-PEG-
MMPsensitive-Lys	 by	 FXIIIa	 indicating	 the	 successful	 incorporation	 of	 the	 linkers	 into	 the	 PEG	 component	 (the	 strong	
bands	 at	 65	 kDa	 in	 the	 Coomassie	 blue	 staining	 are	 caused	 by	 BSA	 used	 as	 carrier	 protein	 for	 FXIIIa).	 Next,	 we	
examined	if	the	engineered	streptavidin	linker	was	indeed	cleavable	by	MMP-1	and	MMP-2.	To	answer	this	question	
we	incubated	the	new	linker	as	well	as	the	non-degradable	linker	with	the	corresponding	proteases	and	analyzed	the	
degradation	products	via	SDS-PAGE	followed	by	Coomassie	blue	staining.	After	1	hour	of	incubation	with	either	10	or	
50	nM	of	MMP-1	or	MMP-2,	the	Gln-streptavidin	remained	stable	as	no	band	shift	is	visible	on	the	SDS-PAGE	(Figure	
3.2B).		
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Figure	3.2.	Characterization	of	the	streptavidin	linkers.		
(A)	The	 incorporation	of	the	two	different	 linkers	 into	the	PEG	system	by	FXIIIa	was	assessed	via	SDS-PAGE	and	Western	blotting	
against	streptavidin.	Samples	without	or	with	FXIIIa	are	indicated	by	-	or	+	respectively.		(B)	The	degradation	of	the	linkers	by	
the	 proteases	MMP-1,	MMP-2	 (both	 at	 10	 or	 50	 nM)	was	 assessed	 after	 1	 hour	 incubation	 via	 SDS-PAGE	 and	 Coomassie	 blue	
staining	to	detect	the	different	degradation	products.	
	
Similarly,	increasing	the	incubation	time	to	20	h	did	not	lead	to	degradation	of	Gln-streptavidin	by	MMPs	(Figure	
3.3).	 In	 contrast,	 all	MMP	 conditions	 resulted	 in	 the	 degradation	 of	 the	MMP-sensitive	 Gln-M3-streptavidin	 linker.	
More	 in	detail,	50	nM	of	either	MMP-1	or	MMP-2	 lead	to	the	full	cleavage	of	all	 three	MMP-sensitive	sites	already	
after	 1	 h	 of	 incubation,	 resulting	 into	 a	 single	 band	 at	 17.5	 kDa.	 Interestingly,	 1	 h	 of	 incubation	 at	 lower	 MMP	
concentration	(10	nM)	revealed	four	different	bands	representing	the	original	size	of	Gln-M3-streptavidin	at	21.5	kDa,	
the	two	intermediates	containing	two	(19.5	kDa)	or	one	(18.5	kDa)	MMP-sensitive	sites,	and	the	final	fragment	lacking	
all	three	MMP-sensitive	sites	at	17.5	kDa	(Figure	3.2B).	However,	all	three	MMP-sensitive	sites	were	fully	cleaved	after	
20	h	of	incubation	with	lower	MMP	concentration	(Figure	3.3).			
Taken	together	the	degradation	results	reveal	that	Gln-M3-streptavidin	is	as	planned	and	designed	sensitive	to	MMP-1	
and	MMP-2	whereas	Gln-streptavidin	is	robust	against	MMPs.		
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Figure	3.3.	Proteolytic	degradation	of	the	streptavidin	linkers	over	1	and	20	hours.		
The	degradation	of	the	linkers	by	the	proteases	MMP-1,	MMP-2	(both	at	10	or	50	nM)	and	plasmin	(150	nM	=	0.025	U	mL-1)	was	
assessed	 after	 1	 hour	 and	 20	 hours	 incubation	 via	 SDS-PAGE	 and	 Coomassie	 blue	 staining	 to	 detect	 the	 different	 degradation	
products.	
	
3.2.3 Binding	of	biotinylated	proteins	to	streptavidin	hydrogels		
In	 order	 to	 demonstrate	 the	 biotin-binding	 ability	 of	matrix-immobilized	 streptavidin	 linkers,	 TG-PEG	 hydrogels	
were	prepared	with	both	variants	of	streptavidin	 linkers	(i.e.	Gln-streptavidin	and	Gln-M3-streptavidin)	at	5	and	100	
µM	and	incubated	in	a	solution	containing	biotinylated	alkaline	phosphatase	(ALP-biotin).	To	determine	the	fraction	of	
hydrogel	captured	ALP-biotin,	the	ALP	enzymatic	activity	remaining	in	the	solution	was	quantified	after	0,	1,	4,	8,	24,	
48	and	120	hours.	Figure	3.4A	shows	that	ALP-biotin	is	captured	faster	and	more	extensively	with	100	µM	than	with	5	
µM	for	both	types	of	 linkers.	Gln-streptavidin	showed	a	 faster	and	more	efficient	uptake	of	ALP-biotin	than	Gln-M3-
streptavidin.	Although	both	variants	possess	the	same	streptavidin	domain,	the	slight	differences	in	uptake	dynamics	
were	 found	 throughout	 all	 uptake	 experiments,	 indicating	 that	 flanking	 regions	 could	 have	 an	 effect	 on	 the	
streptavidin	binding	affinity.	However,	the	concentration	of	streptavidin	linker	(5	or	100	µM)	had	far	less	influence	on	
the	 binding	 of	 ALP-biotin	 if	 the	 biotinylated	 molecule	 was	 coupled	 to	 the	 linkers	 (in	 a	 1:2	 or	 1:40	 molar	 ratio	
respectively)	in	advance	by	a	pre-incubation	step	before	being	incorporated	into	the	hydrogel.	Here,	total	release	of	
ALP-biotin	from	hydrogels	was	assessed	over	a	period	of	7	days,	with	or	without	the	streptavidin	linkers	(Figure	3.4B).	
Almost	the	entirety	of	the	immobilized	ALP-biotin	remained	bound	to	the	hydrogels	when	it	was	coupled	to	either	one	
of	 the	 streptavidin	 linkers,	 independently	 of	 the	 linker	 concentration,	 whereas	 ALP-biotin	 was	 almost	 completely	
released	 into	the	surrounding	buffer	 in	absence	of	 linker.	This	shows	that	the	 linkers	have	very	comparable	binding	
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efficacy	when	there	 is	a	pre-incubation	step	with	biotinylated	molecule	and	that	they	are	capable	of	 immobilizing	 it	
very	efficiently	in	non-proteolytic	conditions.	
 
 
Figure	3.4.	Uptake	and	release	from	streptavidin	hydrogels.		
(A)	 Uptake	 of	 biotinylated	 ALP	 by	 streptavidin-modified	 hydrogels.	 TG-PEG	 hydrogels	 containing	 5	 or	 100	 μM	 of	 linker	 were	
incubated	in	a	solution	containing	ALP-biotin.	The	enzymatic	activity	of	the	remaining	ALP-biotin	in	the	solution	was	measured	with	
the	SEAP	assay	over	a	period	of	5	days	and	compared	 to	 the	 initial	enzymatic	activity	at	 the	start	of	 the	experiment.	Error	bars	
represent	 standard	 deviation,	 n	 =	 4.	 (B)	 Release of immobilized ALP-biotin from streptavidin-modified hydrogels. The 
release of ALP-biotin incorporated in TG-PEG hydrogels containing the different streptavidin linkers was assessed in Tris 
buffer after a period of 7 days. Error bars represent standard deviation, n = 3.	
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3.2.4 Release	of	rhBMP-2-biotin	from	streptavidin	hydrogels	
To	test	the	functionality	and	efficiency	of	this	immobilization	strategy	for	tissue	engineering	applications,	we	chose	
to	 use	 a	 model	 of	 osteogenic	 differentiation	 of	 myoblastic	 and	 mesenchymal	 stem	 cells	 by	 BMP-2	 in	 3D	 TG-PEG	
hydrogels.	 To	 this	 end,	 we	 first	 evaluated	 the	 immobilization	 efficiency	 of	 rhBMP-2,	 which	 was	 biotinylated	 as	
previously	 described[79]	 and	 immobilized	 into	 PEG	 hydrogels	 via	 the	 different	 streptavidin	 linkers.	 In	 the	 following	
experiments,	 rhBMP-2-biotin	was	directly	 coupled	 to	 the	 streptavidin	 linker	 by	 incubating	both	 components	 for	 30	
minutes	at	room	temperature	before	their	 incorporation	 in	the	TG-PEG	hydrogel	mix.	 In	detail,	5	µM	of	streptavidin	
linker	 and	 50	 ng	 of	 rhBMP-2-biotin	 (approximately	 25-fold	 molar	 excess	 of	 streptavidin	 ensures	 sufficient	 binding	
efficacy)	were	 incubated	before	 incorporating	 the	 rhBMP-2/streptavidin	 complex	 into	 TG-PEG	hydrogels.	Hydrogels	
were	 then	 incubated	 in	 a	 microcentrifuge	 tube	 containing	 500	 µL	 of	 Tris	 buffer	 with	 0.5%	 BSA	 for	 up	 to	 7	 days.	
Subsequently,	we	confirmed	the	successful	immobilization	of	rhBMP-2-biotin	by	measuring	non-bound	and	therefore	
diffused/released	rhBMP-2	via	ELISA.	In	the	case	of	a	100%	release	into	the	buffer	or	medium,	the	expected	rhBMP-2-
biotin	 concentration	 is	 approximately	 100	 ng	 mL-1.	 As	 can	 be	 seen	 in	 Figure	 3.5,	 rhBMP-2-biotin	 incorporated	 in	
hydrogels	that	did	not	contain	any	linker	was	almost	completely	released	after	2	days,	with	a	burst	release	of	75%	of	
the	total	rhBMP-2-biotin	in	the	first	24	hours.	In	contrast,	the	hydrogels	containing	rhBMP-2-biotin	immobilized	with	
either	Gln-streptavidin	or	Gln-M3-streptavidin	only	released	around	20%	of	the	total	rhBMP-2-biotin	in	the	course	of	a	
7	days	incubation	period,	meaning	that	the	majority	of	rhBMP-2-biotin	remains	immobilized	in	the	hydrogels.		
 
Figure	3.5.	Cumulative	release	of	immobilized	rhBMP-2-biotin	from	streptavidin-modified	hydrogels.		
The	release	of	rhBMP-2-biotin	incorporated	in	TG-PEG	hydrogels	containing	the	different	streptavidin	linkers	was	assessed	in	Tris	
buffer	over	a	period	of	7	days.	Error	bars	represent	standard	deviation,	n	=	3.	
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3.2.5 Osteogenic	differentiation	of	cells	in	streptavidin	hydrogels	
To	 determine	 if	 the	 incorporation	 of	 proteolytically	 cleavable	 sites	 in	 the	 streptavidin	 linker	 improved	 the	
biological	 efficiency	 of	 immobilized	 growth	 factors,	 we	 cultivated	 C2C12	 cells	 in	 streptavidin-modified	 TG-PEG	
hydrogels	for	each	type	of	linker	with	the	same	total	amount	of	bound	rhBMP-2-biotin.	C2C12	cells	are	a	myoblastic	
cell	 line	that	differentiates	toward	the	osteogenic	lineage	when	exposed	to	BMP-2	in	a	dose-dependent	manner.[139]	
Therefore,	 C2C12	 cells	 were	 cultivated	 in	 the	 rhBMP-2-biotin/streptavidin-modified	 hydrogels	 and	 analyzed	 for	
osteogenic	differentiation.	As	a	positive	control,	C2C12	cells	embedded	in	hydrogels	were	stimulated	with	the	same	
amount	of	rhBMP-2-biotin,	but	soluble	in	the	cell	culture	medium.	After	9	days	of	culture,	the	enzymatic	activity	of	the	
early	osteogenic	marker	alkaline	phosphatase	(ALP)	was	analyzed.	Figure	3.6A	and	B	illustrates	the	enzymatic	activity	
of	ALP	as	 shown	by	ALP	 substrate	 staining	and	by	measurement	of	 the	ALP	activity	of	 retrieved	cells.	As	expected,	
soluble	 rhBMP-2-biotin	 can	 strongly	 induce	 the	 ALP	 activity.	 Presenting	 rhBMP-2-biotin	 with	 the	 Gln-streptavidin	
linker	resulted	in	an	induction	as	well,	however,	ALP	activity	was	lower	than	in	the	soluble	rhBMP-2-biotin	condition.	
Importantly,	 the	measured	ALP	activity	was	the	highest	and	significantly	higher	than	the	other	conditions	(including	
the	soluble	condition)	when	rhBMP-2-biotin	was	 immobilized	by	Gln-M3-streptavidin.	Furthermore,	we	also	showed	
that	 binding	 of	 rhBMP-2-biotin	 to	 the	 different	 streptavidin	 linkers	 did	 not	 influence	 the	 bioactivity	 of	 the	 growth	
factor,	 since	 the	 ALP	 activity	 of	 cells	 stimulated	 with	 the	 linker/growth	 factor	 complex	 in	 soluble	 form	 in	 the	 cell	
culture	medium	was	comparable	to	stimulation	with	only	rhBMP-2-biotin	soluble	in	the	medium	(Figure	3.6C).		
Of	 note,	 although	 the	 total	 amount	 of	 rhBMP-2-biotin	 was	 matched	 throughout	 the	 different	 conditions,	
comparisons	 between	 soluble	 and	 streptavidin-bound	BMP-2	 conditions	 should	 only	 be	made	 very	 carefully	 as	 the	
manner	in	which	the	BMP-2	is	presented	influences	the	local	concentration	perceived	by	cells.	Indeed	although	50	ng	
of	total	rhBMP-2-biotin	was	used	for	both	bound	and	soluble	conditions,	the	local	concentration	of	bound	protein	was	
5	µg	mL-1	 in	relation	to	the	hydrogel	volume,	whereas	the	soluble	protein	concentration	was	100	ng	mL-1	 in	the	cell	
culture	medium.	
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Figure	3.6.	ALP	activity	of	C2C12	cells	cultivated	in	streptavidin-modified	hydrogels	for	9	days.		
(A)	 Enzymatic	 activity	 of	 the	 osteogenic	 marker	 ALP	 was	 assessed	 using	 a	 substrate	 stain	 of	 TG-PEG	 hydrogels	 with	 various	
formulations	of	streptavidin	linkers	and	rhBMP-2-biotin.	(B)	ALP	enzymatic	activity	was	correlated	with	the	hydrolysis	of	a	substrate	
(with	absorption	maximum	at	410	nm)	for	each	type	of	linkers	with	immobilized	rhBMP-2-biotin.	(C)	ALP	enzymatic	activity	was	also	
determined	 for	 the	 soluble	 streptavidin-linker/rhBMP-2-biotin	 complexes.	 Error	 bars	 represent	 standard	 deviation,	 n	 =	 4,	 *	 p	˂	
0.05;	 **	 p	˂	 0.01;	 ***	 p	˂	 0.001	 and	 ‘no	 rhBMP-2-biotin’	 was	 significantly	 different	 from	 all	 other	 conditions	 with	 p	 <	 0.001.	
Samples	were	analyzed	by	one-way	ANOVA	followed	by	a	Bonferroni	post	hoc	test.		
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Furthermore,	 as	 can	 be	 seen	 in	 Figure	 3.7,	 Gln-M3-streptavidin	 can	 also	 be	 employed	 for	 the	 3D	 localized	
differentiation	 of	 cells,	 in	 an	 analogous	 manner	 as	 previously	 shown	 with	 Gln-streptavidin.[79]	 TG-PEG	 hydrogel	
constructs	 containing	 MSCs	 were	 formed	 with	 a	 central	 area	 presenting	 rhBMP-2-biotin	 immobilized	 via	 Gln-M3-
streptavidin	and	an	outer	region	without	rhBMP-2.	After	9	days	of	culture,	ALP	substrate	stains	and	immunostaining	
against	ALP	showed	a	high	ALP	activity	in	the	central	area	of	Gln-M3-streptavidin	containing	hydrogels,	while	the	ALP	
activity	in	the	outer	area	as	well	as	in	the	other	hydrogels	was	much	weaker.		
	
Figure	3.7.	3D-localized	osteogenic	differentiation	of	mesenchymal	stem	cells.		
MSCs	 were	 encapsulated	 in	 hydrogel	 constructs	 made	 from	 an	 inner	 part	 with	 and	 an	 outer	 part	 without	 streptavidin-linker	
immobilized	 rhBMP-2.	 Osteogenic	 differentiation	was	 assessed	 via	 presence	 of	 ALP,	 which	was	 detected	with	 both	 a	 substrate	
staining	(A)	and	by	immunostaining	(B).	
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Finally,	 we	 selected	 the	 Gln-M3-streptavidin	 linker,	 which	 gave	 the	 strongest	 ALP	 response	 in	 the	 previous	
experiment	in	order	to	take	a	closer	look	at	the	effect	of	BMP-2	dose.	We	compared	the	ALP	activity	of	both	C2C12	
cells	 and	 MSCs	 inside	 TG-PEG	 hydrogels	 when	 different	 doses	 of	 rhBMP-2-biotin	 (ranging	 from	 0	 to	 50	 ng)	 were	
presented	to	them	in	soluble	form	or	in	bound	but	MMP	releasable	form.	As	can	be	seen	in	Figure	3.8A	and	Figure	3.9,	
we	obtained	a	 significantly	higher	ALP	activity	when	 rhBMP-2-biotin	was	bound	 to	 the	hydrogel	 via	 the	degradable	
Gln-M3-streptavidin	 linker	 than	 when	 it	 was	 soluble	 in	 the	 cell	 culture	 medium.	 Availability	 and	 efficiency	 of	 the	
immobilized	rhBMP-2	was	thus	improved	by	the	addition	of	MMP-sensitive	sites	in	the	streptavidin	linker,	providing	a	
cell-triggered	release	of	growth	factors.	
To	 confirm	 the	 osteogenic	 differentiation	 by	 streptavidin-based	 BMP-2	 delivery,	 C2C12	 cells	were	 encapsulated	
and	 cultured	 in	 TG-PEG	 hydrogels,	 which	 presented	 50	 ng	 rhBMP-2-biotin	 by	MMP-degradable	 streptavidin	 linker.	
Samples	cultured	in	absence	or	presence	of	soluble	BMP-2-biotin	(50	ng	in	total	at	200	ng	mL-1)	served	as	controls.	
Quantitative	PCR	analysis	after	7	days	of	culture	revealed	that	consistent	with	ALP	activity	both	early	(ALP)	and	late	
(Sp7/osterix)	and	collagen	type	I	alpha	1	(Col1)	osteogenic	markers	were	significantly	upregulated	by	rhBMP-2-biotin	
(Figure	6B).	The	expression	of	these	genes	was	highest	in	hydrogels	where	rhBMP-2-biotin	was	presented	by	Gln-M3-
streptavidin.	 Runt-related	 transcription	 factor	 2	 (Runx2),	 a	 gene	 which	 is	 induced	 very	 early	 in	 osteogenic	
differentiation	 is	only	upregulated	 in	 samples	where	 rhBMP-2-biotin	 is	presented	by	Gln-M3-streptavidin.	 This	data	
demonstrate	that	hydrogel	immobilized	rhBMP-2-biotin	can	induce	osteogenic	differentiation.	However,	whether	the	
enhanced	osteogenic	differentiation	of	C2C12	cells	with	rhBMP-2-biotin	bound	to	the	MMP-degradable	streptavidin	
linker	 is	due	to	increased	BMP	availability	or	more	efficient	 internalization	and	intracellular	trafficking	needs	further	
evaluation.		
	
 
Figure	3.8.	Immobilization	of	BMP-2	via	Gln-M3-streptavidin	with	C2C12	cells.		
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A)	The	enzymatic	activity	of	the	osteogenic	marker	ALP	of	C2C12	cells	was	measured	for	different	doses	of	BMP-2	immobilized	with	
Gln-M3-streptavidin.	Error	bars	 represent	standard	deviation,	n	=	3,	*	p	˂	0.05;	**	p	˂	0.01.	Samples	were	analyzed	by	one-way	
ANOVA	 followed	by	 a	Bonferroni	 post	 hoc	 test.	 B)	Gene	 expression	of	 osteogenic	markers	 in	 PEG	hydrogels	were	measured	by	
means	of	qRT-PCR	and	normalized	on	GAPDH	expression.	Error	bars	represent	standard	deviation,	n	=	3,	*	p	˂	0.05;	**	p	˂	0.01,	
***	p	<	0.001.	Samples	were	analyzed	by	one-way	ANOVA	followed	by	a	Bonferroni	post	hoc	test.		
	
	
Figure	3.9	Immobilization	of	BMP-2	via	Gln-M3-streptavidin	with	hBM-MSCs. 
The	 enzymatic	 activity	 of	 the	 osteogenic	 marker	 ALP	 was	 measured	 for	 different	 doses	 of	 BMP-2	 immobilized	 with	 Gln-M3-
streptavidin.	Error	bars	 represent	standard	deviation,	n	=	3,	*	p	<	0.05;	**	p	<	0.01.	Samples	were	analyzed	by	one-way	ANOVA	
followed	by	a	Bonferroni	post	hoc	test.	
	
3.2.6 Degradable	linkers	for	the	immobilization	and	release	of	growth	factors		
The	 presentation	 of	 growth	 factors	 by	 biomaterials	 is	 desirable	 due	 to	 various	 reasons.	 On	 the	 one	 hand,	 the	
successful	immobilization	of	growth	factors	can	decrease	the	amounts	of	growth	factors	needed	for	biological	effects,	
which	is	an	important	goal	for	the	medical	application	of	biomaterials	in	combination	with	growth	factors.[149]	On	the	
other	 hand,	 the	 immobilization	 of	 growth	 factors	 is	 essential	 for	 relevant	 in	 vitro	 studies,	 as	 in	 vivo	 many	 growth	
factors	are	presented	by	the	ECM.[122]	By	presenting	the	osteoinductive	growth	factor	BMP-2	via	two	different	types	of	
streptavidin	 linkers	 to	 C2C12	 cells	 and	MSCs	we	 compared	 the	 functionality	 and	 performance	 of	 a	 novel	 linker	 for	
tissue	 engineering	 and	 3D	 cell	 biology	 approaches.	 Importantly,	 the	 highest	 osteogenic	 induction	 of	 C2C12	 cells	
(measured	by	ALP	activity)	was	achieved	with	the	MMP-sensitive	Gln-M3-streptavidin	linker,	which	was	able	to	double	
the	response	in	comparison	to	the	previous	non-degradable	Gln-streptavidin	linker.	Moreover,	when	rhBMP-2-biotin	
was	presented	by	Gln-M3-streptavidin,	C2C12	cells	as	well	as	MSC	differentiated	more	efficiently	than	when	the	same	
overall	amount	of	BMP-2	was	applied	soluble.	These	results	suggest	that	the	effect	of	growth	factors	depend	on	the	
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way	in	which	they	are	presented	and	how	they	become	available	for	cells.	 In	this	context,	the	proteolytic	release	of	
BMP-2	 from	 TG-PEG	 hydrogels,	 independently	 of	 hydrogel	 stability,	 resulted	 in	 the	 local	 availability	 of	 BMP-2	 on	
cellular	demand	and	enhanced	the	biological	net	effect	of	BMP-2	in	the	system.	
Taking	advantage	of	the	strong	affinity	between	streptavidin	linkers	and	biotin,	and	the	availability	of	commercial	
biotinylation	methods,	our	system	offers	a	relatively	simple	strategy	for	the	binding	of	growth	factors.	The	advantage	
of	this	indirect	immobilization	strategy,	as	opposed	to	the	direct	incorporation	of	growth	factors	into	the	PEG	matrix,	
is	 its	versatility.	Various	growth	factors	can	be	easily	and	rapidly	biotinylated	and	immobilized	while	using	the	same	
linker	strategy,	which	represents	a	powerful	alternative	to	genetic	engineering	of	proteins.	In	this	study	we	extended	
our	toolbox	by	 introducing	a	proteolytically	degradable	streptavidin/biotin	system	to	 immobilize	growth	factors	 into	
synthetic	 cell-friendly	 hydrogels.	 Such	 streptavidin	 linkers	 can	 be	 readily	 cloned	with	multiple	 alternative	 features,	
efficiently	 purified	 from	 bacterial	 expression	 systems,	 as	 herein	 demonstrated	 by	MMP-	 or	 plasmin-sensitive	 sites.	
Additionally,	refined	individual	functional	properties	of	novel	linkers	can	be	tested	by	in	vitro	assays	allowing	for	their	
efficient	selection.	Therefore,	we	are	convinced	that	herein	described	approach	will	be	applicable	to	develop	novel,	
cell	 and	 application	 specific	 biomimetic	 materials	 for	 the	 recapitulation	 of	 more	 sophisticated	 tissues	
microenvironments.	
	
3.3 Conclusion	
We	have	 established	 proteolytically	 degradable	 streptavidin-based	 growth	 factor	 binding	 linker	modules,	
which	 allow	 the	 cell-mediated	 release	 of	 biotinylated	 growth	 factors	 from	 hydrogels.	 Our	 degradable	 streptavidin	
linker	provides	a	growth	factors	release	strategy,	which	mimics	the	ECM	binding	and	release	as	it	has	been	described	
for	multiple	factors	in	native	tissues.[52,	150,	151]		
This	work	demonstrates	 that	 indeed	by	 the	appropriate	engineering	of	a	 release	 system,	a	growth	 factor	
can	be	delivered	 very	 locally	 and	 in	 such	a	way	 that	 it	 outperforms	 the	 cell	 culture	medium	 supplemented	 soluble	
form.	 Therefore	 these	 results	 suggest	 that	 the	 effect	 of	 growth	 factors	 depends	 on	 the	 way	 in	 which	 they	 are	
presented	and	how	they	become	available	for	cells.	
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3.4 Experimental	Section	
Cloning	of	the	Degradable	Streptavidin	Linker:		
To	 construct	 the	 plasmid	 pPL22	 (Gln-M3-streptavidin),	 three	 repeats	 of	 an	 MMP-1-sensitive	 sequence	
(VPMSMRGG)[159]	were	cloned	into	the	pPL8	(Gln-streptavidin),[79]	so	as	to	be	inserted	between	the	transglutaminase	
sequence	 (Gln)	 and	 the	 streptavidin	 sequence.	 The	 expression	 of	 the	 streptavidin	 linker	 is	 under	 control	 of	 a	 T7	
promoter.	
Production	of	the	Streptavidin	Linker:		
The	 plasmid	 pPL22	was	 transformed	 into	 E.	 coli	 BL21-Gold	 (DE3)pLysS	 (Agilent	 Technologies,	 La	 Jolla	 CA,	 USA).	
Expression	and	purification	of	the	streptavidin	linker	was	done	as	described	previously	for	Gln-streptavidin.[79]	
Cross-Linking	of	the	Streptavidin	Linkers	to	PEG:		
Mixtures	 of	Gln-streptavidin	 or	Gln-M3-streptavidin	 (5	µg)	with	 8-PEG-MMPsensitive-Lys	 (molecular	weight:	 40’000	
Da)	were	 incubated	for	30	minutes	at	37°C	 in	absence	or	presence	of	FXIIIa.	Cross-linking	of	 the	 linker	proteins	was	
assessed	via	15%	SDS-PAGE	followed	by	Coomassie	Blue	staining.	For	Western	blot	detection,	mixtures	were	loaded	
on	 a	 4–20%	 gradient	 SDS-PAGE	 (Bio-Rad,	 Switzerland)	 and	 blotted	 on	 a	 PVDF	 membrane	 (Millipore,	 Switzerland).	
Streptavidin	was	detected	by	 1:1000	mouse	monoclonal	 primary	 antibody	 (sc-52234,	 Santa	Cruz,	USA)	 followed	by	
1:2500	polyclonal	goat	anti-mouse	IgG-HRP	(P	0447,	DAKO,	Switzerland),	both	in	5%	dry	milk.	IgG-HRP	was	visualized	
by	the	Lumi-Light	Western	Blotting	Substrate	(Roche,	Switzerland)	using	the	Fusion	Fx	Imaging	System	(Vilber).	
Degradation	of	the	Streptavidin	Linkers	with	Proteases:		
Each	streptavidin	 linker	(10	µM;	10	µg/50	µl)	was	 incubated	in	degradation	buffer	(50	mM	Tris,	50	mM	NaCl,	10	
mM	CaCl2,	0.05%	(w/v)	Brij	35,	pH	7.5)	for	1	and	20	hours	at	37°C	with	either	10	or	50	nM	MMP-1	(PeproTech,	United	
Kingdom),	10	or	50	nM	MMP-2	(PeproTech,	United	Kingdom)	or	0.025	U	mL-1	of	plasmin	(Sigma-Aldrich,	Switzerland).	
Degradation	products	were	loaded	on	a	15%	SDS-PAGE	for	analysis.	
Formation	of	Hydrogels:		
TG-PEG	hydrogels	were	formed	by	the	cross-linking	of	two	PEG	components	(8-PEG-Gln	and	8-PEG-MMPsensitive-Lys,	
molecular	 weight:	 40’000	 Da)	 via	 FXIIIa	 as	 previously	 described.
[74,	 75]	 Briefly,	 a	 200	 U	 mL-1	 solution	 of	 FXIII	
(Fibrogammin	P,	CSL	Behring,	Switzerland)	was	activated	with	2	U	mL-1	thrombin	(Sigma-Aldrich,	Switzerland)	for	30	
min	at	37°C.	Equimolar	solutions	of	8-PEG-Gln	and	8-PEG-MMPsensitive-Lys	were	prepared	in	50	mM	Tris,	50	mM	calcium	
chloride,	 pH	 7.6	 buffer.	 Precursor	 solutions	 for	 hydrogels	with	 a	 final	 dry	mass	 content	 of	 1.7	 or	 2%	 TG-PEG	were	
prepared	and	growth	 factors,	RGD,	 linker	peptides	and	cells	were	added	according	 to	experiment.	The	cross-linking	
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reaction	was	 initiated	by	addition	of	10	U	mL-1	 FXIIIa.	Disc-shaped	hydrogels	were	obtained	by	placing	 the	 reaction	
mixtures	 between	 sterile	 hydrophobic	microscope	 glass	 slides	 (treated	with	 SigmaCote,	 Sigma-Aldrich,	 Switzerland)	
separated	 by	 1	 mm	 thick	 spacers,	 clamped	 with	 binder	 clips	 and	 incubated	 for	 20	 minutes	 at	 37°C	 to	 allow	
polymerization.	
Uptake	of	Biotinylated	Alkaline	Phosphatase	by	Streptavidin	Hydrogels:		
20	µL	PEG	hydrogels	(2%	w/v)	containing	0,	5	and	100	µM	of	Gln-streptavidin	or	Gln-M3-streptavidin	were	formed	
via	FXIIIa	cross-linking.	The	hydrogels	were	then	washed	in	microcentrifuge	tubes	containing	500	µL	of	Tris	buffer	(50	
mm	Tris,	pH	7.6)	at	4°C	overnight	on	a	shaker.	Hydrogels	were	then	transferred	to	microcentrifuge	tubes	containing	
500	µL	of	a	solution	of	5.5	µg	mL-1	biotinylated	ALP	(Thermo	Scientific,	Switzerland)	in	Tris	buffer.	The	hydrogels	were	
incubated	at	4°C	for	5	days.	20	µL	buffer	samples	were	collected	after	1,	4,	8,	24,	48	and	120	hours	and	the	remaining	
content	 of	 biotinylated	 ALP	was	 quantified	 by	means	 of	 enzymatic	 activity	with	 the	 secreted	 alkaline	 phosphatase	
(SEAP)	assay	as	described	previously.[79]	
Release	of	Biotinylated	Alkaline	Phosphatase	by	Streptavidin	Hydrogels:		
20	µL	TG-PEG	hydrogels	(1.7%	w/v)	containing	approximately	2.3	µM	of	ALP-biotin	with	0,	5	or	100	µM	streptavidin	
linker	were	formed	for	both	types	of	linker.	The	hydrogels	were	incubated	in	500	µL	of	50	mM	Tris,	0.5%	BSA,	pH	7.6	
buffer	 and	 incubated	at	 4°C	on	a	 shaker.	 The	buffer	or	medium	was	 collected	after	 7	days.	 The	ALP	activity	 in	 the	
solution	was	determined	with	the	secreted	alkaline	phosphatase	(SEAP)	assay	as	described	previously.[79]	
Binding	of	Biotinylated	rhBMP-2	by	Streptavidin	Hydrogels:		
10	µL	TG-PEG	hydrogels	(1.7%	w/v)	containing	50	ng	of	rhBMP-2-biotin[79]	with	0	or	5	µM	streptavidin	linker	were	
formed	for	both	types	of	linker.	The	hydrogels	were	incubated	in	500	µL	of	50	mM	Tris,	0.5%	BSA,	pH	7.6	buffer	and	
incubated	at	4°C	on	a	shaker.	The	buffer	or	medium	was	collected	and	freshly	replaced	on	day	1,	2,	3,	5	and	7.	The	
concentration	of	released	rhBMP-2-biotin	was	determined	via	ELISA.	
ELISA	of	BMP-2:		
All	BMP-2	ELISAs	were	performed	using	 the	human	BMP-2	ELISA	Development	Kit	 (PeproTech,	United	Kingdom)	
according	to	the	manufacturer’s	guidelines.	The	solution	 in	which	the	samples	were	diluted	was	used	as	diluent	 for	
both	 samples	 and	 standards.	 The	 standard	 curves	 were	 established	 with	 the	 same	 rhBMP-2-biotin	 used	 for	 the	
experiments.	
Cell	culture:		
Cells	were	 cultured	 at	 37°C	 in	 a	 humidified	 atmosphere	 at	 5%	 CO2.	 C2C12	 cells	 (ATCC,	USA)	were	 expanded	 in	
DMEM	supplemented	with	FBS	(10%),	penicillin-streptomycin	(1%)	and	L-Glutamine	(2mM).	The	cells	were	passaged	
every	2-3	days	at	70%	confluence.	Human	bone	marrow-derived	mesenchymal	stem	cells	were	isolated	as	described	
previously[160]	 from	bone	marrow	aspirated	of	healthy	donors	obtained	during	orthopedic	 surgical	procedures	after	
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informed	consent	and	 in	accordance	with	 the	 local	ethical	 committee	 (University	Hospital	Basel;	Prof.	Dr.	Kummer;	
approval	 date	 26/03/2007	 Ref	 Number	 78/07).	 The	 cells	 were	 maintained	 in	 Minimum	 Essential	 Medium	 Alpha	
(MEMα)	supplemented	with	FBS	(10%),	penicillin-streptomycin	(1%)	and	bFGF	(5	ng	mL-1)	and	passaged	every	2-3	days	
at	70-80%	confluence.	
For	 differentiation	 assays,	 both	 cell	 types	 were	 cultured	 in	 MEMα	 supplemented	 with	 FBS	 (10%),	 penicillin-
streptomycin	(1%)	and	L-ascorbic	acid	(50	µg	mL-1).		
3D	differentiation	of	cells	in	hydrogels	with	immobilized	rhBMP-2-biotin:		
10	µL	TG-PEG	hydrogels	(1.7	%	w/v)	containing	Lys-RGD	(50	µM)	and	different	combinations	of	either	0	or	5	µM	of	
streptavidin	 linker	and	0	or	50	ng	rhBMP-2-biotin	were	formed	with	a	final	single	cell	concentration	of	1.5×106	cells	
mL-1.	After	polymerization,	the	hydrogels	were	glued	to	the	bottom	of	a	48-well	plate	with	a	TG-PEG	(2%	w/v)	solution	
and	cultured	with	the	appropriate	medium	for	7-9	days.	
Alkaline	Phosphatase	Colorimetric	Staining	and	Enzymatic	Activity	Assay:		
For	the	colorimetric	staining,	medium	was	removed	from	the	wells	and	the	hydrogels	were	washed	with	PBS.	250	
µL	of	substrate	solution	made	from	SIGMAFAST	BCIP/NBT	tablets	(Sigma-Aldrich,	Switzerland)	and	prepared	according	
to	 the	manufacturer’s	 guidelines	were	 added	 to	 each	well	 followed	by	 incubation	 at	 37°C.	Once	 enough	 color	 had	
visually	 developed	 (5-10	 minutes),	 the	 substrate	 solution	 was	 removed	 and	 the	 hydrogels	 were	 fixed	 with	 a	 4%	
paraformaldehyde	 solution	 for	 10	 minutes.	 Finally	 the	 hydrogels	 were	 washed	 with	 PBS	 and	 imaged	 with	 a	 light	
microscope.	 For	 the	 enzymatic	 activity	 assay,	 the	 medium	 was	 removed	 from	 the	 wells	 and	 the	 hydrogels	 were	
washed	 with	 PBS.	 Each	 hydrogel	 was	 collected	 and	 transferred	 to	 a	 microcentrifuge	 tube	 and	 digested	 in	 an	
equivalent	 volume	 of	 collagenase	 A	 solution	 (2	mg/mL	 in	 PBS,	 Roche,	 Switzerland)	 at	 37°C	 for	 10	minutes	 or	 until	
completely	dissolved.	Lysis	buffer	(0.56	M	2-amino-2-methyl-1-propanol,	0.2%	Triton	X-100,	pH	10	in	ddH2O)	was	then	
added	 to	 each	 tube	 for	 a	 final	 volume	 of	 500	 µL	 and	 the	 cell	 lysates	were	 incubated	 at	 room	 temperature	 for	 30	
minutes,	followed	by	1	minute	of	homogenization	(Omni	TH220	tissue	homogenizer,	Omni	International,	USA).	After	
centrifugation	of	the	cell	lysate	at	10’000	rpm	for	10	minutes,	the	supernatant	was	collected.	50	µL	of	cell	lysate	was	
mixed	with	 50	 µL	 of	 ALP	 reagent	 (20mM	 4-nitrophenyl	 phosphate	 disodium	 salt	 hexahydrate,	 4	mM	MgCl2	 in	 lysis	
buffer)	 in	 a	 96-well	 plate	 and	 incubated	 at	 37°C	 for	 10	 minutes	 before	 reading	 absorbance	 at	 410	 nm	 with	 a	
microplate	reader.	For	each	sample,	 the	absorbance	values	were	normalized	to	the	total	protein	content	 in	the	cell	
lysate,	which	was	measure	via	Bradford	assay.	
Gene	expression	analysis	using	qRT-PCR:		
C2C12	cells	were	encapsulated	in	10	µL	PEG	hydrogels	(1.7%	PEG,	50	µm	RGD)	at	a	final	concentration	of	1.5×106	
mL-1.	 Hydrogels	 were	 cultured	 for	 7	 days	 in	 MEMα,	 FCS	 (10%),	 penicillin-streptomycin	 (1%)	 and	 50	 ng	 BMP-2	
presented	soluble	in	the	cell	culture	medium	or	bound	to	the	PEG	hydrogel	by	5	µm	Gln-M3-streptavidin	linker.	After	
7	days,	hydrogels	were	digested	in	30	µL	of	collagenase	A	solution	(2	mg	mL-1	in	PBS,	Roche,	Switzerland)	for	30	min	
at	37°C.	Next,	cells	were	collected	by	centrifugation	and	total	RNA	was	isolated	from	the	cells	by	the	RNeasy	Micro	Kit	
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(Qiagen)	 according	 to	 the	manufacturer’s	 instructions.	 For	 quantitative	 real-time	 PCR	 (qRT-PCR),	 200	 ng	 RNA	were	
converted	into	40	µL	cDNA	by	means	of	the	High-Capacity	cDNA	Reverse	Transcription	Kit	(Applied	Biosystems).	qRT-
PCR	was	carried	out	using	2	µL	cDNA	template,	the	TaqMan	Universal	PCR	Master	Mix	(Applied	Biosystems)	and	the	
StepOnePlus	 Real-Time	 PCR	 System	 (Applied	 Biosystems).	 The	 following	 TaqMan	 primer/probe	 sets	 were	 used	 for	
gene	 expression	 tests:	 Mm00475834_m1	 (Alpl),	 Mm00501584_m1	 (Runx2),	 Mm04209856_m1	 (Sp7),	
Mn00801666_g1	 (Col1a1).	 Data	 were	 normalized	 on	 Mm99999915_g1	 (Gapdh)	 and	 relative	 gene	 expression	 was	
calculated	by	the	comparative	Ct	method.	
Localized	3D	differentiation	of	cells	in	hydrogels:		
Small	 10	 µL	 TG-PEG	 hydrogels	 (1.7%	 w/v)	 containing	 Lys-RGD	 (50	 µM)	 and	 combinations	 of	 the	 different	
streptavidin	 linkers	 (5	 µM)	 with	 or	 without	 rhBMP-2-biotin	 (50	 ng)	 were	 formed	 with	 single	 cells	 at	 a	 final	
concentration	of	2	×106	cells	mL-1.	These	hydrogels	were	then	embedded	in	a	second	20	µL	hydrogel	with	the	same	
formulation	except	that	no	rhBMP-2-biotin	was	included.	The	hydrogel	constructs	were	then	glued	at	the	bottom	of	a	
48-well	plate	and	cultured	in	the	appropriate	cell	culture	medium.	Medium	was	replaced	every	second	day	and	cells	
were	 cultured	 up	 to	 9	 days.	 The	 hydrogel	 constructs	 were	 then	 either	 stained	 with	 ALP	 substrate	 or	 fixed	 in	 4%	
paraformaldehyde	for	10	minutes	before	proceeding	to	immunostaining.	
Immunostaining	of	alkaline	phosphatase:		
The	hydrogel	constructs	were	fixed	in	4%	paraformaldehyde	for	20	minutes.	Cell	nuclei	were	stained	with	Hoechst	
and	 presence	 of	 ALP	 was	 assessed	 with	 mouse	 anti-bone	 alkaline	 phosphatase	 primary	 antibody	 (Abcam,	 United	
Kingdom)	 at	 a	 1:500	 dilution	 and	 goat	 anti-mouse	 IgG	H&L	 (Alexa	 Fluor®	 488)	 secondary	 antibody	 (Abcam,	United	
Kingdom)	at	 a	1:1000	dilution.	 Images	were	acquired	with	a	 confocal	 laser	 scanning	microscope	Leica	SP5,	150	µm	
stack	with	2.5	µm	z-step.	
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Chapter	4 Evaluation	 of	 growth	 factors	 modulating	
angiogenesis	
	
4.1 Introduction	
Blood	 vessels	 growth	 is	 an	 important	 factor	 in	 regenerative	 medicine	 and	 in	 the	 design	 of	 engineered	
tissues.	 On	 the	 one	 hand,	 gaining	 knowledge	 on	 angiogenesis	 allows	 developing	 strategies	 for	 the	 treatment	 of	
ischemic	 diseases.	 On	 the	 other	 hand,	 vascularization	 is	 a	 factor	 that	 can	 strongly	 limit	 the	 size	 of	 engineered	
constructs	and	that	is	critical	to	ensure	their	viability	upon	transplantation,	by	providing	oxygen	and	nutrients	to	the	
cells	and	their	microenvironment.	Angiogenesis	in	vivo	is	a	complex	process	that	is	tightly	regulated.	In	order	to	allow	
the	growth	of	new	vascular	structures,	angiogenic	signals	require	proper	spatial	and	temporal	localization	in	the	ECM,	
an	aspect	that	is	crucial	to	include	in	the	engineering	of	tissue	constructs.[161,	162]		
Amongst	 the	most	 commonly	 employed	 angiogenic	 factors	 for	 such	 scaffold	 engineering	 approaches	 are	 VEGF,	
FGF-2	and	PDGF,	which	all	play	a	 role	 in	endothelial	cell	 recruitment,	capillary	 formation	and	vessel	maturation.[163]	
The	ephrins	and	their	Eph	receptors	(described	in	Section	1.5.3)	represent	another	category	of	growth	factors,	which	
have	 also	 been	 studied	 for	 their	 role	 in	 angiogenesis.	 Eph	 receptors	 are	 an	 important	 family	 of	 receptor	 tyrosine	
kinase,	which	bind	to	their	ephrin	counterparts	and	play	an	important	role	in	cell-cell	interactions.	They	are	involved	in	
many	 biological	 processes	 as	 mediators	 of	 cell	 adhesion,	 repulsion,	 migration	 and	 ECM	 attachment	 and	 are	 of	
particular	interest	due	to	their	ability	to	induce	bi-directional	signaling	during	cell-cell	interactions.[105]	In	recent	years,	
many	 studies	 have	 shown	 their	 involvement	 in	 vascular	 development.	 They	 are	 commonly	 used	 as	 markers	 to	
differentiate	between	 venous	 and	 arterial	 endothelial	 cells	 during	 the	 early	 stages	of	 vessel	 formation,	 and	 can	be	
expressed	by	mesenchymal	 supporting	cells	as	well.[104,	 107]	Ephrins	and	Eph	 receptors	 represent	 thus	an	 interesting	
target	 for	 the	 study	 and	 recapitulation	 of	 vascular	 networks	 and	 could	 potentially	 serve	 as	 important	 co-factor	
alongside	 angiogenic	 factors	 to	 obtain	 controlled	 blood	 vessel	 formation	 in	 engineered	 tissues.	 For	 this	work,	 four	
different	ephrin	proteins	were	 selected	 to	assess	 their	effect	on	endothelial	 cell	migration	and	 the	development	of	
vascular	 structures:	 ephrin-A1,	 ephrin-A5,	 ephrin-B1	 and	ephrin-B2.	 Expression	of	 ephrin-A1	has	been	 shown	 to	be	
present	in	vasculature	during	mouse	embryonic	development,[164]	and	is	also	involved	in	vascular	signaling	pathways	
in	conjunction	to	VEGF	and	TNF-α,	as	well	as	in	EC	migration	and	assembly,	along	with	its	receptor	EphA2.[104,	165,	166]	
Ephrin-A5	 has	 mainly	 been	 studied	 in	 the	 context	 of	 neurogenesis	 and	 cancer	 for	 its	 repulsive	 effect	 on	 cell	
migration,[167,	168]	and	although	little	is	known	on	its	function	in	angiogenesis,	 its	high	affinity	for	the	EphB2	receptor	
that	normally	binds	ephrinB1	and	ephrinB2	(both	involved	in	angiogenesis)	makes	it	an	interesting	candidate.[107,	167]	
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Ephrin-B1	has	been	shown	to	have	a	pro-angiogenic	role	and	is	assumed	to	be	involved	in	EC	attachment	to	the	ECM	
by	activation	of	integrins.[107,	169,	170]	Finally,	ephrin-B2	plays	an	important	role	in	vascular	development	by	regulating	
remodeling,	 vessel	 maturation,	 VEGF-induced	 angiogenesis,	 and	 is	 involved	 in	 spatial	 guidance	 and	 discrimination	
between	arterial	and	venous	structure.[89,	169-171]	Furthermore	the	role	of	netrin-4,	which	has	been	described	in	Section	
1.5.3,	was	assessed	in	the	context	of	blood	vessel	development	by	evaluating	its	anti-angiogenic	effects	on	the	chicken	
chorioallantoic	membrane	assay.			
The	 chicken	 chorioallantoic	membrane	 (CAM)	 is	 an	easily	 accessible,	 technically	 simple,	 rapid	and	 cost-effective	
model	 for	 the	 screening	of	 tissue-engineered	constructs.[171,	 172]	 The	CAM	 is	an	extra-embryonic	membrane	present	
during	the	development	of	the	chick	embryo	and	is	mainly	responsible	for	gas	exchange	and	distribution	of	nutrients.	
It	is	highly	vascularized	and	is	thus	commonly	used	to	study	angiogenesis	in	short-term	and	large-scale	screenings.[173]	
Typically,	 the	 CAM	 starts	 forming	 on	 day	 3-4	 after	 incubation	 and	 is	 mainly	 composed	 of	 undifferentiated	 blood	
vessels	distributed	across	the	mesoderm.	These	vascular	structures	develop	and	grow	rapidly	until	day	8,	when	some	
vessels	start	differentiating	into	capillaries	that	will	form	a	network	at	the	base	of	the	ectoderm.	The	capillary	network	
continues	to	develop	and	is	generally	completed	by	day	10.	By	day	13-14	the	capillary	network	is	fully	differentiated	
and	has	reached	the	surface	of	the	ectoderm,	just	beneath	the	shell	membrane.	From	a	histological	view,	the	CAM	is	
composed	 of	 two	 epithelial	 layers	 that	 border	 a	 thin	 layer	 of	 stroma.	 The	 capillary	 plexus	 is	 located	 in	 the	 upper	
portion	 of	 the	 stroma,	 lining	 the	 upper	 epithelium.	 The	 rest	 of	 the	 vasculature	 as	 well	 as	 lymphatic	 vessels	 are	
distributed	across	the	stroma.[171,	174]		
Due	 to	 its	 ease	of	 access,	 cost-effectiveness	and	 its	 extensive	 vascularization,	 the	 chicken	CAM	 is	often	used	 to	
evaluate	 angiogenic	 processes	 and	 to	 determine	 the	 effects	 of	 certain	 molecules	 and	 growth	 factors	 on	 vascular	
development	 and	 morphogenesis	 or	 for	 studying	 tumor	 growth.[174].	 This	 can	 be	 done	 by	 a	 variety	 of	 methods,	
including	stimulation	with	pro-	and	anti-angiogenic	factors,	and	vascularization	of	tissue	grafts.[171]	Furthermore,	the	
CAM	vasculature	develops	 in	 a	 short	 time,	which	offers	 a	window	 for	 the	 study	of	 processes	 at	 different	 stages	of	
vascular	growth	and	of	developmental	pathways,	with	relatively	low	immunogenic	responses	from	the	CAM.	But	it	is	
important	 to	mention	 that	 limitations	 can	 arise	 due	 to	 species-related	 incompatibilities.	 Nevertheless,	 the	 chicken	
CAM	assay	represents	an	attractive	model	for	the	rapid	screening	of	factors	and	their	angiogenic	effects.	
Taken	 together,	 these	 different	 aspects	 of	 vascular	 development	 in	 tissue	 engineering	 show	 that	 the	 selected	
factors	could	be	interesting	targets	for	the	development	of	pre-vascularized	tissue	constructs,	especially	in	regards	to	
spatial	 and	 temporal	 control	 of	 vessel	 growth	 combined	 to	 a	modular	 PEG	 hydrogel	 platform	 for	 support.	 And	 to	
understand	the	roles	of	these	growth	factors	on	vasculature,	the	CAM	assay	represents	a	relatively	easy	method	for	
obtaining	the	first	insights	on	the	effect	of	ephrin	signaling	on	vascular	morphology	and	development.	
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4.1.1 Objective	
With	the	tools	in	hand	to	design	and	assemble	tunable	microenvironment	for	cells,	it	becomes	important	to	assess	
if	these	strategies	can	be	combined	with	vascularization.	The	TG-PEG	platform	used	here	has	recently	been	shown	to	
be	 able	 to	 host	microvascular-like	 networks	 formed	 co-cultures	 of	 BM-MSC	 and	 ECs.[80]	 Therefore,	 it	 would	 be	 an	
advantage	 to	 have	 a	 relatively	 simple	 and	 fast	 method	 for	 the	 first	 screening	 of	 angiogenic	 factors,	 which	 could	
facilitate	the	formation,	guidance	and	maintenance	of	pre-vascular	structures	 in	TG-PEG	hydrogels.	To	this	purpose,	
we	studied	the	effects	of	such	angiogenic	factors	on	the	vasculature	of	the	chicken	CAM.	Netrin-4	was	selected	due	to	
its	potential	anti-angiogenic	effect,	which	was	assessed	on	the	chicken	CAM.	Ephrin-A1,	A5,	B1	and	B2	were	selected	
for	their	known	role	as	cell	guidance	cues	and	role	in	the	regulation	of	angiogenesis	and	their	effect	was	evaluated	on	
the	chicken	CAM	as	well	as	in	cell	migration	assays.	VEGF-A	was	chosen	as	a	benchmark	pro-angiogenic	factor,	since	
its	implication	in	angiogenesis[99,	175]	and	its	effect	on	the	chicken	CAM	have	already	been	characterized.[75,	176,	177]	
	
4.2 Results	and	discussion	
4.2.1 Anti-angiogenic	effect	of	netrin-4	on	the	chicken	CAM2	
The	chicken	CAM	vasculature	was	stimulated	with	full-length	netrin-4	over	a	period	of	48	hours.	To	do	so,	soluble	
netrin-4	was	 incorporated	 in	TG-PEG	hydrogels,	which	were	placed	on	the	surface	of	the	CAM	vasculature	on	day	9	
after	 incubation	of	 the	eggs.	BSA	 incorporated	 in	 the	hydrogels	was	used	as	protein	control	and	 to	ensure	 that	 the	
application	of	the	TG-PEG	hydrogel	itself	had	no	influence	on	the	vasculature.	Results	were	furthermore	compared	to	
areas	of	 the	vasculature	 that	had	 received	no	 treatment.	The	effects	of	netrin-4	were	 then	assessed	12,	24	and	48	
hours	post-treatment.	For	each	time	point	and	treatment,	images	of	the	chicken	CAM	blood	vessels	were	acquired	via	
fluorescent	microscopy	after	injection	of	a	FITC-Dextran	solution	in	the	vascular	network.	The	vascularized	area	for	the	
treatment	and	control	was	quantified	with	a	semi-automated	image	analysis	script	that	measures	the	hole	area	of	the	
capillary	plexus.	As	can	be	seen	in	Figure	4.1A,	the	percentage	of	the	vascularized	area	in	CAMs	treated	with	netrin-4	
(~75%)	 already	 showed	 a	 slight	 decrease	 in	 comparison	 to	 the	 control	 (~80%)	 after	 12	 hours.	 Following	 24	 and	 48	
hours,	 the	 decrease	 in	 vascularized	 area	 became	 even	 more	 significant	 reaching	 approximately	 70%	 then	 55%	
respectively,	whereas	the	control	area	remained	constant	 (~80%).	 	Additionally,	we	performed	histological	stainings	
(eosin	and	hematoxylin)	of	the	CAMs	after	48	hours	of	treatment	to	highlight	the	changes	in	capillary	density	(Figure	
4.1B).	Control	area	of	the	CAMs	showed	a	dense	distribution	of	the	capillary	lining	the	epithelium,	but	netrin-4	treated	
regions	only	possessed	a	few	capillaries	dispersed	along	the	epithelial	layer.	
																																																																										
2	Adapted	from:	R	Reuten,	S	Metzger,	Z	Zhou,	J	Kaltenberg,	KK	McKee,	M	McDougall,	T	Bald,	K	Pool,	T	Tüting,	B	Brachvogel,	P	Zi-
grino,	J	Stetefeld,	V	Djonov,	W	Bloch,	PD	Yurchenco,	E	Pöschl,	M	Ehrbar,	M	Koch,	Netrin-4	regulates	functional	vascular	basement	
membrane	assembly	and	neo-angiogenic	events,	submitted	for	publication,	2016.	
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As	 netrin	 is	 known	 to	 be	 able	 to	 strongly	 interact	 with	 laminin[178,	 179]	 we	 hypothesized	 that	 netrin-4	 could	
potentially	influence	the	vascular	basement	membrane	by	interacting	with	laminin.	This	could	in	turn	have	an	effect	
on	pericytes	and	on	 the	stability	of	 the	vascular	epithelium.	Therefore	we	performed	ultrastructural	analysis	of	 the	
CAM	after	48	hours	of	treatment	to	assess	the	state	of	the	basement	membrane	(Figure	4.1C).	In	CAMs	treated	with	
netrin-4,	 pericytes	 appeared	 detached	 from	 ECs,	 compared	 to	 the	 control	 where	 pericytes	 are	 normally	 in	 close	
contact	with	ECs.	Additionally,	where	the	basement	membrane	can	be	seen	surrounding	and	embedding	pericytes	and	
ECs	in	the	control,	it	was	almost	completely	absent	in	the	CAMs	treated	with	netrin-4.	These	results	show	that	netrin-
4	has	a	detrimental	effect	on	the	capillary	network,	in	the	context	of	the	chicken	CAM.	Furthermore,	this	effect	seems	
to	be	linked	with	the	stability	of	the	basement	membrane	and	the	stabilizing	interactions	between	pericytes	and	ECs,	
which	 are	 compromised	 in	 presence	 of	 netrin-4.	 This	 shows	 the	 strong	 potential	 of	 netrin-4	 as	 an	 anti-angiogenic	
factor,	which	could	be	used	in	order	to	regulate	angiogenesis.	
	
	
Figure	4.1.	Netrin-4	inhibits	angiogenesis	in	the	ex	ovo	chicken	CAM	assay.		
A)	Visualization	of	capillaries	via	FITC-dextran	injection	of	untreated	(ctrl),	BSA-	and	netrin-4-treated	CAMs	after	12,	24	and	48	h,	
scale	bars	=	100	µm.	The	vascularized	area	from	different	protein	treatments	was	determined	at	12,	24	and	48	h	(mean	±	s.d.;	n	=	5;	
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****P	<	0.0001,	Student’s	t-test).	B)	H&E	staining	of	untreated	(ctrl),	BSA-	and	netrin-4-treated	CAMs	after	48	h.	Red	lines	indicate	
holes	in	the	capillary	plexus.	Scale	bar	=	20	µm.	C)	Ultrastructural	analyses	of	control	and	netrin-4	treated	CAMs	using	transmission	
electron	microscopy.	 Images	 show	 the	 capillary	 endothelium	 surrounded	by	perivascular	 cells.	 The	endothelium	E	 is	 shown	and	
perivascular	 cells	 (PVCs)	 are	 indicated	 as	 P.	 Electron	microscopy	 images	 highlight	 the	 vascular	 basement	membrane	 [vBM,	 red	
arrow	heads	(middle)	and	red	asterisks	(bottom)]	between	the	endothelium	and	PVCs,	which	are	surrounded	by	a	vBM	layer.	Scale	
bars	=	top:	2	µm;	middle:	1	µm;	bottom:	0.5	µm.	
	
4.2.2 Effects	of	ephrins	and	VEGF	on	the	chicken	CAM	
To	 determine	 if	 ephrins	 could	 be	 candidates	 in	 the	 establishment	 of	 a	 hydrogel	 platform	 allowing	 controlled	
vascularization,	we	assessed	their	effects	on	the	capillary	network	of	the	chicken	CAM.	To	do	so,	we	stimulated	the	
chicken	CAM	with	ephrin-A1,	A5,	B1	and	B2,	which	were	delivered	in	soluble	form	via	TG-PEG	hydrogel	placed	on	the	
surface	of	the	CAM	capillary	network	on	day	9	after	incubation	of	the	eggs.	Treatment	with	VEGF165	was	used	as	pro-
angiogenic	control,	whereas	non-treated	areas	served	as	negative	control	(control).	Hydrogels	containing	no	protein	
were	 used	 as	 an	 additional	 control	 to	 ensure	 that	 the	 hydrogel	 itself	 had	 no	 effect	 on	 the	 CAM	 (not	 shown).	 The	
vasculature	 was	 imaged	 using	 fluorescence	 microscopy	 after	 injection	 of	 a	 FITC-Dextran	 solution	 in	 the	 vascular	
network.	Looking	at	the	morphology	of	the	blood	vessels	and	capillaries	in	Figure	4.2,	VEGF165	treatment	resulted	in	
thicker	 blood	 vessels	 and	 more	 chaotic	 architecture	 compared	 to	 the	 control.	 Furthermore,	 the	 blood	 vessels	
presented	the	typical	spiral-like	or	“corkscrew-like”	structures,	as	described	in	other	studies	about	the	effects	of	VEGF	
on	 the	 CAM	 vasculature.[180,	 181]	 The	 capillary	 density	 seemed	 increased	 as	 well,	 as	 can	 be	 seen	 from	 the	 higher	
fluorescent	background.	Ephrin-A1,	B1,	and	B2	all	seemed	to	have	rather	pro-angiogenic	effects	on	the	vasculature	to	
some	extent,	 as	 could	be	 seen	 from	 the	 chaotic	 vessel	 growth,	 the	 spiral-like	 structures	 and	 the	 increase	 in	 vessel	
diameter.	 Ephrin-A1	 treatment	 induced	particularly	more	 spiral-like	 structures,	especially	on	blood	vessels	of	 lower	
hierarchy	that	connect	to	the	capillary	plexus.	For	both	ephrin-A1	and	B1,	the	capillary	density	was	also	increased	and	
appeared	almost	leaky	in	some	areas.	Ephrin-B2	induced	a	blood	vessel	morphology	that	was	very	similar	to	the	effect	
of	 VEGF165	 with	 thick	 wavy	 vascular	 structures.	 Ephrin-A5	 had	 a	 very	 different	 effect	 and	 reduced	 the	 overall	
vascularization.	The	blood	vessels	appeared	very	thin	and	with	less	hierarchical	structure.	The	strongest	effect	could	
be	seen	on	the	capillary	plexus,	where	 large	non-vascularized	areas	 in	the	form	of	hole	 in	the	capillary	network	are	
present.	Although	the	role	of	ephrin-A5	in	angiogenesis	if	any	is	not	yet	well	understood,	it	has	been	shown	to	interact	
with	the	EphB2	receptor,	which	is	involved	in	vascular	development.[107,	167]	We	thus	hypothesize	that	ephrin-A5	could	
be	used	as	an	anti-angiogenic	guiding	cue	to	set	boundaries	to	the	development	of	blood	vessels.	
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Figure	4.2.	Effects	of	ephrins	and	VEGF	on	the	morphology	of	the	CAM	vasculature.		
Visualization	of	the	capillaries	via	FITC-dextran	injection	in	untreated	CAMs	(control),	or	CAMs	stimulated	with	either	VEGF,	ephrin-
A1,	ephrin-A5,	ephrin-B1	or	ephrin-B2	at	48	h	post-treatment	(scale	bar	=	250	µm).	
	
Due	 to	 the	 chaotic	morphology	 and	 increased	 capillary	density	 (leading	 to	 a	high	background	noise),	 the	 image	
analysis	used	to	quantify	the	effect	of	netrin-4	under	Section	4.2.1	could	not	be	used	to	quantify	the	effects	of	VEGF	
and	the	selected	ephrins.	However	it	would	be	of	great	interest	to	have	access	to	an	automated	and	reliable	method	
that	could	analyze	different	morphological	parameters	such	as	branching,	vessel	 length,	number	and	diameter.	The	
next	section	addresses	the	possibility	of	developing	such	method.		
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4.2.3 Casting	of	the	CAM	with	polyurethane	for	µCT	quantification	
Because	morphological	analysis	of	the	vasculature	could	not	be	automated	for	the	images	obtained	from	VEGF165,	
and	 ephrin	 treatment	 with	 live	 fluorescence	 microscopy,	 we	 developed	 a	 technique	 that	 allowed	 us	 to	 inject	 a	
polyurethane	 solution	 in	 the	 CAM	 vasculature	 for	 corrosion	 casting	 (Figure	 4.3).	 Using	 a	 syringe	 pump,	 untreated	
CAMs	were	first	perfused	with	a	1%	PFA	solution	 in	order	to	 flush	the	blood	and	fix	 the	vasculature.	Next	the	CAM	
vasculature	was	perfused	with	polyurethane	resin,	again	with	the	help	of	the	syringe	pump	to	obtain	a	constant	and	
controlled	 flow	 rate.	The	polyurethane	solution	polymerized	 to	a	hard	plastic	within	1	hour	and	 the	 remaining	 soft	
tissues	were	dissolved	during	24	hours	using	a	7.5%	KOH	solution,	followed	by	a	neutralization	step	of	12	hours	in	a	
5%	formic	acid	solution.	After	 the	polyurethane	cast	was	allowed	to	dry,	6mm-biopsy	punches	were	retrieved	 from	
the	CAMs	and	processed	by	µCT	 imaging.	The	obtained	 images	were	then	reconstructed	to	obtain	3D	model	of	 the	
vascular	network.	This	shows	that	casting	of	CAMs	and	µCT	imaging	could	be	an	efficient	method	for	the	computed	
analysis	of	the	CAM	vasculature,	as	has	been	successfully	done	with	the	same	polyurethane	resin	in	mice.[182,	183]		
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Figure	4.3.	Polyurethane	casting	of	the	chicken	CAM	and	analysis.	
A)	The	cast	is	obtained	by	injecting	polyurethane	resin	in	the	vascular	system	of	the	CAM.	The	resin	polymerizes	within	1	h	and	the	
soft	 tissues	 can	 then	be	dissolved.	 B)	 Left	 -	 remaining	polyurethane	 cast	 after	 complete	digestion	of	 the	 soft	 tissues,	 right	 -	 3D	
representation	of	µCT	scan	obtained	from	a	6mm	biopsy	punch	of	a	cast.	Scale	bars	=	1	cm	and	1	mm	respectively.	C)	Brightfield	
and	fluorescence	microscopy	images	of	the	cast.	Scale	bar	=	250	µm.	
	
4.2.4 Effects	of	ephrins	cell	migration	
After	showing	that	ephrins	could	influence	blood	vessel	morphology	and	capillary	density	of	the	CAM	vasculature,	
we	wanted	to	assess	their	effect	on	the	migration	of	cells	as	ephrins	are	often	described	acting	as	guidance	cues.	
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4.2.4.1 Ephrins	and	2D	cancer	cell	migration	
In	order	to	study	cell	migration	upon	ephrin	stimulation,	we	wanted	to	develop	a	system	using	our	synthetic	TG-
PEG	hydrogels.	To	establish	the	system,	we	chose	to	study	the	cell	migration	of	the	cancer	cell	line	PC-3,	as	a	previous	
study[168]	showed	and	quantified	how	ephrins	could	influence	the	migration	direction	of	these	cells	in	2D.	We	seeded	
PC-3	cells	on	the	surface	of	TG-PEG	hydrogels	patterned	with	four	different	types	of	Fc-tagged	ephrins	(Fc-ephrin-A1,	
Fc-ephrin-A5,	 Fc-ephrin-B1	 and	 Fc-ephrin-B2).	 The	 ephrins	 were	 immobilized	 via	 the	 Gln-ZZ[81]	 linker	 that	 was	
incorporated	in	the	hydrogels.	Because	clustering	of	ephrins	is	known	to	affect	ephrin	signaling,	the	experiment	was	
also	carried	out	with	ephrin	cluster	patterns,	obtained	from	multimerizing	the	Fc-tagged	ephrins	with	human	anti-IgG	
antibody	before	patterning.	 Cell	migration	was	 then	 recorded	 via	 time-lapse	microscopy	over	 a	 period	of	 24	hours	
(Figure	4.4).	Using	an	 image	analysis	 script,	 cells	 randomly	 selected	within	 the	patterned	 regions	were	 tracked	and	
total	migration	distance	was	quantified	and	compared	to	cells	seeded	outside	of	the	ephrin	patterns.		
	
	
Figure	4.4.	Effects	of	ephrin	presentation	on	the	2D	migration	of	PC-3	cells.	
Total	distance	travelled	was	measured	by	cell	tracking	for	each	condition.	(*,	p	<	0.05;	**,	p	<	0.01;	***,	p	<	0.001,	Student’s	t-test).		
	
The	 acquired	 data	 showed	 that	 the	 total	migration	 distance	was	 only	 significantly	 affected	 by	 stimulation	with	 Fc-
ephrin-A5,	which	showed	an	increase	in	distance.	Also,	cells	migrated	on	shorter	distances	when	stimulated	with	Fc-
ephrin-A5	 clusters.	 Fc-ephrin-B2	 did	 not	 show	 significant	 changes	 in	migratory	 behavior,	 but	 the	 clustering	 of	 the	
factor	reduced	the	migration	of	cells.	Although	Fc-ephrin-A1	stimulation	hinted	towards	an	increase	in	migration	and	
Fc-ephrin-B1	 stimulation	 created	 a	 slightly	 decreased	 migration,	 results	 were	 not	 significantly	 different	 from	 the	
control.	Furthermore	both	Fc-ephrin-A1	and	Fc-ephrin-B1	clustering	did	not	have	a	significant	effect.		
These	preliminary	results	suggested	that	Fc-ephrin-A5	and	Fc-ephrin-B2	could	be	potential	candidates	for	studying	the	
effects	of	ephrins	on	cell	migration,	but	further	experiments	are	necessary.	However,	during	the	development	of	this	
migration	assay,	technical	and	biological	limitations	made	it	evident	that	a	3D	experiment	setup	was	needed.	Indeed	
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studying	 the	 cell	 migration	 in	 3D	 conditions	 would	 be	 more	 pertinent	 to	 our	 goal	 of	 designing	 cell-instructive	
microenvironments.	Moreover	distribution	and	immobilization	of	ephrins	in	3D	matrices	would	be	more	relevant,	as	
2D	patterning	of	ephrins	make	it	difficult	to	determine	the	appropriate	concentrations	needed	for	stimulation	and	is	
far	from	physiological	conditions.	
	
4.2.4.2 Ephrins	and	3D	endothelial	cell	migration	
To	have	a	better	adapted	method	for	the	assessment	of	ephrin	effects	on	endothelial	cell	migration,	we	chose	to	
study	 the	 3D	 cell	 sprouting	 from	 spheroids.	 Cell	 spheroids	 were	 formed	 with	 HUVECs	 incorporated	 in	 TG-PEG	
hydrogels.	 Cell	 migration	 from	 the	 spheroids	 was	 assessed	 for	 24	 hours	 after	 stimulation	 with	 the	 four	 different	
ephrins,	 which	were	 added	 solubly	 at	 a	 concentration	 of	 1µg/mL	 to	 the	 culture	medium.	 The	 cell	 spheroids	 were	
stimulated	with	the	clustered	ephrins	as	well	for	comparison.	The	positive	control	for	migration	was	soluble	VEGF165	at	
a	concentration	of	100ng/mL	and	the	negative	control	was	the	medium	without	addition	of	any	protein.	Cell	migration	
was	recorded	by	time-lapse	microscopy	over	a	period	of	24	hours	(Figure	4.5).		
	
Figure	4.5.	HUVEC	sprouting	from	spheroids	after	18	hours	of	stimulation	with	ephrins	and	VEGF	(scale	bar	=	100	µm).	
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Our	preliminary	results	indicated	that	ephrin-A1	induced	some	migration	from	the	spheroids,	which	was	however	not	
comparable	to	the	positive	control	(VEGF165).	Clustering	the	protein	with	antibody	did	not	seem	to	influence	the	effect	
on	 cell	 migration.	 Stimulation	 with	 ephrin-A5	 appeared	 to	 completely	 prevent	 cells	 from	 migrating	 out	 of	 the	
spheroids,	 although	 the	 cells	 remained	 active	 as	 could	 be	 seen	 from	 the	 extension	 of	 filopodia.	 Interestingly,	
clustering	of	ephrin-A5	canceled	this	effect	and	cells	could	sprout	from	the	spheroid.	For	ephrin-B1,	only	a	few	cells	
migrated	 out	 of	 the	 spheroids	 and	 clustering	 did	 not	 have	 any	 significant	 effect.	 Ephrin-B2	 induced	 the	 strongest	
migration	 amongst	 the	 tested	 ephrins	 (comparable	 to	 VEGF165)	 and	 its	 effect	 seemed	 to	 be	 decreased	 when	 pre-
clustered	with	an	antibody.	Moreover,	these	results	follow	the	same	trends	observed	in	the	2D	migration	assay	under	
Section	4.2.4.1,	i.e.	that	clustering	of	ephrin-A5	and	ephrin-B2	seem	to	alter	their	effect	on	cells,	but	not	for	ephrin-A1	
and	B1.	
These	data	show	again	that	ephrins,	in	particular	ephrin-A5	and	ephrin-B2,	can	influence	cell	migration	and	could	be	
integrated	in	our	TG-PEG	hydrogel	platform	to	regulate	cell	migration.	Additional	experiments	are	of	course	necessary	
to	fully	understand	if	and	how	these	proteins	can	be	used	for	that	purpose.	
	
4.3 Conclusion	
We	 have	 shown	 the	 effect	 of	 the	 angiogenic	 factors	 netrin-4,	 VEGF,	 ephrin-A1,	 A5,	 B1	 and	 B2	 on	 the	
vascularization	of	the	chicken	CAM	and	demonstrated	that	ephrins	are	able	to	influence	EC	migration.		
Netrin-4	had	a	very	strong	anti-angiogenic	effect	on	the	capillaries	and	blood	vessels	of	 the	CAM	and	 induced	a	
decrease	 in	 capillary	 density	 as	well	 as	 a	 reduction	 in	 blood	 vessel	 diameter.	We	 hypothesized	 that	 netrin-4	 could	
destabilize	 the	 basement	 membrane	 by	 interacting	 with	 laminin	 and	 were	 able	 to	 show	 a	 disrupted	 basement	
membrane	in	the	CAM	vasculature	with	netrin-4	treatment.	
Amongst	 the	ephrins	used	 to	 treat	 the	CAM,	ephrin-A5	and	ephrin-B2	 showed	 the	 strongest	 and	perhaps	more	
interesting	effects.	Ephrin-A5	had	a	strong	anti-angiogenic	effect	that	lead	to	the	degradation	of	the	capillary	network,	
whereas	 ephrin-B2	 induced	 chaotic	 vascular	 structures	 and	 increased	 blood	 vessel	 diameter	 and	 a	 blood	 vessel	
morphology	similar	to	the	effect	of	VEGF165.	Interestingly,	these	results	could	be	paralleled	in	the	context	of	our	cell	
migration	 experiment,	 where	 ephrin-A5	 prevented	 the	 sprouting	 of	 ECs	 from	 cell	 spheroids,	 whereas	 ephrin-B2	
stimulated	cell	migration	in	a	comparable	manner	as	VEGF165.	
These	preliminary	data	indicate	that	these	factors	play	an	important	role	in	the	formation	of	blood	vessel	and	thus	
it	would	be	of	great	 interest	to	 incorporate	them	to	our	modular	TG-PEG	hydrogel	platform	in	order	to	 facilitate	or	
even	induce	the	formation	of	microvascular	structures.	
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4.4 Experimental	Section	
Chick	Chorioallantoic	Membrane	(CAM)	angiogenesis	assay	and	live	imaging:	
The	ex	ovo	culture	of	 the	chicken	embryos	was	adapted	 from	Auerbach	et	al.[184].	Briefly,	 fertilized	Ross	chicken	
eggs	(Wüthrich	Brüterei	AG,	Switzerland)	were	incubated	at	37°C	for	3	days	in	humidified	atmosphere.	On	day	3,	the	
eggs	were	carefully	opened	and	their	content	was	transferred	into	100	x	20	mm	Petri	dishes	(Corning,	Switzerland).	
The	chicken	embryos	were	incubated	in	the	same	conditions	for	6	more	days.	On	day	9,	the	PEG	hydrogels	with	and	
without	 growth	 factors	were	placed	on	 the	 surface	of	 the	CAM.	 15	µL	 PEG	hydrogels	were	 formed	by	 Factor	 XIIIa-
catalyzed	cross-linking	of	two	8-arm	PEG	components	(8-PEG-Gln	and	8-PEG-MMPsensitive-Lys)	in	50	mM	Tris	pH	7.6,	50	
mM	CaCl2	buffer	to	a	final	PEG	concentration	of	2%	(w/v).
[75]		
In	 Section	 4.2.1,	 hydrogels	 contained	 4.25	 µg	 of	 recombinant	 netrin-4	 per	 gel.	 In	 Section	 4.2.2,	 hydrogels	 either	
contained	1	µg/mL	recombinant	Fc-ephrin	protein	or	100	ng/mL	VEGF.	
After	48	h	of	treatment,	100	µl	of	2.5%	FITC-dextran	(MW	20,000,	Sigma-Aldrich,	Switzerland)	 in	0.9%	NaCl	solution	
were	 injected	 intravenously	 in	 the	 CAM.	 The	 vasculature	 was	 visualized	 by	 fluorescence	 microscopy	 and	 images	
around	the	treatment	site	were	collected.	
The	 images	 collected	 by	 fluorescence	 microscopy	 were	 analyzed	 using	 the	 ImageJ	 software	 (ImageJ	 1.48,	
http://imagej.nih.gov/)	using	a	script	based	on	the	quantification	method	developed	by	Blacher	et	al.[185]	Background	
of	 each	 image	 was	 evened	 out	 and	 the	 contrast	 was	 enhanced.	 Then	 the	 threshold	 was	 adjusted	 manually	 do	
discriminate	 the	 vascularized	 area	 from	 the	 non-vascularized	 area,	 and	 the	 image	 was	 transformed	 into	 a	 binary	
image.	 A	 series	 of	 filters	 were	 applied	 then	 to	 refine	 the	 capillary	 structures.	 ROIs	 were	 set	 manually	 to	 exclude	
second-order	and	higher-ranking	blood	vessels	and	regions	with	underlying	blood	vessels.	The	non-vascularized	areas	
within	 the	 ROIs,	 as	 well	 as	 the	 total	 ROI	 area,	 were	measured.	 The	 obtained	 values	 were	 used	 to	 determine	 the	
distribution	non-vascularized	areas	in	the	capillary	network.	
Immunohistochemistry	of	the	CAM:	
After	live	imaging,	the	CAMs	were	fixed	with	4%	paraformaldehyde	solution	by	applying	the	solution	both	on	top	
and	beneath	the	CAM	membranes	and	 incubated	at	room	temperature	for	1	h.	The	area	around	the	treatment	site	
was	 carefully	 cut	 out	 and	 placed	 between	 cellulose	 sheets	 before	 being	 processed	 for	 paraffin	 embedding.	 Tissue	
sections	of	4	µm	were	cut	with	a	microtome	and	mounted	on	glass	slides	for	hematoxylin	and	eosin	staining.	
Transmission	electron	microscopy	analyses	of	the	capillary	structure	within	the	CAM:	
After	live	imaging,	CAMs	were	fixed	with	2.5%	glutaraldehyde	(buffered	with	0.1M	sodium-cacodylate,	pH	7.4,	540	
mOsm.)	by	applying	 the	 solution	both	on	 top	and	beneath	 the	CAM	membranes.	 They	were	post-fixed	 in	1%	OsO4	
(0.1M	 sodium-cacodylate,	 pH	 7.4,	 340mOsm),	 dehydrated	 in	 ethanol,	 and	 embedded	 in	 Epon	 812	 (Fluka,	 Buchs,	
Evaluation	of	growth	factors	modulating	angiogenesis	
71	
Switzerland).	Semi-thin	sections	were	prepared,	stained	with	toluidine	blue,	and	analyzed	with	a	light	microscope[186].	
Representative	areas	were	selected	and	further	imaged	by	transmission	electron	microscopy.	
Corrosion	casting	of	the	CAM:	
After	live	imaging,	the	CAMs	were	perfused	via	the	umbilical	artery	with	4%	PFA	in	PBS	using	a	syringe	pump	(Pico	
Pump,	KD	Scientific,	USA)	at	a	flow	rate	of	5	µL/min.	Immediately	following	perfusion,	a	solution	of	polyurethane	PU4ii	
supplemented	 with	 fluorescent	 UV	 dye	 (vasQtec,	 Switzerland)	 prepared	 according	 to	 manufacturer’s	 notice	 was	
infused	with	the	syringe	pump	at	a	flow	rate	of	3	µL/min.	After	resin	curing	for	1-2	hours	at	room	temperature,	the	
soft	tissues	were	macerated	in	7.5%	KOH	for	24	hours	at	room	temperature,	followed	by	decalcification	in	5%	formic	
acid	solution	for	12	hours	at	room	temperature.	Casts	were	washed	with	distillated	water	and	dried.	
For	microCT,	6mm	CAM	biopsy	punches	of	the	treated	areas	were	sent	to	b-cube	AG	(Switzerland)	for	imaging	with	
a	µCT	40	desktop	scanner	(Scanco	Medical	AG,	Switzerland)	and	3D	reconstruction.	
	
2D	cell	migration	assay:	
20	 µL	 PEG	 hydrogels	 (5%	 w/v)	 with	 a	 final	 concentration	 of	 5	 µM	 Gln-ZZ	 linker	 were	 formed	 as	 described	
previously.	The	Fc-ephrins	were	deposited	as	droplets	on	the	surface	of	the	PEG	gels	(2µL	droplets	containing	200ng	
Fc-ephrin)	 and	 given	 2	 hours	 to	 bind	 to	 the	 gel	 surface	 before	washing	 in	 50	mM	 Tris	 pH	 7.6	 buffer.	 FITC	 labeled	
antibody	was	added	with	each	droplet	to	help	localize	the	ephrin	patterns.	PC-3	cells	were	seeded	on	the	surface	of	
the	gel	 (0.5·105	 cells/mL)	and	cell	migration	was	 recorded	over	a	period	of	24	hours	by	 time-lapse	microscopy.	 For	
analysis,	5	cells	per	patterned	and	control	region	(4	regions	per	condition)	were	randomly	selected,	insofar	as	the	cells	
were	not	part	of	cell	cluster,	dividing	during	the	duration	of	the	time-lapse	movie	or	migrating	out	of	the	frame.	The	
cells	were	then	tracked	with	the	Manual	Tracking	plug-in	(ImageJ).	Mean	velocity	and	total	distance	for	each	cell	were	
analyzed.	
3D	endothelial	cell	spheroid	sprouting	assay:	
Spheroids	containing	500	HUVECs	were	formed	overnight	with	the	hanging	drop	technique	and	then	incorporated	
at	approximately	5	spheroids	per	PEG	hydrogel	(1.5%	w/v).	Each	hydrogel	was	then	glued	to	the	bottom	a	well	of	a	48-
well	plate,	and	cultured	in	500	µL	DMEM:EBM-2	(4:1)	medium	(with	10%	FCS),	supplemented	with	either	1µg/mL	of	
Fc-ephrin,	1	µg/mL	of	Fc-ephrin	pre-clustered	with	200ng/mL	of	anti-human	IgG	(Fc-specific)	antibody	(Sigma-Aldrich,	
Switzerland),	 or	 100ng/mL	 of	 VEGF165.	 Cell	 culture	 medium	 without	 addition	 of	 any	 protein	 served	 as	 control.	
Migration	was	recorded	with	by	time-lapse	microscopy	(Leica,	Switzerland)	over	a	period	of	24	hours.		
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Chapter	5 Conclusion	
	
	
5.1 Achieved	results	
In	 the	 natural	 ECM,	 growth	 factors	 often	 interact	 with	 the	 proteoglycans	 that	 constitute	 the	 cellular	
microenvironment,	which	crucially	contributes	to	the	preservation	of	growth	factor	bioactivity	and	which	can	improve	
and	 is	 sometimes	 required	 to	 induce	 the	 desired	 signaling	 response.	 Different	 strategies	 exist	 that	 mimic	 these	
properties.	 Some	 are	 based	 on	 the	 chemical	 and	 genetic	 engineering	 of	 growth-factor	 binding	 sites	 into	 synthetic	
scaffolds	 or	 the	modification	 of	 scaffolds	 and	 growth	 factors	with	 corresponding	 affinity	 binding	 domains.[81,	 120-128]	
Although	 many	 of	 these	 strategies	 are	 very	 promising,	 they	 can	 require	 time-consuming	 processes	 for	 the	
customization	of	each	growth	factor	and	can	sometimes	negatively	impact	growth	factor	functionality.	Furthermore,	
vascularization	 is	 essential	 to	 the	 survival	 of	 tissues,	 enabling	 the	 exchange	 of	 gases	 and	 nutrients,	 and	 the	
perivascular	ECM	play	a	critical	role	 in	the	development	of	blood	vessels.	 It	 is	therefore	very	desirable	to	reproduce	
vascular	structures	in	engineered	tissues.[83,	85,	163]	
The	 overall	 objective	 of	 this	 work	 was	 thus	 to	 develop	 a	 cell-responsive	 artificial	 microenvironment	 for	 the	
modular	presentation	of	growth	 factors,	 in	order	 to	 regulate	cell	behavior	 in	a	controlled	and	3D	 localized	manner.	
Furthermore,	we	investigated	potential	growth	factors	for	the	establishment	of	pre-vascular	networks	in	our	scaffolds.	
	
5.1.1 Streptavidin	linker	for	the	controlled	and	localized	immobilization	of	growth	factors	
With	these	aspects	in	mind,	the	purpose	of	the	work	in	Chapter	2	was	to	develop	a	strategy	for	the	immobilization	
of	 growth	 factors,	with	 relative	 ease	 of	 implementation	 and	 flexibility	 in	 the	 selection	 of	 growth	 factors.	We	 took	
advantage	of	 the	strong	affinity	of	 the	streptavidin-biotin	 interaction	 to	design	and	synthesize	a	peptide	 linker	 that	
could	be	covalently	 incorporated	 in	our	TG-PEG	hydrogels.	Several	commercial	biotinylation	kits	exist	with	different	
specificities	 for	 functional	 groups	 (such	 as	 primary	 amines,	 sulfhydryl	 groups	or	 carbohydrate	 residues)	 and	 can	be	
selected	 to	 biotinylate	 most	 of	 the	 desired	 growth	 factors	 without	 harming	 the	 target	 molecule,	 while	 the	
biotinylation	conditions	can	also	be	further	adapted	to	have	a	minimal	impact	on	the	growth	factor	biofunctionality.			
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To	 demonstrate	 the	 effectiveness	 of	 the	 synthesized	 streptavidin	 peptide	 linker,	 we	 chose	 to	 induce	 the	
differentiation	of	C2C12	cells	and	MSCs	with	immobilized	biotinylated	rhBMP-2.	Not	only	could	we	successfully	show	
the	osteogenic	differentiation	in	these	cells,	we	were	also	able	to	obtained	hydrogel	constructs	with	3D-localized	cell	
differentiation	corresponding	to	the	immobilized	rhBMP-2-biotin	pattern.	Although	the	constructs	shown	in	this	work	
had	 a	 very	 simple	 circular	 architecture,	 we	 hypothesize	 that	 this	 tool	 could	 be	 easily	 transferred	 to	 automated	
patterning	 technologies	 such	as	bio-printing.	 Thus,	 this	platform	 represents	a	 step	 towards	 the	generation	of	more	
complex	3D	cellular	architectures	to	better	mimic	native	tissues.	
	
5.1.2 MMP-sensitive	streptavidin	linker	for	cell-dependent	release	of	immobilized	growth	factors	
In	the	above	mentioned	streptavidin-biotin	immobilization	strategy,	the	release	of	growth	factor	depended	mainly	
on	 the	 degradation	 of	 the	 TG-PEG	 scaffold,	 which	 contains	 a	 collagen-derived	 protease-sensitive	 sequence.	 But	
despite	 successful	 cell	 differentiation,	 our	 results	 suggested	 that	 a	 portion	 of	 the	 immobilized	 growth	 factors	
remained	 inaccessible	 to	 the	cells,	decreasing	 the	dose	efficiency	of	 the	growth	 factor.	The	 focus	of	Chapter	3	was	
thus	to	design	a	peptide	linker	which	allowed	the	release	of	growth	factors	independently	from	scaffold	degradation.		
To	achieve	this,	we	developed	and	synthesized	a	streptavidin	linker	that	contained	three	repeats	of	a	proteolytically	
degradable	 domain	 specific	 to	 MMP-1	 and	 MMP-2,	 in	 order	 to	 increase	 the	 rate	 of	 growth	 factor	 release	 in	 the	
immediate	 vicinity	of	 the	 cells,	 depending	on	 their	proteolytic	 activity.	As	with	 the	previously	developed	 linker,	we	
demonstrated	 its	 covalent	 incorporation	 in	 the	 TG-PEG	 hydrogel	 backbone	 and	 its	 ability	 to	 efficiently	 immobilize	
biotinylated	proteins.	We	characterized	and	showed	the	specific	proteolytic	degradation	by	MMP-1	and	MMP-2.	Using	
the	model	of	BMP-2	 induced	osteogenic	differentiation	of	C2C12	 cells	 and	MSCs,	we	were	able	 to	demonstrate	an	
improved	 response	 in	 comparison	 to	 the	non-degradable	 linker.	Additionally,	our	 results	 showed	 that	 for	 the	 same	
total	amount	of	rhBMP-2-biotin	delivered,	immobilization	via	the	proteolytically	degradable	linker	outperformed	the	
presentation	 of	 soluble	 growth	 factor	 supplemented	 to	 the	 medium	 in	 relation	 to	 osteogenic	 differentiation.	 We	
believe	 that	 the	 availability	 of	 an	 MMP-sensitive	 peptide	 linker	 allows	 for	 an	 improved	 response	 to	 immobilized	
growth	factors	due	to	the	better	overall	release.		
	
5.1.3 Growth	factors	modulating	angiogenesis	
Furthermore,	 we	 addressed	 the	 vascularization	 of	 engineered	 tissues,	 which	 poses	 great	 limitations	 in	 the	
development	of	clinically	relevant	tissue	constructs,	by	evaluating	the	potential	of	selected	growth	factors	as	guiding	
cues	 and	 regulators	 of	 angiogenesis.	 In	 Chapter	 4,	 their	 effects	 on	 vascular	 morphology	 were	 assessed	 using	 the	
chicken	CAM	model	and	 their	 influence	on	cell	migration	was	 studied	 in	 the	prospect	of	establishing	microvascular	
networks	in	tissue-engineered	constructs.	
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5.1.3.1 Netrin-4	as	an	anti-angiogenic	factor	
In	our	investigation	of	factors	regulating	angiogenesis,	we	were	able	to	demonstrate	the	role	of	netrin-4	as	an	anti-
angiogenic	factor	using	the	chicken	CAM	model.	By	treating	the	vasculature	of	the	CAM	with	netrin-4	delivered	via	TG-
PEG	hydrogels,	we	could	observe	the	significant	reduction	of	the	vascularized	area	over	a	period	of	48	hours,	through	
live	imaging	of	the	vasculature	and	through	histological	staining	of	the	membrane.	Additionally,	we	investigated	the	
integrity	of	 the	vascular	basement	membrane	with	ultrastructural	analysis,	 since	 it	has	been	 reported	 that	netrin-4	
can	 interact	 with	 laminin.	 Indeed,	 we	 showed	 that	 in	 the	 capillary	 networks	 treated	 with	 netrin-4,	 the	 basement	
membrane	surrounding	the	pericytes	and	ECs	was	almost	completely	disrupted	and	that	the	pericytes	were	detached	
from	the	endothelium.	Our	data	thus	suggest	that	netrin-4	could	be	used	as	an	inhibitor	of	angiogenesis	or	as	a	tool	to	
study	the	effects	of	basement	membrane	disruption.	
	
5.1.3.2 Ephrins	as	guidance	cues	for	vascular	endothelial	cell	migration	
In	our	search	for	potential	cues	for	the	establishment	of	pre-vascular	structures	in	TG-PEG	constructs,	we	reported	
the	different	effects	of	ephrin-A1,	A5,	B1	and	B2	on	the	vascular	development	of	the	chicken	CAM.	We	delivered	the	
ephrins	on	the	CAM	vasculature	and	observed	the	changes	in	morphology.	Ephrin-A1	and	ephrin-B1	induced	chaotic	
vessel	growth	and	morphology	as	well	as	a	slight	increase	in	vessel	diameter.	Ephrin-A5	had	a	strong	anti-angiogenic	
effect,	disrupting	the	capillary	network	and	resulting	in	thinner	blood	vessels.	Ephrin-B2	had	an	effect	very	similar	to	
treatment	with	 the	well-know	 pro-angiogenic	 factor	 VEGF165,	with	 the	 appearance	 of	 blood	 vessels	with	 increased	
diameter,	increased	capillary	density	and	chaotic	vessel	morphology.	
Furthermore	 we	 collected	 preliminary	 data	 on	 the	 effects	 of	 ephrin	 in	 cell	 migration,	 as	 well	 as	 regarding	 the	
effects	of	ephrin	clustering.	Using	the	endothelial	cell	spheroid	sprouting	assay,	we	demonstrated	the	inhibitory	effect	
of	 ephrin-A5	 on	 cell	migration.	On	 the	 other	 hand,	 ephrin-B2	 strongly	 stimulated	 the	migration	 of	 cells	 out	 of	 the	
spheroid	 in	 a	 similar	 fashion	 to	 VEGF165.	 Both	 ephrin-A1	 and	 ephrin-B1	 only	 slightly	 induced	 the	migration	 of	 ECs.	
Regarding	clustering	of	ephrins,	both	the	endothelial	cell	spheroid	sprouting	assay	with	HUVECs	and	the	2D	cancer	cell	
migration	assay	with	PC-3	cells	showed	that	clustering	of	ephrin-A5	and	B2	influenced	their	biological	effect,	whereas	
this	could	not	be	observed	for	ephrin-A1	and	B1.	In	the	2D	cell	migration	assay,	clustering	of	both	ephrin-A5	and	B2	
lead	to	a	significant	decrease	of	the	measured	migration	distance.	In	3D	cell	sprouting	assay,	clustering	of	ephrin-A5	
and	ephrin-B2	appeared	to	either	invert	or	reduced	their	effects.	Indeed	stimulation	with	ephrin-A5	clusters	cancelled	
the	inhibitory	effect	on	cell	migration,	whereas	stimulation	with	ephrin-B2	clusters	reduced	the	previously	observed	
positive	effect	on	cell	sprouting.		
These	 data	 support	 the	 hypothesis	 that	 ephrins	 can	 be	 used	 as	 regulators	 of	 endothelial	 cell	 migration,	 which	
could	be	 a	 promising	 tool	 in	 the	 establishment	of	 pre-vascular	 networks	 in	 tissue	 engineered	 constructs	 or	 for	 the	
stimulation	of	graft	vascularization	from	the	host	upon	transplantation.	
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5.2 Future	developments	
Altogether,	 this	 thesis	presents	useful	 advances	 for	 the	development	of	 tissue-engineered	constructs.	 Two	efficient	
strategies	for	the	immobilization	and	delivery	of	growth	factors	in	synthetic	poly(ethylene	glycol)	scaffolds	have	been	
developed	and	used	successfully	for	the	controlled	differentiation	of	cells.	Additional	growth	factors,	such	has	PDGF,	
FGF-2	 and	 TGF-β,	 have	 been	 successfully	 biotinylated	 and	 are	 currently	 being	 tested	 in	 combination	 with	 the	
streptavidin	 linkers	 for	 different	 cell	 differentiation/recruitment	 approaches.	 We	 thus	 believe	 that	 the	 developed	
linkers	are	versatile	and	can	allow	the	immobilization	of	large	variety	of	growth	factors,	which	can	be	biotinylated	with	
relatively	 easy-to-use	 commercial	 biotinylation	 kits.	 The	 presented	 results	 also	 gave	 us	 valuable	 insights	 on	 the	
important	role	of	growth	factor	immobilization	and	how	the	way	in	which	they	are	presented	and	made	available	for	
cells	can	influence	their	biological	effects.	
The	 availability	 of	 a	 protease-sensitive	 linker	 also	 opens	 the	 possibility	 of	 using	 varying	 combinations	 of	 non-
degradable	 and	 degradable	 linkers	 to	 fine-tune	 the	 release	 of	 immobilized	 growth	 factors	 and	 to	 mimic	 ECM	
properties	even	more	 closely.	 In	order	 to	do	 so,	detailed	 release	 studies	are	needed	 to	determine	 the	 influence	of	
degradable	vs.	non-degradable	mixture	ratios	on	the	release	kinetics.	An	interesting	aspect	would	be	to	determine	if	
such	mixtures	of	peptide	linkers	could	help	enhance	the	effect	of	the	immobilized	growth	factors	by	providing	a	rapid	
cell-triggered	release	of	factors	for	an	immediate	effect,	while	also	guaranteeing	the	availability	of	bioactive	factor	on	
the	 long-term	through	the	non-degradable	peptide	 linker,	 in	a	similar	manner	to	what	happens	 in	the	natural	ECM.	
For	 instance,	 the	 data	 on	 cell	 differentiation	 presented	 in	 this	 thesis	 never	 evaluated	 the	 effects	 of	 immobilized	
rhBMP-2-biotin	 for	periods	 longer	 than	9	days.	 It	would	 thus	be	 important	 to	 assess	 the	bioactivity	of	 immobilized	
growth	factors	over	longer	time	periods	and	to	compare	them	with	the	bioactivity	of	growth	factors	presented	in	their	
soluble	form	in	the	cell	culture	medium.	Furthermore,	due	to	the	simple	and	efficient	production	and	purification	of	
these	small	peptide	linkers	in	bacteria	in	large	amounts,	the	development	of	additional	degradable	linker	with	other	
known	protease-specific	domains[158,	 159]	 seems	straightforward.	This	would	allow	the	creation	of	 linkers	customized	
for	 specific	 types	 of	 proteases	 and	 could	 be	 an	 interesting	 perspective	 in	 the	 design	 of	 cell-responsive	
microenvironments	or	for	the	adjustment	of	release	kinetics.	
Moreover,	our	TG-PEG	hydrogel	platform	and	the	streptavidin	linkers	can	be	combined	with	other	types	of	affinity	
linkers,	such	as	the	previously	developed	and	compatible	Gln-ZZ	linker[81],	to	facilitate	the	controlled	immobilization	of	
several	growth	factors	in	the	same	constructs.	Additionally,	we	believe	that	this	platform	could	potentially	be	adapted	
to	 become	 a	 printable	 ink	 and	 used	 with	 available	 bio-printing	 technologies[82]	 in	 order	 to	 generate	 hydrogel	
constructs	with	precise	3D	growth	factors	patterns.	The	next	step	for	this	project	is	the	printing	of	controlled	rhBMP-
2-biotin	 regions	 in	TG-PEG	hydrogel	mixtures	and	 confirming	 that	encapsulated	 cells	 still	 show	 localized	osteogenic	
differentiation.	 If	successful,	such	an	approach	could	represent	the	first	step	to	the	formation	of	distinct	osteogenic	
areas	during	the	in	vitro	creation	3D-bone-mimicking	tissues.	
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Overall,	 the	 development	 of	 both	 types	 of	 streptavidin	 linkers	 has	 lead	 up	 to	 several	 scientific	 collaborations.	
Currently,	 both	 types	 of	 streptavidin	 linkers	 are	 being	 used	 for	 the	 presentation	 of	 other	 growth	 factors	 and	 the	
development	 of	 different	 types	 of	 cellular	 microenvironment,	 notably	 for	 the	 establishment	 of	 microvascular	
networks	 using	 immobilized	 FGF-2	 in	 TG-PEG	 scaffolds[187]	 and	 for	 the	 creation	 of	 a	 3D	 cell	 culture	 system	 for	 the	
chondrogenic	differentiation	of	MSCs	using	immobilized	TGF-β3.	In	the	domain	of	bone	repair,	the	first	in	vivo	study	in	
mice	 involving	Gln-streptavidin	 and	 rhBMP-2-biotin	 has	 been	 carried	 out,	 leading	 to	 promising	 results	 (Figure	 5.1),	
where	immobilized	BMP-2	was	shown	to	perform	as	well	as	soluble	BMP	and	to	contribute	to	bone	healing.		
	
Figure	5.1.	Effects	of	Gln-streptavidin-immobilized	rhBMP-2-biotin	in	calvarial	bone	defects.3	
A	4mm	circular	bone	defect	was	created	in	the	left	and	right	parietal	bones	of	C57Bl/6	mice.	Preformed	hydrogel	implants	with	the	
indicated	amount	of	soluble	or	matrix-immobilized	BMP-2	were	placed	in	the	defect.	A)	Quantitative	assessment	of	bone	volume	4	
weeks	post-op	 (n≥5),	depicted	as	mean	±	SD,	n.s.	=	not	 significant	 (1-way	ANOVA	with	Tukey-Kramer	post-hoc	 test),	B)	4	weeks	
post-op	bone	regeneration	was	assessed	ex	vivo.	Representative	top	(left	panels)	and	side	views	(upper	right	panels)	of	3D	surface	
rendered	micro-CT	measurements	 and	 H&E	 stained	 sections	 (lower	 right	 panel)	 of	 coronal	 cross	 sections	 are	 displayed	 for	 the	
indicated	conditions.	Scale	bars	=	1	mm,	C)	8	days	post-op	presence	of	Sca-1+	cells	and	blood	vessels	on	the	dorsal	and	ventral	sides	
of	the	hydrogel	implants	were	assessed	ex	vivo	using	immunohistological	stains	against	Sca-1	and	CD31.	Scale	bar	=	10	µm.		
																																																																										
3	Adapted	from:	PS	Lienemann,	P	Papageorgiou,	U	Blache,	S	Metzger,	A	Kiveliö,	V	Milleret,	Q	Vallmajo-Martin,	A	Sala,	S	Hohnel,	A	
Roch,	R	Reuten,	M	Koch,	O	Naveiras,	FE	Weber,	W	Weber,	MP	Lutolf,	and	M	Ehrbar,	Top-down	design	of	a	biomimetic	cell	trap	to	
amplify	low-dose	BMP-2	treatment	for	bone	regeneration	by	augmenting	homing	of	endogenous	MSCs,	in	preparation,	2016.	
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In	future,	we	expect	that	the	TG-PEG	platform	in	combination	with	the	streptavidin	linkers	will	continue	to	be	used	
in	vivo	for	the	improvement	of	bone	healing	strategies,	but	also	serve	for	the	in	vitro	localized	assembly	of	various	cell	
types	 in	 their	customized	cell-instructive	matrices	with	complex	structural	 features,	especially	 if	we	can	successfully	
combine	this	system	with	bio-printing.	
Regarding	 the	 regulation	 of	 vascular	 processes,	 the	work	 done	 in	 thesis	 has	 shown	 that	 various	 growth	 factors	
could	play	an	important	role	as	regulators	of	vascularization	in	synthetic	scaffolds.	Both	netrins	and	ephrins	are	often	
studied	as	potential	 targets	of	cancer	 therapy,	especially	 in	 the	context	of	 restraining	tumor	angiogenesis.[107,	 188-190]	
We	thus	believe	that	these	growth	factors,	in	combination	with	other	angiogenic	factors	such	as	VEGF,	could	be	used	
to	either	form	pre-vascular	structures	in	tissue	constructs	before	implantation,	or	help	the	anastomosis	of	the	graft	to	
the	host	vasculature.	Because	the	angiogenic	mechanisms	of	netrins	and	ephrins	are	not	yet	fully	understood,	it	would	
be	 crucial	 to	 characterize	 their	 effect	 on	 developing	 vascular	 networks,	 such	 as	 the	 chicken	 CAM,	 but	 also	 to	
investigate	 their	 effects	 in	 vitro	 on	 cell	 migration	 by	 looking	 at	 receptors	 phosphorylation	 and	 at	 the	 activated	
signaling	 cascades.	 Ephrins	 are	 of	 particular	 interest,	 since	 they	 have	 been	 reported	 to	 regulate	 cell	 migration	 by	
modifying	the	actin	cytoskeleton	and	by	interactions	between	integrins	and	adhesion	molecules.[105]	Thus,	they	would	
be	an	ideal	target	for	the	improvement	of	engineered	microenvironment,	not	only	in	terms	of	vascularization	but	also	
for	cell	guidance	 in	general	and	establishment	of	tissue	boundaries.	We	thus	are	convinced	that	these	factors	could	
become	useful	tools	in	combination	with	our	modular	TG-PEG	hydrogel	platform	for	the	design	of	engineered	tissues.	
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